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Zusammenfassung
Hintergrund: Wissenschaftler der pharmazeutischen Industrie und der akademi-
schen Forschung arbeiten gemeinsam an der Erforschung der grundlegenden Ursa-
che einer Erkrankung auf zellulärer Ebene bis hin zum zugelassenen neuen Medika-
ment. Analysen der Wirkungsweise (mode of action) neuer Substanzen sind unter
zunehmenden Sicherheits- und Nutzenanforderungen ein immer wichtiger werden-
der Beitrag in der Entwicklung eines neuen Wirkstoﬀs. Dabei wird zwischen den
Eﬀekten am gewünschten Zielprotein (on-target) und den Eﬀekten an möglicherwei-
se unbekannten Zielproteinen (oﬀ-targets) unterschieden. Häuﬁg ist das Wissen über
diese Eﬀekte sehr begrenzt. Da die Wirkung hauptsächlich durch Wechselwirkun-
gen von Proteinen oder Signalkaskaden vermittelt wird, ist ihre Untersuchung auf
der Basis von Proteininteraktionsnetzwerken (PI-Netzwerke) ein vielversprechender
Ansatz. Die Menge an verfügbaren biologische Daten aus verschiedensten Quellen
steigt stetig an. Die Integration dieses Wissens ist wichtig, um ein tieferes Verständ-
nis der zugrundeliegenden Biologie zu erlangen. Häuﬁg werden Genexpressionsstu-
dien von erkranktem Gewebe und/oder wirkstoﬀbehandelten biologischen Proben
durchgeführt, um die Wirkungsweise neuer Wirkstoﬀe unter Berücksichtigung von
transkriptionellen Änderungen verstehen zu können.
Status quo: Die Wirkungsweise von Substanzen kann analysiert werden, indem die
Teile von Proteininteraktionsnetzwerken untersucht werden, in denen aufgrund von
Wirkstoﬀbehandlung Änderungen zu beobachten sind. Mathematische oder graph-
theoretische in silico Methoden, die interessante Teile von Netzwerken identiﬁzieren,
ﬁnden weit verbreiteten Einsatz. Fragestellungen reichen dabei von der Ermittlung
stark vernetzter Subgraphen über die Identiﬁzierung kürzester Wege bis hin zur
Berechnung von Subgraphen oder Modulen, die bestimmte Zielfunktionen optimie-
ren. Entsprechende Algorithmen können auf biologische Fragestellungen angewandt
werden, um beispielsweise konditionsresponsive Subnetzwerke in verschiedensten Ar-
ten von biologischen Netzwerken zu identiﬁzieren. Gegenwärtige Methoden, die zur
Analyse der Wirkungsweise eingesetzt werden können, befassen sich hauptsächlich
mit der Detektion von Subnetzwerken, in denen Informationen aus dem Bereich der
funktionellen Genomik angereichert sind, z.B. Anreicherung an deregulierten Genen.
Diese Methoden vernachlässigen die Existenz von regulatorischen Mechanismen auf
post-transkriptionaler und auch post-translationaler Ebene wie miRNA-Interferenz
oder Protein-Phosphorylierung. Außerdem detektieren gängige Methoden häuﬁg re-
lativ große Module. Dabei deckt ein solches Modul möglicherweise mehrere Prozesse
gleichzeitig ab, beispielsweise sowohl on- als auch oﬀ-target Eﬀekte. Zur Detektion
und Interpretation von Einzeleﬀekten innerhalb eines biologischen Systems wäre es
hilfreich, kleinere Module identiﬁzieren zu können.
Einige frühere Arbeiten fokussieren sich auf die Vorhersage und Gewichtung von Pro-
teininteraktionen unter Berücksichtigung von vorhandenem Wissen. In den meisten
Fällen werden die Interaktionen dabei bezüglich eines als Gold-Standard betrachte-
ten Datensatzes gewichtet. Da unser Wissen über die Rolle von Genen und Proteinen
nach wie vor sehr unvollständig ist, gibt es keinen Gold-Standard, der die Realität
exakt widerspiegelt. Des Weiteren sind gegenwärtig verwendete Gewichtungsmetho-
den häuﬁg weder einfach zu verwenden noch einfach zu interpretieren. Eine ideale
Gewichtung sollte die einfache Integration zusätzlicher Datenquellen und deren in-
dividuelle Gewichtung basierend auf Expertenwissen ermöglichen.
Vorgehen & Ergebnisse: In der vorliegenden Arbeit werden Genexpressionsdaten
analysiert, die der Aufdeckung von on- und oﬀ-target Eﬀekten verschiedener Wirk-
stoﬀe zur Inhibition von TGF-βR1 dienen sollen. Um eine verlässliche Basis für die
Datenanalyse zu schaﬀen, werden im ersten Teil der Arbeit verschiedene Aspekte
zur Auswahl einer geeigneten Normalisierungsmethode vorgestellt. Unter deren Be-
rücksichtigung wird schließlich eine optimale Normalisierungsstrategie gewählt.
Um die Wirkmechanismen der verschiedenen Substanzen zu analysieren, wird ein
Verfahren vorgeschlagen, das die Interaktionen zwischen Proteinen mittels verschie-
dener Evidenzien gewichtet. Die Relevanz der Proteine wird dabei nicht nur über
die Expression ihrer kodierenden Gene sondern auch durch ihre Beziehung zu an-
deren Proteinen bewertet. Dadurch werden Analysen über die Genexpressionsebene
hinaus erweitert. Die Bewertung dieser Beziehungen erfolgt über die Gewichtung
der Proteininteraktionen. Dazu werden Informationen über molekulare Funktionen,
biologische Prozesse, zelluläre Kompartimente, Transkriptionsfaktorbindestellen und
literaturbasierte Konﬁdenzwerte integriert, um die entsprechenden Kanten im Netz-
werk zu gewichten. Expressionsdaten dienen als Ankerpunkt der Analysen, um das
Netzwerk schließlich in den biologischen Kontext zu transferieren.
Des Weiteren wird in dieser Arbeit eine neue Methode zur Extraktion von Modulen
aus gewichteten PI-Netzwerken entwickelt, modEx. Mittels der durch modEx ex-
trahierten Module ist es möglich, Einzeleﬀekte innerhalb des biologischen Systems
abzugreifen.
Für den vorliegenden Expressiondatensatz kann gezeigt werden, dass die vorgeschla-
gene Kantengewichtung der weit akzeptierten STRING-Gewichtung überlegen ist.
Darüber hinaus können unter Verwendung von modEx Module extrahiert werden,
die den zugrundeliegenden biologischen Mechanismus besser repräsentieren als Mo-
dule, die durch das gängige jActiveModule identiﬁziert werden.
Die vorgestellten Methoden werden verwendet, um den Wirkungmechanismus, d. h.
sowohl die on- als auch oﬀ-target Eﬀekte verschiedener Wirkstoﬀe zu analysieren.
Es kann gezeigt werden, dass dadurch ein fokussierterer Blick auf die Eﬀekte der
Wirkstoﬀe möglich ist als durch gegenwärtige state-of-the-art Analysen eines Gen-
expressionsdatensatzes.

Abstract
Background: Scientists in pharmaceutical as well as academic research work to-
gether to solve the challenging puzzle from the basic causes of disease at the level
of genes, proteins and cells up to a marketed new drug. Analyses of mode of ac-
tion (MoA) of new chemical entities (NCEs) are a very important step in the de-
velopment of new drugs. One distinguishes between eﬀects induced by modulating
the compounds' actual target protein (on-target eﬀects) and eﬀects induced by ad-
ditional, possibly unknown targets (oﬀ-target eﬀects). Quite often knowledge about
either of these eﬀects is limited. Since MoA is mainly triggered by the interplay of
proteins or signaling cascades, investigating the change and subsequent inﬂuence of
the changed molecules in a protein interaction (PI) network is a promising initial
step to further analyses. As more and more data from diverse sources becomes avail-
able, the integration of this knowledge is important for generating a deeper insight
into biology. In addition, expression experiments based on disease tissue and/or
compound treatment are frequently conducted to get insight into transcriptional
changes that could explain compounds' MoA.
Status quo: MoA could be analyzed by investigating those parts of a PI network
that show changes based on compound treatment. Mathematical or graph theoret-
ical in silico methods to identify interesting parts of a network based on diﬀerent
criteria are widely used. Criteria range from detection of highly connected sub-
graphs to subgraphs maximizing weights assigned to parts of the network under
investigation. These methods can be transferred to biology and can be used to, e. g.
identify condition responsive subnetworks on various types of molecular networks.
Present questions addressed mainly focus on the detection of subnetworks enriched
in information from functional genomics, e.g. diﬀerentially expressed genes. They
neglect the existence of distance regulatory functions on the post-transcriptional as
well as post-translational level like miRNA interference or protein phosphorylation.
Further, available methods usually detect relatively large modules. It is easily possi-
ble that more processes, i. e. the on- and several oﬀ-target eﬀects, are covered by one
larger module. Thus, the individual eﬀects are diﬃcult to detect and interpret. To
be able to derive individual eﬀects, it is necessary to reveal small modules that are
related to the individual eﬀects present in the biological system under investigation.
Previous works focus on predicting and weighting interactions between proteins
based on prior knowledge. In most cases interactions are weighted according to
a gold standard which always depends on the current knowledge. Our knowledge
about the role of genes/proteins is far from complete and still accumulating and
evolving, thus, a gold standard does not reﬂect reality. Present scoring methods
lack ease of use as well as ease of interpretation of scoring function to describe the
pairwise relatedness of proteins. Further, an ideal score should be highly ﬂexible by
allowing easy integration of newly gained knowledge and it should oﬀer the possi-
bility to diﬀerentially weight individual evidence based on expert knowledge.
Methods & Results: In this work, I made use of a gene expression data set in-
vestigating the inhibition of the TGF-β signaling pathway by diﬀerent compounds
targeting TGF-βR1. To gain a sound basis for follow-up analyses, diﬀerent aspects
of how to select the best suited normalization procedure for the underlying expres-
sion data are proposed in the ﬁrst part of this thesis.
To analyze compounds' MoA, I propose a method that weights interactions between
proteins based on diﬀerent kinds of evidence. In this method, the relevance of the
proteins is based on the biological relatedness to other possibly not deregulated
protein coding genes. Thereby, analyses are expanded beyond transcriptional dereg-
ulation. To elucidate the biological relatedness, information on molecular function,
biological processes and cellular compartment, information on transcription factor
binding sites and literature-based conﬁdence scores are integrated for weighting the
edges between proteins. To transfer the network into the biological context of inter-
est, expression experiments are used as anchoring points for the analyses.
Further, I introduce modEx, a method to extract small modules out of a weighted
protein interaction network. Modules extracted using modEx reﬂect the individual
eﬀects present in the biological system under investigation.
For the expression data set used, the proposed edge scoring is shown to be superior
to the widely accepted STRING scoring. Furthermore, modEx extracts modules
that represent the underlying mechanism better than jActiveModule, a commonly
used subgraph extraction method. These newly proposed approaches are applied to
elucidate the MoA, i. e. the on- as well as oﬀ-target eﬀects, of compounds. They
are shown to grant a more focused view on the eﬀects of compounds than current
state-of-the-art methods applied for the analysis of gene expression data.
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Chapter 1
Background
Scientists in pharmaceutical as well as academic research work together to solve the
challenging puzzle of basic causes of disease at the level of genes, proteins and cells
up to a marketed new drug. This drug in the ideal case inhibits or reverses the
disease progression or at least treats the symptoms of the disease to relieve patients
of their suﬀering. Researchers work to identify and validate disease related target
molecules, discover and optimize the right new chemical or biological entity (NCE
or NBE, respectively) to interact with that molecule, test for safety and eﬃcacy and
gain approval to get the new drug into clinical practice. This whole process takes
10 to 15 years with an estimated average cost for research and development (R&D)
of a successful drug in the range of $800 million to $1 billion. This number includes
the cost of the thousands of failures: For every 5,000 - 10,000 compounds that enter
the R&D pipeline, ultimately only one receives approval. [3, 4]
In this chapter, I ﬁrst give an overview over the drug development process in
Section 1.1, reveal the importance of analyses of compounds' mode of action in
Section 1.2, summarize the objective of this thesis in Section 1.3, and describe the
structure of this thesis in Section 1.4.
1.1 Drug Development Process
The development of a new drug can be split into two phases, namely drug discovery
and clinical trials. This section gives a short introduction into both. A schematic
overview of the complete process together with expected times needed for the indi-
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vidual steps is given in Figure 1.1.
1.1.1 Drug Discovery Process
Pre-discovery
The basis of every drug development process is the sound understanding of the
disease mechanisms to treat. This could for example be achieved by linking an
induced disease state to altered gene expression in diseased versus healthy samples.
Next, the role of the respective proteins, how they interact with each other in living
cells, and how this ultimately leads to the disease is investigated. This knowledge
provides the basis for revealing the relevant pathomechanisms. However, even with
new tools and insights, this research takes many years of work and quite often leads
to abrupt ends.
Target Identiﬁcation
Once researchers gain enough understanding of the underlying disease, a target is
selected. A target is commonly a single molecule, in most cases a protein, which is
involved in the mechanism of a particular disease. To achieve a desired eﬀect, it is
critical that researchers pick a druggable target. A biological entity is druggable if
its behavior can be modulated by a drug molecule thereby achieving a desired eﬀect
like for example inhibition of enzymatic activity.
New approaches that are applied for identifying this type of target are text-
and data mining [58]. In text mining, literature is screened by computational
approaches. Applied methods range from investigating co-occurrences of words, for
example a gene mentioned together with the disease of interest, to more sophisticated
methods like natural language processing (NLP) which are capable of reading the
text in a human like fashion. By data mining diﬀerent kind of information sources
are integrated. Applying text mining as well as data mining, the list of possible
targets could be narrowed down, ultimately leading to a handful of targets. In the
following, these targets need to be validated.
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Target Validation
After a target has been identiﬁed on a more or less theoretical basis, researchers
need to prove the positive eﬀect of modulating the target towards the healthy state.
By conscientious target validation dead ends can be identiﬁed early in the pipeline.
Thereby costly failures of projects in later phases are prevented. State of the art
methods for target validation range from gene expression analysis, siRNA screen-
ing, use of tool compounds, image analysis like high content screening [9] or tissue
array investigations [10] to studies using viral vectors [11] or genetically modiﬁed
mice [1215]. siRNAs, for instance, could be used to mimic the eﬀects of compounds
inhibiting the protein encoded by the siRNA's target transcript. A further example
in this regard is target validation using Adeno-associated virus (AAV) [16]. AAV
infects humans and some other primate species. Only inducing a very mild immune
response, is currently not known to cause disease. The virus speciﬁcally integrates
its genome into that of the host cell. Thus, it is a very attractive approach to cre-
ate viral vectors for the over-expression of genes, thereby elevating the level of the
respective proteins. Targets like E3-ligases, leading to the ubiquitination and subse-
quent degradation of target proteins, could be validated using such an approach. If
the enrichment of proteins leads to the desired eﬀect, the target would be validated.
After successful validation of a target, a lead has to be identiﬁed that modulates the
respective target in the desired way.
Lead Identiﬁcation
The main goal of lead identiﬁcation is to ﬁnd a chemical, a so called lead compound
or simply lead, that may act on the target to alter the disease. This molecule con-
stitutes the initial scaﬀold for the new drug.
High-throughput screening (HTS) is the most common way that leads are found.
Advances in robotics and computational power allow researchers to test hundreds
of thousands of compounds against a target. The compounds present in screening
pools cover a wide range of the chemical space. Many successful drugs are derived
from naturally occurring molecules. Penicillin which is produced by the fungus Peni-
cillium when its growth is inhibited by stress [17] is possibly the most prominent
example. But also butylscopolamine and acetylsalicylic acid which are the active
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ingredients for Buscopan R© [18, 19] and Aspirin R© [20], respectively, constitute very
successful drugs of natural origin. Thus, parts of compounds present in libraries for
HTS are nature product-like [21, 22]. Based on the results of HTS, several lead
compounds are usually selected for further study.
Besides HTS, in rational design detailed structural knowledge of the targets' ac-
tive site can be used by chemists to design molecules that interact with this site. Ad-
ditionally, in de novo synthesis by computational chemistry sophisticated computer
modeling is used to predict what type of molecule could be used as a lead. Typically
the 3D-structure of at least the target protein's active site has to be resolved in ad-
vance, again, either by computational modeling or by X-ray crystallography [2325].
After a lead has been successfully identiﬁed, this structure is subsequently opti-
mized towards diﬀerent parameters during lead optimization.
Lead Optimization
Compounds that were selected in the initial screening are optimized or altered in
order to maximize eﬃcacy, speciﬁcity and period of impact while at the same time
minimizing side eﬀects and toxicity. Based on their chemical and physical properties
and the resulting biological eﬀects researchers try to infer the behavior of leads to
minimize the failure rate in a later stage of the drug development process.
The structure activity relationship (SAR) describes the relationship of the lead's
structure to its pharmacodynamic as well as pharmacokinetic properties. Physical
and chemical properties are used to quantify the structure activity relationships
(QSAR). Pharmacodynamic refers to mechanism of the drug at the target, pharma-
cokinetic to its distribution in the organism and in which concentration the drug and
its metabolites are present. Pharmacokinetic is described in terms of LADME/Tox
parameters which characterize the compound with regard to liberation, absorption,
distribution, metabolism, elimination, and toxicity: Liberation refers to the release
of the active ingredient from the drug, absorption to the entering into the blood
stream, distribution to the circulation to the proper site of action, metabolism to
the decomposition, elimination to the excretion of the drug and toxicity to potential
or real toxicity. Resorption and bioavailability are closely linked to LADME/Tox
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parameters. They describe the uptake of substances into the blood and the frac-
tion of active ingredients available to the organism, respectively. For an optimal
resorption and bioavailability and thereby for a better eﬃcacy and duration of eﬀect
the lipophilicity, the size of the molecule and the related metabolic stability of a
molecule are decisive. Quite often leads fail in early stages due to low bioavailabilty
and due to toxic metabolites. Thus, LADME parameters are taken into account
in early stages. The most famous parameters which are considered with respect
to LADME are probably Lipinski's rule of ﬁve. Analyzing the properties of about
2,250 compounds of the Derwent World Drug Index (WDI) Lipinski et al. were able
to summarize properties that were common to 90% of the compounds [26]. Lip-
inski assumes that as soon as more than one property is not met by a compound
the success rate gets relatively low since absorption and permeability are decreased.
However, Lipinski's rule of ﬁve should be considered as guidelines, not as hard rules.
LADME/Tox studies are performed in living cells, in animals and via computa-
tional models. They help researchers prioritize lead compounds early in the discov-
ery process. Technologies such as magnetic resonance imaging and X-ray crystal-
lography, along with powerful computer modeling capabilities support chemists to
design chemical structures to optimize LADME/Tox properties. Additionally, the
molecules are changed to minimize possible interactions with other molecules, thus
reducing the potential for side eﬀects.
Diﬀerent variations or analogues of the initial leads are designed and tested. The
resulting compounds represent the candidate drugs that enter pre-clinical testing.
Pre-clinical Testing
Regulatory institutions require extremely thorough testing before the candidate drug
can be studied in humans. To meet these high standards, scientists carry out in-
depth in vitro and in vivo tests to understand how the drug works and what its
safety proﬁle looks like in pre-clinical tests.
After starting with 5,000 up to 10,000 compounds (Figure 1.1), between one and
ﬁve molecules will be studied in clinical trials. Diﬀerent authorities around the
world are in charge of approving drugs for clinical testing and marketing. The most
1. Background 6
inﬂuential ones are probably the U.S. Food and Drug Administration (FDA) [27],
the European Medicines Agency (EMA) [28] and Japan's Ministry of Health, Labour
and Welfare (MHLW) [29]. Great eﬀorts are made by the International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) to harmonize the process of registration. Thus, in the following
I focus on the guidelines as set by the FDA, which can be found on the respective
web page [27]. Guidelines set by other institutions are, by and large, comparable.
Investigational New Drug (IND) Application and Safety
The goals of the IND are to provide enough information to permit FDA reviewers to
determine whether the drug is safe enough to start ﬁrst human trials. Basis for this
application are all results gathered during the pre-clinical work in the drug discovery
process: the candidate drug's chemical structure, how it is thought to work in the
body, a listing of any side eﬀects and manufacturing information. Additionally, the
IND also provides a detailed clinical trial plan.
1.1.2 Clinical Trials
To provide conﬁdent results, drug trials are generally placebo-controlled, randomized
and double-blinded.
• Placebo-controlled: Some subjects will receive the new drug candidate and
others will receive a placebo. In some instances, the drug candidate may be
tested against another treatment rather than a placebo.
• Randomized: Each of the study subjects in the trial is assigned randomly to
one of the treatments.
• Double-blinded: Neither the researchers nor the subjects know which treat-
ment is being delivered until the study is over.
Such a study design provides the best evidence of a direct relationship between the
drug and its eﬀect on the disease.
The number of subjects participating in a trial has to be carefully considered:
On the one hand, the more subjects take part in the study, the more likely real
eﬀects are detected. On the other hand, the more subjects are investigated, the
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Figure 1.1: Drug Development Process. The diﬀerent phases as well as the
compounds left for consideration and the approximate time necessary for each phase
are displayed. Additionally, the number of participants in the clinical trials are listed.
This ﬁgure was taken from [3,4].
more expensive and diﬃcult is the trial. Additionally futility has to be taken into
account. It is unethical to expose unnecessary many people to the unavoidable risk
of clinical trials as long as the eﬀects of the drug candidate is not ensured.
The Phases of Clinical Trials
Recently, the FDA has established the Phase 0 trial, which allows researchers to
test a very low drug dose in a small cohort of volunteers to quickly identify drug
candidates that are ineﬀective. Thereby, costs and lengths of clinical trials can be
eﬃciently reduced.
In Phase 1 trials the candidate drug is tested in a bigger cohort of volunteers for
the ﬁrst time. These studies are usually conducted with about 20 to 100 healthy
volunteers. The main goal of a Phase 1 trial is to discover if the drug is safe in
humans. Researchers look at the pharmacokinetics and the pharmacodynamics of
a drug. People participating in these trials are at any time monitored thoughtfully.
Based on these trials, the safe dosing range is determined and it is decided whether
the drug should be pushed forward to the next phase.
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In Phase 2 trials researchers evaluate the candidate drug in about 100 to 500
patients suﬀering from the disease, and examine possible short-term side eﬀects.
This phase could also be split up into Phase 2a and 2b. Phase 2a would investigate
eﬃcacy and dosage in a small group of patients. Based on these results, Phase 2b
could be optimally designed for a larger group of patients. During Phase 2 mecha-
nism and eﬃcacy as well as optimal dose strength and schedules are investigated to
optimally design a Phase 3 trial.
In Phase 3 trials researchers study the drug candidate in about 1,000-5,000 pa-
tients to generate statistically signiﬁcant data. This phase is key in determining
whether the drug is eﬀective and safe. Phase 3 trials are both the most expensive
and the most time-consuming trials.
During all clinical phases researchers are conducting many other critical stud-
ies like investigations for large scale production. Further, the complex application
required by the authorities for approval of the new drug has to be prepared.
New Drug Application (NDA)
The goals of the NDA are to provide enough information to permit FDA reviewers
to reach the following key decisions:
• Whether the drug is safe and eﬀective and whether the beneﬁts of the drug
outweigh the risks.
• Whether the package insert is appropriate and what it should contain.
• Whether the methods used in manufacturing the drug and the controls used
to maintain the drug's quality are suﬃcient.
If the review is positive, the new drug gets approved.
Post-marketing phase
Even if a new drug has been approved and is already marketed, it is still monitored
with respect to detection, assessment, understanding and prevention of adverse ef-
fects as well as the patients overall satisfaction related to the treatment. This process
is called pharmacovigilance. Surveys are conducted and information is collected to
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further evaluate the drug. The most important aim is to identify possible hazards
associated with drugs as soon as possible to prevent unnecessary harm to patients.
1.2 Mode of Action
Analyzing mode of action (MoA) of compounds or new drugs is one of the most
important but also probably the most diﬃcult part during the drug development
process. Negligent analyses of mode of action can easily lead to costly late failures
of compounds, in the worst case constituted by severe eﬀects observed in patients as
it was the case for torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor.
At the time Pﬁzer discontinued its so-called ILLUMINATE (Investigation of Lipid
Level Management to Understand its Impact in Atherosclerotic Events) trial, the
company already had spent $800 millions on R&D. Analyses of the clinical trial led
to the suggestion of adverse events that may have been responsible for an observed
increase in mortality rate of patients treated with torcetrapib in combination with
atorvastatin (82) compared to patients only treated with atorvastatin (51) [30]. Since
research on compounds targeting CETP was and is still going on at other companies,
it has indeed been conﬁrmed in animal experiments that an oﬀ-target mechanism
of torcetrapib increases blood pressure [31]. Further, in rats, torcetrapib was shown
to be associated with an increase in plasma levels of aldosterone and corticosterone
and, in vitro, with an release of aldosterone from adrenocortical cells. The increase
in blood pressure was not mediated by the increased levels of steroids but was shown
to be dependent on intact adrenal glands. In later studies the oﬀ-target eﬀect of
torcetrapib could be further narrowed down to be related to an increase in the expres-
sion of the alpha subunit 1C from the voltage-gated L -type Ca2+ channel [32]. By
siRNA mediated knockdown of L-type Ca2+ channel subunits alpha 1C and alpha
1D, Clerc et al. [32] could show the decrease of aldosterone and aldosterone syn-
thase (CYP11B2). Thereby, they provided a mechanistic link between torcetrapib
and aldosterone that is related to activation of the L -type Ca2+ channel. In rats,
torcetrapib has been shown to induce a potent hypertensive eﬀect mediated by the
L-type Ca2+ channel. Clerc et al. conclude that steroidogenic and hypertensive side
eﬀects of torcetrapib may be linked and involve voltage-gated L-type Ca2+ channels.
1. Background 10
Additional to this prominent example, analyses of Thomson Reuters Life Sciences
Consulting reveals 83 failures during phase 3 trials and submissions for the period
from 2007 to 2010 [33]. Main reasons for these failures were lack of eﬃcacy (66%)
and safety issues (21%). Large proportion of failures are observed for drugs with
novel machanism of action that at the same time are located in areas of high unmet
medical needs. Such indication areas face reasearchers with challenging science as
well as put high competitive pressure on companies to ﬁll their pipelines with com-
pounds that turn to account. To achieve fast success, companies are willing to take
higher risk and move forward their compounds although they only display marginal
statistical signiﬁcance. Additionally, indication areas like cancer tempt researchers
to prematurely try to reposition drugs/targets from one cancer type to another
without suﬃciently testing the relevance of the mechanism of action. Examples are
sunitinib (Pﬁzer) in hepatic cancer and bevacizumab (Genentech/Roche) in gastric
cancer.
Success rates can be improved only by relying on high quality scientiﬁc evidence,
by fully testing mechanism and by thoughtful planning of clinical studies with well
deﬁned end-points. This could lead to higher failure rates in early phases but at
the same time would save money that would better be invested into other drug can-
didates, which may in the end lead to a sound pipeline containing more promising
drugs.
To validate a compound it is most important to know as much as possible about
its mode of action. Mode of action of compounds can be broadly split into two
classes, the on- as well as the oﬀ-target eﬀects. An on-target eﬀect is an eﬀect in-
duced through the direct interaction, i.e. inhibition or activation, of the compound
with the intended target molecule. On the contrary, an oﬀ-target eﬀect is an eﬀect
induced by the unwanted interaction of the compound with a diﬀerent molecule
than the target. Although these eﬀects are generally unwanted, there are exam-
ples for which oﬀ-target eﬀects of existing drugs show potential for new indications.
Example are Nelﬁnavir [34, 35] or Xenical [36]. However, there are of course many
examples were undesired oﬀ-target or adverse eﬀects led to failure or in the worst
case even withdrawal of drugs. Examples for expensive failure in Phase 3 studies
have been described previously. A prominent example for a withdrawal is rofecoxib
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(Vioxx R©) which has been withdrawn from the market in 2004 based on early re-
sults of the APPROVe (Adenomatous Polyp PRevention On Vioxx) trial with the
primary aim of evaluating the eﬃcacy of rofecoxib for the prophylaxis of colorectal
polyps [37, 38]. This study conﬁrmed a higher risk for cardiovascular events (i.e.
heart attack and stroke) only after 18 months of chronic use of the drug. Each phar-
maceutical company wants to avoid such dramatic failures. First, they potentially
harm patients, second, they are bad for reputation, and patients possibly lose trust
in drugs marketed by the respective companies no matter how safe they are.
1.3 Objective of the Thesis
The aim of this thesis is to develop a method that supports researchers in focusing
the drug development process by revealing unpromising directions as early as pos-
sible. This could be achieved by analyzing mode of action and potential side eﬀects
by incorporating existing prior biological knowledge. By supporting the analyses
of mode of action and by ﬁltering for more promising drug candidates in early
phases, the process is not only more focused but also cheapened and more human-
ized. Dramatic failures due to lethal adverse events as well as animal experiments
for unpromising compounds can hopefully be prevented.
To analyze compounds' mode of action, one important step is the understanding
of cellular mechanisms induced by the drug candidate. Possibilities to survey these
cellular processes include gene expression analyses or investigation of protein levels.
For the drug development process it is of importance to conduct high-throughput
experiments which help to get an understanding of underlying cellular processes.
Gene expression analyses are commonly conducted at the very beginning of the
drug development process. By analyzing such data, researchers try to explain the
biological causes and consequences of transcriptional changes.
For gene expression measurements using microarrays, normalization of the data
has to be performed to minimize systematic eﬀects that are not constant between
diﬀerent samples of an experiment and that are not due to the factors under investi-
gation (e.g. treatment, time). Optimal selection of a normalization method heavily
depends on the nature of the experiment. Factors like comparability and quality
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of single runs play a major role. It has been shown that the normalization method
used may inﬂuence further downstream analysis to a great extend [39], and thus,
has to be carefully chosen based on the actual data. Therefore, the ﬁrst part of this
thesis is concerned with the decision on an optimal normalization procedure for the
experiment under investigation. Based on the normalized data, genes diﬀerentially
expressed between distinct conditions like diseased versus healthy or compound-
treated versus untreated cells can be detected.
Algorithms analyzing diﬀerentially expressed genes with respect to the biological
process the genes are associated with have been studied thoroughly [4051]. Based
on diﬀerentially expressed genes, these methods search for gene sets or modules of
genes that are related to the biological process studied in the expression experi-
ment. Such approaches are state-of-the-art methods that could be used to analyze
compounds' mode of action based on gene expression data. In the second part of
this thesis, some of these well established methods were considered in basic state-
of-the-art in silico analyses of gene expression data. Expression proﬁles of several
compounds are investigated with respect to their biological characteristics as poten-
tial drugs.
One challenge in the interpretation of the data is that regulation does not only
occur on the transcriptional level. Additionally, compound eﬀects are mediated by
binding of compounds to proteins and subsequently inﬂuencing related regulatory
networks within the organism. Discovering key proteins as well as their meaning in
a broader biological context is one of the most promising ways to answer questions
with respect to the mode of action. As more and more data from diverse sources
become available, the integration of this knowledge is important for generating a
deeper insight into biology. Existing methods for the analysis of gene expression
data only make very limited use of prior knowledge. To my knowledge, so far no
method exists that eﬃciently integrates prior knowledge with data from functional
genomics to elucidate the mode of action of compounds. To help closing this gap,
the third part of this work is concerned with a mathematical model for the devel-
opment of a new knowledge mining approach.
In the fourth part I focus on the development of an algorithm to identify modules
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of genes/proteins that help explaining the mode of action by utilizing the previously
proposed knowledge mining approach.
Finally, in the last part of this work, the newly developed methods are compared
to existing ones, and analyzed with respect to possible advantages and improve-
ments.
1.4 Overview of the Thesis
After having given the basic background and objective in this chapter, I give a brief
overview of the layout for the remaining main part of my thesis:
In Chapter 2, I review existing knowledge related to this thesis:
In Section 2.1, TGF-β-signaling, the biological system used throughout this work,
is described. In the remaining sections of that chapter, I give an overview of work
available in the ﬁeld of computational biology that could be helpful for the analysis
of mode of action: Section 2.2 describes existing methods for data integration, Sec-
tions 2.3 and 2.4 give an overview of gene based analyses that can give insight into
underlying biological processes.
In Chapter 3, the methods used throughout this thesis are described, Chapter 4
summarizes results applying these methods:
All laboratory work described in Section 3.1 has been conducted by Dr. Patrick Baum
in the scope of his PhD thesis [52]. It is mentioned here for completeness. These ex-
perimental data have been used to assess the new methods developed in the present
work with respect to the analysis of mode of action.
In Section 3.2 methods used to select an optimal normalization procedure for the
TGF-β gene expression data are described. Respective results are presented in Sec-
tion 4.1 and discussed in Section 5.1. This part of my thesis has been published in
BMC Genomics [53].
In Section 3.3, I describe how we derived on- and oﬀ-target signatures and intro-
duce available methods for the analysis of diﬀerentially expressed genes. Results
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applying these methods are presented in Section 4.2 and are part of a PLoS One
publication [54].
In Section 3.4, I describe diﬀerent data sources and how they can be used to mea-
sure the biological relatedness for pairs of proteins. Section 3.4.6 states the ﬁnal
formula (Equation 3.30) to integrate the data. In Section 3.5 modEx, the newly
proposed module extraction method, is introduced. modEx is a heuristic that could
be applied to solve diﬀerent optimization problems. These problems are stated in
Section 3.5.2, their complexity is analyzed in Section 4.5.2. Weighted protein inter-
action networks constitute the input to modEx. Weights of the networks used in
the presented use cases have been calculated by the newly proposed data integration
method (Section 3.4.6). Section 3.6 states possibilities of how to assess the signiﬁ-
cance of extracted modules. In Sections 4.3, the newly proposed approaches are ﬁrst
assessed using TGF-β signaling (Section 4.3.2) and ﬁnally use cases of how they can
be applied to complement the analysis of MoA are given based on two exemplarily
selected compounds inhibiting TGF-β signaling (Section 4.3.3).
Section 3.7 explains how the newly proposed integration method and modEx are
compared to widely accepted approaches, namely STRING [55] and jActiveMod-
ule [48]. The comparisons to these approaches is described in Section 4.4.
Results are discussed in Chapter 5. Sections 5.2 and 5.3 evaluate the general
ﬁndings for the newly proposed data integration method and for modEx, respec-
tively. Assessments of the methods with respect to TGF-β signaling and analysis
of mode of action are discussed in Section 5.4. This section also comments on the
comparison to STRING and jActiveModule.
Finally, I conclude my work in Chapter 6 and give a perspective on possible future
work.
Chapter 2
Literature Review
In this chapter, I give an overview of existing approaches related to this thesis.
In Section 2.1, I describe the biological system used for the underlying experi-
ments [52, 54]. In the remaining sections, I review work available in the ﬁeld of
computational biology that could be helpful for the analysis of mode of action.
Section 2.2 describes existing methods for data integration, Section 2.3 gives an
overview of gene expression analyses which could be applied to get insight in the
underlying biological processes.
2.1 Biological System Used
2.1.1 TGF-β Signaling
The transforming growth factor β (TGF-β) family is composed of structurally re-
lated cytokines which eﬀect processes like morphogenesis of many organs and tissues
as well as proliferation, diﬀerentiation, migration and apoptosis of many diﬀerent
cell types [59]. Examples are TGF-β1, TGF-β2, TGF-β3, the family of activins and
nodal. The basic TGF-β signaling system consists of two receptor serine/threonine
protein kinases (TGF-β receptor types I and II, TGF-βR1 & R2) and the SMAD pro-
teins. Figure 2.1 schematically displays the pathway in a simpliﬁed way, a more bio-
logical representation is given in Appendix A.1. Components of this pathway, which
is brieﬂy summarized in the following, have been studied extensively [59, 6164].
Prior to activation of TGF-β signaling, factors like SARA (SMAD Anchor for
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Figure 2.1: Schematic representation of the TGF-β signaling pathway. Ba-
sic molecular events involved in TGF-β signaling via SMAD proteins. At least three,
and perhaps four to ﬁve amino acid residues of TGF-βR1 must be phosphorylated to
fully activate the protein [5658]. For simplicity, only one P is depicted per TGF-βR1
to indicate overall phosphorylation/activation. Also for the the SMAD2/3 complexe,
we only depict one P, though the activation is achieved through two phosphoryla-
tions of two amino acid residues in both, SMAD2 and SMAD3 [59, 60]. A more
detailed, biological representation is displayed in Appendix A.1. TF: Transcription
factor, P: Indicates phosphorylation, i.e. activation.
Receptor Activation) recruit the regulated SMADs (R-SMADS) into proximity of
the TGF-β receptor kinases. Signaling is initiated by binding of a TGF-β ligand
dimer to TGF-βR2. The activated TGF-βR2 in turn recruits TGF-βR1 to build a
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heterotetrameric complex with the ligand dimer [61]. The serine/threonine kinase
region of TGF-βR2 catalyzes the phosphorylation of serine residues of TGF-βR1.
Activated TGF-βR1 further propagates the signaling by phosphorylation and subse-
quent activation of SMAD2 and SMAD3, the R-SMADS. Phosphorylation induces
a conformational change of R-SMADs which leads to dissociation from the receptor
complex and SARA. The free and phosphorylated R-SMADs have a high aﬃnity to
form heteromeric complexes with common-mediator SMAD (co-SMAD), SMAD4.
These phosphorylated R-SMAD/SMAD4 complexes enter the nucleus where they
partner with other transcription factors resulting in cell-state speciﬁc modulation of
transcription (Figure 2.1) [64].
TGF-β signaling is regulated at several levels. First, the access of the R-SMADs
to activated TGF-βR1 is controlled by SARA. Second, the E3 ubiquitin ligase,
SMAD ubiquitination regulatory factor-2 (SMURF2), attacks cytoplasmic R-SMADs
which leads to proteasomal degradation of R-SMADs. Third, SMAD7, the in-
hibitory SMAD (I-SMAD), acts antagonistically and inhibits receptor mediated
activation of R-SMADs. It also associates with SMURFs to form the SMAD7-
SMURF complex after TGF-β stimulation and ubiquitinates the receptors on the
cell surface or endosomal membranes; these are then targeted for degradation in pro-
teasomes and lysosomes [65]. The oncoprotein c-Ski functions as a direct antagonist
of TGF-βR1 [66]. Further, STRAP1 enhances the inhibitory activity of SMAD7 by
binding to TGF-βR1 and SMAD7 [67]. Another level of control of the SMAD path-
way is via the regulation of nuclear accumulation of SMADs, by the Ras-extracellular
signal kinase (ERK) pathway. SnoN (SKIL) constitutes a self-regulatory mechanism
of TGF-β signaling. Expression of SnoN is activated by TGF-β signaling. On the
one hand, SnoN regulates TGF-β signaling by binding to SMADs to block tran-
scriptional activation. On the other hand, nuclear R-SMAD-SMURF complexes
recruit transcriptional repressors SnoN for ubiquitin-mediated degradation and thus
down-regulate the repressor. Thus, TGF-β signaling causes degradation of SnoN,
releasing SMADs to regulate transcription, but also activates expression of SnoN to
down-regulate SMAD signaling at later times [67].
There are also non-SMAD mediated signaling events [68]. For instance, TGF-βR1
can mediate JNK signaling by interacting with E3 ubiquitin ligase TRAF6 and sub-
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sequent activation of TAK1 and the MKK3/4, a mitogen activated protein kinase ki-
nase complex, to trigger TAK1-p38/JNK pathway-dependent apoptosis [69,70] (Ap-
pendix A.1).
2.1.2 Diseases Related to TGF-β Signaling
Malfunctions within the TGF-β signaling pathway may result in cancer, ﬁbrosis and
diverse hereditary disorders [7173]. During cancerogenesis the function of TGF-β
has been shown to be dependent on the tumor state [7476]. On the one hand,
TGF-β acts as tumor suppressor by inhibiting the proliferation of normal epithelial,
endothelial haematopoietic cells, and early epithelial cancer cells. In early cancers,
for instance, cells are still subject to TGF-β-mediated growth inhibition. On the
other hand, once tumorgenesis has been initiated tumor cells escape this growth
control and produce high levels of TGF-β resulting in promoted tumor growth
and metastasis. Dumont et al. [76] revealed that induction of epithelial mesenchy-
mal transition (EMT) leads to repression of CDH1 through histone deacetylation.
Longterm silencing is maintained by subsequent promoter hypermethylation. Fur-
ther, Chou et al. [75, 77, 78] could show that such epigenetic eﬀects contribute to
the disruption of TGF-β signaling in ovarian cancer. Agents that inhibit epigenetic
modifying enzymes like DNA methyltransferases and Histone deacetylases are in-
vestigated as cancer therapies [78]. Since activation of TGF-β signaling can induce
EMT trough epigenetic silencing, blocking TGF-β signaling could possibly reverse
the epigenetic modiﬁcations thereby preventing or even reversing EMT. Indeed this
could be achieved for a mesenchymal breast cancer cell line [79].
Fibrosis, goblet cell hyperplasia and smooth muscle thickening are implications of
diseases like asthma, chronic obstructive pulmonary disease (COPD), and idiopathic
pulmonary ﬁbrosis (IPF) [80,81]. Among other growth factors and cytokines, TGF-β
is highly expressed in ﬁbrotic tissues and up-regulates the expression of adhesion
molecules required for the recruitment of monocytes and neutrophils which both
initiate inﬂammatory responses. Furthermore, TGF-β plays a pivotal role in the
biosynthesis and turnover of extracellular matrix (ECM) proteins like collagens,
ﬁbronectin and proteoglycans, thereby contributing to ﬁbrosis and smooth muscle
cell proliferation [82].
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Figure 2.2: Therapeutic groups for drugs targeting TGF-βR1 or TGF-β.
Displayed are the percent of drugs investigated in diﬀerent therapeutic groups. In total,
Thomson Reuters' Integrity returns 78 drugs targeting TGF-βR1 or TGF-β which are or
have been tested (June 2011). 68 are reported to be in the phase of biological testing, 9 are
listed under pre-clinical testing, and even one, Fresolimumab [83], a monoclonal antibody
against TGF-β1-3, has entered Phase 2.
2.1.3 Conclusion
TGF-β signaling is a relatively well studied pathway with high therapeutic potential.
Clearly, inhibition of TGF-βR1 holds promise for the treatment of ﬁbrotic diseases
and cancer. This is also reﬂected by Integrity [84] as displayed in Figure 2.2. Several
small molecules inhibiting TGF-βR1 have been proposed [1]. Some of them have
been sucessfully applied to prevent tumor progression in human cancer [85, 86].
Most known TGF-βR1 inhibitors occupy similar positions in the ATP pocket of the
TGF-βR1 kinase domain. As these are domains conserved in several kinases [8789],
this approach holds potential for cross reactivity between oﬀ-target kinases and the
compounds. Boehringer Ingelheim provided a set of 7 compounds which target the
ATP binding cassette of TGF-βR1, one of the initial components of the pathway.
Since patents are held for these compounds, we are granted freedom to operate. This
is the ideal pre-requisite to be able to conduct an in-depth and thorough analysis of
mode of action for both, on- as well as oﬀ-target eﬀects. We do so by ﬁrst using state-
of-the-art methods and in a later step develop new computational methodologies that
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could be applied to support and streamline necessary follow up wet-lab experiments
in future projects.
2.2 Existing Methods for Data Integration
As more and more diverse and even high throughput technologies get available, more
and more data is generated that could help to explain biological processes. These
data usually originate from diﬀerent sources like proteomics and genomics. To be
able to conduct computational analyses that make use of diverse data, the integra-
tion of this knowledge is an important step. In this section, I give an overview of
existing methods for data consolidation and integration.
All the methods described in this section are based on protein interactions. A pro-
tein interaction refers to two proteins that either show a direct physical interaction
or that are functionally associated in a biological system. We do not refer to ge-
netic linkage which in contrast describes the tendency of genetic loci to be inherited
together. In a theoretical setting, protein interactions are commonly represented as
graphs.
Deﬁnition 2.2.1. Graph theoretical representation of protein interactions.
Protein interactions can be represented as an undirected graph G=(V,E).
The set of nodes/vertices V refers to the proteins/genes, additionally,
each pair of interacting proteins {vi, vj}⊆V , {i, j}∈N is represented by
an undirected edge evi,vj ∈E.
As each protein is encoded by a gene, I do not strictly diﬀerentiate between these
two terms and, in the graph representations, use them interchangeably throughout
the thesis. Further, the terms graph and network are used interchangeably.
Based on these graphs, additional data could be integrated. This could be done
by giving diﬀerent weights to the edges of the graph based on prior knowledge.
Deﬁnition 2.2.2. Edge-weighted graph.
An edge-weighted graph is a pair (G,ω), where G = (V,E) is an undi-
rected graph and ω : E → R is a weighting function assigning a weight
ω(vi, vj) to all evi,vj ∈ E.
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The weighting function ω could for example describe the probability of a real
physical interaction or the degree of biological relatedness, i.e. the functional asso-
ciation, of two connected proteins based on prior knowledge.
Various approaches for the integration of heterogeneous data sources have been
applied to the prediction of protein function as well as for the generation of function-
ally linked gene networks. The ﬁrst ones have been proposed by Marcotte et al. [90]
and Yanai et al. [91], applying the intersection or the union of distinct sets of evi-
dence, respectively. More sophisticated approaches have been, for example, proposed
by von Mering et al. [55], by Lee et al. [92, 93], and by Linghu et al. [94, 95]. They
are described in more detail in Sections 2.2.5 to 2.2.7.
2.2.1 iRefIndex
Multiple databases/repositories exist that contain information about protein inter-
actions. Interaction data for a single protein could be spread across these databases.
Razick et al. [96] propose a method to consolidate the information of diﬀerent pro-
tein interaction databases. They integrated data from BIND [97, 98], BioGrid [99],
DIP [100], HPRD [101,102], IntAct [103,104], MINT [105], MPact [106], MPPI [107]
and OPHID [108]. Based on the primary sequence of the respective proteins as well
as their taxonomy identiﬁers, a unique key for a protein interaction as well as for
each participant protein is generated. Thus, the same key is only generated for
identical pairs of protein sequences and taxonomy identiﬁers. Thereby, it is possi-
ble to ﬁlter for redundant information contained in the diﬀerent protein interaction
databases. The resulting interaction Reference Index (iRefIndex) is provided in
PSI-MITAB 2.5 [109], via a queryable web server (iRefWeb) as well as via a plug-in
(iRefScape) for Cytoscape [110] and via a web service. Based on this data, a graph
G describing a consolidated set of protein iteractions can be derived.
2.2.2 Michigan Molecular Interactions (MiMI)
MiMI [111, 112] provides access to knowledge and data that was merged and inte-
grated from numerous databases. Each repository for protein interaction data has
its own data format, molecule identiﬁer, and supplementary information. Molecules
that may have diﬀerent identiﬁers but represent the same entity are merged. Thus,
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MiMI allows the user to retrieve information from diﬀerent databases at once, high-
lighting complementary and contradictory information. Because the merge process
is an automated process, and no curation occurs, any errors in the original data
sources will also exist in MiMI.
MiMI gives access to the following information:
• Information on genes like Gene Ontology annotations [113], interactions, lit-
erature citations, compounds, and annotated text extracted through NLP.
• Link-outs to tools to analyze overrepresented MeSH terms for genes of interest,
read additional NLP-mined text passages, and explore interactive graphics of
networks of interactions
• Link-outs to PubMed and NCIBI's MiSearch interface to PubMed for better
relevance rankings
• Querying by keywords, genes, lists or interactions
The MiMI database lists genes together with supplementary information like inter-
actions, Gene Ontology information, Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways [114,115] the gene occurs in and relevant publications.
Data in MiMI can be accessed in three diﬀerent ways, via a web-interface, via
a web-service, and as PSI-MITAB formatted ﬂat ﬁle. The PSI-MITAB ﬁles only
represent a subset of the data available in MiMI. While UniProt and RefSeq iden-
tiﬁers are included for each interactor, provenance is only included for parts of the
interactions. Pathways and metabolomics data is not included at all. To visualize
interactions of interest, a Cytoscape plug-in is available.
2.2.3 PINA
The Protein Interaction Network Analysis (PINA) [116,117] system is an integrated
platform for protein interaction network construction, ﬁltering, analysis, visualiza-
tion and management. It integrates protein-protein interaction data from six public
curated databases and aims to supply a complete, non-redundant protein interac-
tion dataset for six model organisms. PINA allows users to either edit the networks
generated from the public data, or combine them with uploaded private interactions
to build more complete protein-protein interaction networks. Moreover, it provides
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a variety of built-in tools to ﬁlter and analyze the network for gaining more focused
insight. These analyses include enriched GO term and KEGG pathways identiﬁca-
tion, topology feature calculation, identiﬁcation of topologically important proteins
in the interaction network, and identiﬁcation of common interacting proteins. Net-
works can be ﬁltered based on annotation or based on the semantic similarity score
between annotated GO terms of interacting proteins.
Interaction networks can be downloaded in GraphML format, PSI-MITAB for-
mat or PINA tab-delimited format, complete and annotated lists of protein-protein
interactions (PPI) for the diﬀerent organisms can be obtained in PSI-MITAB for-
mat. Registered users can save protein interaction networks generated from user
query or the output of the analysis tool on the server for further analysis.
2.2.4 Distributed Annotation System for Molecular Interac-
tions (DASMI)
DASMI [118] is based on the decentralized client-server architecture of the Dis-
tributed Annotation System [119] and consists of a data exchange speciﬁcation,
interaction data servers, and visualization clients. DASMI provides a collection of
protein-protein interaction datasets and domain-domain interaction datasets. Addi-
tionally, two systems can be used to assess the conﬁdence of interactions: FunSim-
Mat and Domain support. FunSimMat calculates the similarity of genes based on
their GO annotations. Domain support is based on domain interactions that have
been derived from crystal structures or were computationally predicted.
For deriving the data, a web server, DASMIweb [120], can be used. It is also
possible to perform queries in batch mode. Finally, DASMI oﬀers the possibility to
integrate interaction data from PSI-MI XML ﬁles.
2.2.5 STRING
One of the ﬁrst and most popular methods for data integration was proposed by
von Mering et al. [121]. They introduced a Search Tool for the Retrieval of In-
teracting Genes/Proteins (STRING). In the underlying database, information on
possible protein-protein associations is aggregated. This database does not only
2. Literature Review 24
focus on direct protein-protein interactions but also links functionally associated
pairs of proteins. Version 8.3 of STRING covers about 2.5 million proteins from
630 organisms. Protein interactions are scored and weighted by a quantitative in-
tegration of predictions based on genomic context, high-throughput experiments,
co-expression and previous knowledge as available in protein interaction databases
and literature as sources. For each individual source k, raw scores are calculated
and benchmarked against a set of trusted true associations taken from KEGG as
a gold standard. A predicted association {vi, vj} is counted as a true positive as-
sociation if the respective proteins vi and vj occur in the same KEGG pathway.
The true positive rate referred to as conﬁdence score S˜k(vi, vj) generally represents
the probability of ﬁnding the linked proteins within the same KEGG pathway. Un-
der the simplifying assumption of independence for the diﬀerent sources used, the
k individual scores for a pair of proteins vi, vj are combined in a naïve Bayesian
fashion:
Svi,vj = 1−
∏
k
(1− S˜k(vi, vj)),
were k refers to the k-th source and S˜k(vi, vj) to the conﬁdence score derived based
on the k-th source. Svi,vj and the respective protein pairs {vi, vj} can then be used
to deﬁne an edge weighted graph G = (V,E) with edge weights ω(evi,vj) = Svi,vj
(see Deﬁnition 2.2.2, page 20).
2.2.6 Log Likelihood Score as Method to Integrate Hetero-
geneous Data Sources
The method proposed by Lee et al. [92,93] is based on Bayesian statistics applying a
log likelihood score (LLS). Based on each data set to integrate, an odds ratio is cal-
culated. The odds ratio represents the likelihood that a pair of genes is functionally
linked. If P (L|E) represents the probability that two genes {vi, vj} are functionally
linked given a dataset E, P (L¯|E) gives the probability that the two genes {vi, vj}
are not linked, and P (L) is the unconditional probability that two genes vi, vj are
functionally linked, then the odds ratio (OR) that a given pair of proteins vi, vj is
functionally linked is given by:
OR(L,E) =
P (L|E)/P (L¯|E)
P (L)/P (L¯)
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Here, P (L)/P (L¯) represents the prior odds. It is estimated by the number of gene
pairs with a shared functional annotation divided by the number of gene pairs
without any shared function based on a single source of functional annotation, e.g.
KEGG. P (L|E)/P (L¯|E) represents the posterior odds. It is estimated by the num-
ber of gene pairs that share functional annotation and that are supported by the
given evidence E divided by the number of gene pairs that do not share functional
annotation based on the given evidence E. To create an additive score such that
linkage information OR(L,E) calculated based on diﬀerent evidence E can be com-
bined, the log likelihood score is ﬁnally calculated as LLS = ln(OR(L,E)), where
ln is the natural logarithm.
To combine diﬀerent kinds of evidence, Lee et al. propose to link the LLS scores
calculated for each evidence using a weighted sum [92, 93]. This weighted sum is
based on a Bayesian approach as it already had been used by Jansen et al. [122],
by von Mering et al. [55], or by Troyanskaya et al. [123]. Bayesian approaches
assume independence for the individual data sets to integrate. As this can not
be generally assumed for biological data, in contrast to these previous methods,
Lee et al. propose an heuristic modiﬁcation of the strict Bayesian approach. The
resulting weighted sum (WS) incorporates the relative weighting of the data and
captures simple aspects of their relative independence either in an exponential [92]
WSvi,vj =
n∑
d=1
LLSd
Dd−1
,
or in a linear manner [93]
WSvi,vj = LLS0 +
n∑
d=1
LLSd
D · d , for all LLS ≥ T.
LLSd represents the LLS based on a single data set d, where d = 1, ..., n, D ∈ [1,∞)
represents the degree of dependence between the diﬀerent data sets, and d is the
rank index of the n log likelihood scores for the given gene pair vi, vj. D is chosen
such that it optimizes the accuracy and coverage on a benchmark, e.g. KEGG. T is
used as a threshold to exclude noisy low scoring LLS. The calculated WSvi,vj can
be used to derive an edge-weighted protein interaction graph G = (V,E) with edge
weights ω(evi,vj) = WSvi,vj (see Deﬁnition 2.2.2, page 20). The authors could show
that both methods perform better compared to the naïve Bayesian approach and
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successfully applied them to score probabilistic functional networks for yeast.
2.2.7 Functional Linkage Network
Linghu et al. [94, 95] apply machine learning techniques to combine various data
sources to construct so-called functional linkage networks. In these edge-weighted
networks nearest neighbors are likely to be functionally related. They use such
networks either to assign function to unannotated proteins [94] or to prioritize disease
genes [95].
2.2.8 Conclusion
Drawbacks of MiMI, PINA and DASMI in our opinion are that all the information
that can be downloaded is only listed and not used to describe the associations of
pairs of genes or proteins like it is the case for STRING. They are appropriate to
obtain ﬁrst information on a gene but are not so much useful for deeper follow-up
analyses where the association between diﬀerent genes and the related biological
processes are of interest. The advantage of DASMI and PINA over MiMI are the
availability of conﬁdence scores, which could be used as a basis for further data
integration.
iRefIndex provides a sound basis for protein interaction data which I will use as
one source of data in this thesis. It does not integrate any additional information,
however, this is also out of the scope of the index. To our knowledge, STRING con-
stitutes the most comprehensive set of protein-protein associations available. Thus,
we decided to integrate it in our analyses.
The drawback of the described approaches by LLS [92, 93] and STRING [55] to
score pairs of proteins are that they combine diﬀerent scores in a Bayesian fashion,
for which independence of the individual scores is a prerequisite. This does often
not hold true for most biological data. Although Lee et al. [93] try to overcome this
hurdle by utilizing their weighted sum approach, it is still an issue when combining
evidence which possibly is not independent from each other.
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For many machine learning techniques it is rather diﬃcult to judge where the
calculated scores originate from. In contrast, I focus on developing a transparent
method for scoring. Thereby, it should be possible to judge how sound the score
is with respect to biology. Moreover, we always need a gold standard to perform
machine learning or to calculate LLS or STRING scores. Our knowledge about the
role of genes/proteins is far from complete and still accumulating and evolving, thus
the gold standard, a set of true positives and true negatives, is not the complete
truth. A method independent from such a preliminary truth would be beneﬁcial
to be as unbiased as possible. Further, it is cumbersome to extend the described
scores by personal data as for example derived by wet-lab experiments. None of
the proposed methods makes it possible to easily integrate speciﬁc knowledge about
the biology under investigation; expert biologists would possibly like to give higher
weights to certain evidence.
In summary, we are seeking for an easy to use as well as easy to interpret scor-
ing function to describe the pairwise relatedness of proteins. This score should be
independent from a gold standard, highly ﬂexible by allowing easy integration of
newly gained knowledge and it should oﬀer the possibility to diﬀerentially weight
individual evidence.
2.3 Existing Methods to Resolve Processes Aﬀected
by Gene Expression Changes
Methods that, based on gene expression experiments, could be used to identify
condition responsive subnetworks out of various types of molecular networks already
exist [4851, 124, 125]. These methods focus on the detection of subnetworks or
modules that are enriched in deregulated genes. Thus, I refer to them as module
detection methods. Among the most widely used are for example jActiveModule [48],
the method proposed by Cabusora et al. [125], GXNA [50] and the methods proposed
by Guo et al. [49] and Dittrich et al. [51].
Deﬁnition 2.3.1. Subnetwork/Module.
Let G = (V,E) be an undirected graph. A graph G′ = (V ′, E ′) is a
subgraph of G if and only if V ′ ⊆ V , E ′ ⊆ E and for all evi,vj ⊆ E ′ ⇒
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{vi, vj} ⊆ V ′.
A subgraph does not need to have all possible edges present in E. If a subgraph
has every possible edge, it is referred to as an induced subgraph:
Deﬁnition 2.3.2. Induced subgraph/module.
Let G = (V,E) be a graph and let V ′ ⊆ V be a subset of vertices of G.
The subgraph of G induced by V ′ is the subgraph G′ = (V ′, E ′) such that
for all {vi, vj} ⊆ V ′, evi,vj ∈ E ⇔ evi,vj ∈ E ′. That is, G′ contains all
the edges of G that connect elements of V ′ ⊆ V .
Deﬁnition 2.3.3. Node-weighted graph.
A node-weighted graph is a pair (G,ω), where G = (V,E) is an undirected
graph and ω : V → R is a weighting function assigning a weight ω(v)
to every node v ∈ V .
Usually the module identiﬁcation tasks are formulated as optimization problems.
The objective function is based on a subnetwork or module score evaluating the sig-
niﬁcance of diﬀerential expression [48,50,51,125,126] and/or co-expression [49,127].
Based on an edge- and/or node-weighted graph (Deﬁnitions 2.2.2, page 20, and 2.3.3,
page 28, respectively), subnetworks optimizing the objective function are usually de-
termined by heuristic searches or exact solutions using integer linear programming.
In this section, I brieﬂy describe the existing approaches and summarize their
pros and cons thereby concluding why further development is necessary.
2.3.1 jActiveModule
jActiveModule was proposed by Ideker et al. [48]. It constitutes one of the most
widely used and accepted module identiﬁcation methods. In this approach, nodes,
i.e. proteins, of a protein-protein and protein-DNA interaction network are weighted
according to p-values derived by diﬀerential expression analysis. To get an additive
weight, the inverse of the normal cumulative distribution function (CDF) Φ is used
to transform the p-values pi for node vi: zi = Φ−1(1 − pi). Thus, lower p-values
correspond to higher zi. Based on these zi Ideker et al. propose to optimize modules
G′ = (V ′, E ′) with respect to zG′ = 1√k
∑
vi∈V ′ zi, where |V ′| = k. To determine
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whether the score of the network is higher than what would be expected randomly,
a z-score transformation is used. Gene sets of size k are randomly sampled and zG′
is computed for each of the sampled gene sets to estimate the mean µk and the
standard deviation σk for random G′s. Then the transformed score
sG′ =
zG′ − µk
σk
(2.1)
is N(0, 1) distributed and the values calculated for diﬀerent modules G′ are compa-
rable.
Input: A node-weighted graph G = (V,E), a number n of iterations, and
a temperature function Tj which decreases with increasing j.
Output: An working subgraph Gw of G and its highest-scoring component
G′ = (V ′, E ′).
01 randomly set every node v ∈ V as active with probability 0.5
02 for j = 1 . . . n do
03 randomly pick a node v ∈ V and invert its state
04 identify the highest scoring component sG′,j of Gw
05 if sG′,j > sG′,j−1 do
06 keep the state of v
07 else
08 keep the state of v with probability p = e(sG′,j−sG′,j−1)/Tj
09 done
10 done
11 return Gw and its highest-scoring component G′.
Figure 2.3: Algorithm proposed by Ideker et al. Brief description of the al-
gorithm as implemented in the Cytoscape plugin jActiveModule. Throughout the
algorithm, an `active/inactive' state is associated with each node. Gw denotes the
working subgraph induced by the active nodes. At each iteration j, sG′,j denotes
the score sG′ (Eq. 2.1, page 29) for the highest-scoring component of Gw. Tj denotes
the temperature that is decreasing with increasing j.
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The authors provide an NP-hardness proof for a simpliﬁed variant of their central
search problem, namely for Maximum Weight Connected Subgraph. Since
NP-hard problems are computationally expensive, they propose a simulated anneal-
ing algorithm to optimize their score. Simulated annealing (SA) refers to the way
in which a metal cools and freezes into a minimum energy structure during the an-
nealing process. In analogy to the annealing process, SA is a heuristic technique for
trying to ﬁnd the global optimum of an objective function that may possess sev-
eral local optima. Probabilistically accepting worse solutions allows the algorithm
to explore more of the possible space of solutions, thereby escaping local optima.
p = e−∆/T is the probability with which worse solutions are accepted. T , by analogy
with the original application known as the system temperature, is a control pa-
rameter which decreases over time, i.e. wi each iteration, and ∆ is calculated as the
change of the objective function. SA is used in the implementation of jActiveModule
as brieﬂy summarized in Figure 2.3.
2.3.2 Rajagopalan and Agarwal
Rajagopalan and Agarwal propose an improvement over the jActiveModule algo-
rithm (see Section 2.3.1) [124]. They argue that about half the nodes in the
network have positive scores zi. This leads to the generation of arbitrarily large
modules. By introducing a parameter β to reduce the number of nodes with pos-
itive zi, smaller modules are generated in general. For highly connected networks,
however, extracted modules stay large. According to the authors, the higher the
degree of a node, the more likely one of the neighbouring nodes has a high positive
zi which in turn leads to larger modules. Thus, based on the degree of a node, the
authors introduce an edge penalty to further reduce the scores for highly connected
nodes. Thereby, they ﬁnally achieve smaller subnetworks.
In brief, Rajagopalan and Agarwal propose the following heuristic to extract
subnetworks:
1. Group nodes with positive score into subnetworks using breadth-ﬁrst search.
2. Merge subnetworks via non-positive nodes if this produces a higher score.
3. Apply a ﬁnal pruning step. This step checks whether removal of nodes with a
small positive individual score increases the overall score.
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2.3.3 Cabusora et al.
Cabusora et al. [125] base their analysis on a network derived from protein inter-
actions, metabolic reactions and co-expressed genes. As an example they use in-
formation available for Mycobacterium tuberculosis. Gene expression data for drug
treatment and respective controls are used to score the network. In contrast to
Ideker et al. [48], Cabusora et al. calculate scores for the edges and not for the
nodes.
Let vi and vj be two gene products in the network that are connected by an
edge evi,vj . Further, let pi be the p-value derived for vi or let Pi be the vector
of p-values for gene vi in case multiple p-values are available. The weight zi,j of
edge evi,vj is then either calculated as the product probability pi,j = pi · pj or as
the empirical correlation pi,j = cor(Pi, Pj) in case multiple p-values are available.
Following Ideker et al., Cabusora et al. transform these values into an additive weight
zi,j = Φ
−1(1−pi,j). The objective function which is to be optimized for a subnetwork
G = (V ′, E ′) states:
zG′ =
1√
m
∑
evi,vj∈E′
zi,j , where m = |E ′|.
As already proposed by previous approaches, this score is normalized towards ran-
domly sampled subnetworks of size n: sG′ =
zG′−µn
σn
.
The general idea of the algorithm is to calculate the k shortest paths between
selected seed nodes. Brieﬂy, it works as follows:
1. Integers k and l as well as seed nodes (in their exemplary study, Cabusora
et al. use the most signiﬁcantly deregulated genes) are chosen as input to the
algorithm.
2. Shortest, second-shortest, third-shortest,... up to the kth-shortest path be-
tween all pairs of seed nodes with restricted maximal path length l are calcu-
lated.
3. G′ is composed of all edges and nodes that are on the paths calculated in 2..
Based on subnetwork G′, zG′ is calculated as previously deﬁned.
2. Literature Review 32
This approach guarantees a best scored subnetwork for a set of seed nodes. To obtain
an optimized set of seed nodes for a better scoring sub-network Cabusora et al.
propose a heuristic. They reduce the problem by ﬁnding best scoring pathways
between pairs of seed nodes selected based on a rank-weighted random distribution.
Again, the shortest pathway between these nodes is identiﬁed, subnetwork scores
are calculated and the node pair recorded. After convergence to highest scoring
pathways, a sub-network G′ and its corresponding score sG′ is computed using nodes
with the highest pathway score.
2.3.4 ToPNet
Hanisch and Sohler [128,129] developed a framework called ToPNet. It oﬀers several
possibilities to analyze biological networks, e.g. navigating the network based on the
neighborhood of a gene (iterative exploration). I will brieﬂy describe the application
of Hanisch's and Sohler's pathway queries and signiﬁcant area search, since these
are related to the methods I am focusing on.
Signiﬁcant area search
A signiﬁcant area search is performed in the following way:
1. Select seed nodes, e.g. based on a gene expression experiment.
2. Greedily expand around this seed node by including the most signiﬁcant neigh-
bors.
3. Determine the signiﬁcance of the selected gene sets using Fisher's inverse χ2
method [130].
Pathway queries
These kinds of queries are XML-based and allow for complex and at the same time
speciﬁc queries which could also take into account gene expression data, gene anno-
tation like GO, information on transcriptional regulation, and so forth. Following
example is given by Sohler et al. [128]: We look for kinases that are directly con-
nected to both Fus3 and Kss1. Fus3 and Kss1 must be connected via at most one
additional protein to a transcription factor that regulates genes that are diﬀeren-
tially expressed in knockout experiments. In their publication they also display an
XML template which is used to perform a similar query.
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2.3.5 Graph Based Iterative Groups Analysis (GiGA)
Breitling et al. [131] include GO annotation as evidence into their analysis. They do
this by introducing evidence graphs, bipartite graphs which contain two kinds of
nodes, one for genes and one for the associated evidence. Such a graph is converted
into a simple graph by introducing edges between all pairs of genes that share the
same evidence node and subsequently removing all evidence nodes. Additional to
this graph, a list of genes ranked according to absolute fold change is used to label the
genes in the graph with their corresponding ranks in that list. All genes that are not
contained in the list are removed from the graph. In short, the algorithm proposed
by Breitling et al. [131] works as follows: First, nodes that are of lower rank (have
higher fold change) than all their neighbours are selected as seed nodes. These
seed nodes are iteratively extended to include their most signiﬁcant neighbours,
and p-values based on the cumulative hypergeometric distribution are calculated
for the extended modules in each iteration. The extension is stopped either after
all nodes reachable from the actual module are included or after a maximum size
is reached. For each modules generated in this way, that module is selected as
regulated neighbourhood that yielded the smallest p-value.
2.3.6 MATISSE and CEZANNE
In 2007 Ulitsky et al. proposed a method for Module Analysis via Topology of
INteractions and Similarity SEts (MATISSE) [132]. The method can be based on
any interaction network G = (V,E). In their publication they show results based on
a protein-protein and protein-DNA interaction network for Saccharomyces cerevisiae
as well as on a protein-protein interaction network for human. Additional to the
network G, the algorithm takes a symmetric similarity matrix S as input. The
entries sij of S describe the similarity between genes i and j. This similarity can,
for example, be calculated as the Pearson correlation between the respective gene
expression patterns. S is further used to calculate an edge weight. Ulitsky et al.
deﬁne two co-expressed genes as mates. Each edge in the network is weighted
using the log-likelihood score of the adjacent genes being mates compared to not
being mates. By this means, they deﬁne the similarity graph GS = (Vsim, ES) with
Vsim ⊆ V and ES = (Vsim × Vsim). Based on this input, the algorithm tries to
detect jointly active connected subnetworks (JACS). JACS are deﬁned as disjoint
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sets U1, U2, ..., Um that induce connected subgraphs in G and heavy subgraphs in
GS. Since this problem is NP-hard, the authors propose several heuristics which are
all split into three phases:
1. Detection of small, high-scoring gene sets as seeds.
2. Improvement of the seed.
For optimizing the seeds identiﬁed using one of the previous heuristics a greedy
approach is used. All seeds are optimized simultaneously either by addition
of an unassigned node to an existing JACS, removal of a node from a JACS,
exchange of a node between JACSs, or merge of two JACSs. The algorithm
keeps those moves that improve the overall score of the solution and that main-
tain the connectivity of the JACSs. If no such move exists, nodes ∈ V \ Vsim
are removed as long as they do not disconnect any of the JACS. As soon as
no nodes can be removed, the algorithm terminates.
3. Filtering based on signiﬁcance.
Empirical similarity scores as well as empirical p-values are calculated for
JACS by randomly sampling gene groups of the same size. Based on these
p-values and the average similarity scores, the JACS are ﬁltered to obtain the
most relevant ones.
In 2009 the same authors proposed an improvement over MATISSE [133]. The
diﬀerence betweenCo-Expression ZoneANalysis usingNEtworks, CEZANNE, and
MATISSE is that for CEZANNE every edge e ∈ E is weighted by the probability
p(e) ∈ [0; 1] that the edge, i.e. the interaction, exists. The authors applied their
method to a network and conﬁdence values for S. cerevisiae which were based on
puriﬁcation enrichment (PE) scores [134]; this score measures the likelihood of ob-
served experimental results given the hypothesis that an interaction is genuine rel-
ative to the likelihood of the same results if the interaction is not real. The overall
aim is to detect modules that are q-connected and have a maximum co-expression
score. A set of vertices U ⊆ V is called q-connected if for all U ′ ⊂ U the probability
that at least one edge connects U ′ with U \ U ′ is ≥ q. The problem is solved in
three steps similar to the MATISSE algorithm with the diﬀerence that during the
optimization step the q-connectivity has to be maintained. The authors showed that
q-connectivity is fulﬁlled as long as the weight of every minimum cut of the module
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under consideration exceeds T = −log(1 − q). The signiﬁcance of the optimized
modules is again determined based on empirically derived p-values.
2.3.7 GXNA
Gene eXpression Network Analysis (GXNA) is a method for module extraction that
has been proposed by Nacu et al. [50]. The authors make use of gene interaction data
available from EntrezGene [135] and KEGG [114] and combine it with expression
data. They propose several methods to score sets of genes V ′, i.e. subnetworks
G′ = (V ′, E ′) of the gene interaction network. The scores are based on the t-statistic
Tgi which is used to calculate the diﬀerential expression for gene gi.
1. Averaging the test statistics:
(a)
f1(G
′) =
1
k
k∑
i=1
Tgi , where k = |V ′|.
(b) To take into account modules that contain both, up- and down-regulated
genes the absolute value of the t-statistic can be applied
f2(G
′) =
1
k
k∑
i=1
|Tgi | , where k = |V ′|.
2. Averaging gene expression:
(a) Calculate group expression
Sj(G
′) =
k∑
i=1
Xgij
where Xgij refers to the expression level of gene i in sample j.
(b) To take into account modules that contain both, up- and downregulated
genes, the authors propose to include signs in the group expression for-
mula
Sj(G
′) =
k∑
i=1
i ·Xgij
where i = −1 if the t-statistic for gene i is negative.
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Based on these values, the t-statistic is calculated for G′:
f3(G
′) = (µ1 − µ0)/
√
σ21/n1 + σ
2
0/n0,
where µ0 and σ0 are the mean and the standard deviation of Sj(G′) for samples
of the control group, respectively. Analogously, µ1 and σ1 are the mean and
the standard deviation of the treatment group.
To extract modules, Nacu et al. propose two basic ideas, the ball B(x, r) and an
adaptive subgraph search. Both ideas are based on seed nodes that can be arbitrarily
selected. In their publication, Nacu et al. sequentially select each gene as seed node.
The ball: Compute score f(G′) for G′ = B(v, r) where B(v, r) describes the ball
centered at node v with radius r. That is, the subgraph G′ is composed of all
nodes that are connected to v by a path of length ≤ r and the edges induced
by these nodes.
Adaptive subgraph search: The basic idea is to start with a seed node v and
gradually expand around it. The authors propose two diﬀerent approaches for
expansion:
1. Randomly pick a vertex with higher probability assigned to vertices that
yield higher scores.
2. Pick a vertex such that the present subgraph has maximal score f(G′)
(greedy search).
The algorithm stops either after G′ reaches a predeﬁned size or when f(G′)
can no longer be increased.
For nodes of a high degree, B(v, r) is not very selective and rather unspeciﬁc. This
problem is addressed by adaptive search algorithms. The adaptive search algorithm
as described in the ﬁrst approach (1.) is slower, and since greedy search described
in the second approach (2.) works reasonably well, the authors propose to use the
latter method for speed and simplicity.
2.3.8 Guo et al.
In the approach proposed by Guo et al. [49], protein interactions from HPRD [101]
and DIP [100] as well as gene expression data have been used. Proteins without
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gene expression data are deleted. In this method gene expression data is used
to weight the edge e(x,y) between directly connected proteins x and y by the co-
variance of the respective expression vectors X and Y : ω(e(x,y)) = cov(X, Y ) =
cor(X, Y ) ·σ(X) ·σ(Y ), where cor(X, Y ) is the Pearson correlation of X and Y and
σ(X) and σ(Y ) their standard deviations.
Based on the edge-weighted network, Guo et al. use the following score for sub-
networks: T (G′) =
∑
e∈E′ ω(e). After standardizing this score using a z-score trans-
formation based on 10,000 randomly sampled edge sets E ′rand with |E ′rand| = k, the
objective function is given by S(G′) = T (G
′)−µk
σk
. Here, µk is the mean of the 10,000
values for T (G′rand) and σk their standard deviation. Following Ideker et al., they
solve the optimization problem using simulated annealing. Default output is the
best module contained in the optimized solution.
2.3.9 Dittrich et al.
Dittrich et al. [51] solve the module extraction problem by integer linear program-
ming. They transform the underlying optimization problem already stated by
Ideker et al. as the Maximum-Weight Connected Subgraph Problem (MWCS) to the
well studied Price Collecting Steiner Tree Problem (PCST). Ljubi¢ et al. [136] pro-
posed an integer linear programming algorithm which is currently the fastest to solve
PCST. This algorithm is applied by Dittrich et al. to solve the MWCS to optimality.
The input to their algorithm are protein interactions as provided by HPRD [101].
The proteins, i.e. the nodes present in the respective network are weighted by aggre-
gated p-values derived from gene expression data. To show the applicability of their
method, Dittrich et al. used a gene expression data set from diﬀuse large B-cell lym-
phoma [137] together with survival information from the respective patients. They
aggregate p-values derived from diﬀerential expression analysis comparing two tu-
mor subtypes and p-values derived from analysis of survival times using Cox regres-
sion [138] used to analyze the survival data. For combining the p-values, Dittrich
et al. developed an additive score where positive values represent interesting genes
and negative values denote background noise.
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2.3.10 ClustEx
ClustEx proposed by Gu et al. [139] makes use of protein-protein interaction data
taken from HPRD [101]. Additionally, they utilize gene expression data. Only
genes present on the microarray are used in the analysis. The overall aim is to de-
tect groups of diﬀerentially as well as co-expressed genes that are closely connected.
To detect the responsive gene modules, ﬁrst, diﬀerentially expressed genes are
identiﬁed. In a second step, the correlation of expression levels X and Y for genes
x and y are used to weight the edges present in the protein interaction network:
ω(ex,y) = |cor(X, Y )| .
Based on this weight, the distance between two interacting proteins x, y is calculated
as
dist(x, y) = 1− ω(ex,y) = 1− |cor(X, Y )| .
Based on dist(x, y), shortest paths are calculated between pairs of diﬀerentially
expressed genes. The diﬀerentially expressed genes are then clustered based on the
lengths of the shortest paths. Based on this clustering, genes are separated into
gene groups. To connect the diﬀerentially expressed genes, all genes on the shortest
paths between the diﬀerentially expressed genes were added such that a connected
sub-network is generated. Then the subnetwork was extended by one step, i.e. edge,
in the whole gene network. To ﬁnally obtain the responsive gene-module, the genes
contained in each of these groups need to be connected to a subnetwork. The authors
do that by using all genes and edges on the 10 shortest paths between all the pairs
of the diﬀerentially expressed genes in the extended sub-network.
2.3.11 Pandora
Although they only look at information available for yeast, Zhang et al. [140] are
the only ones who go beyond the use of interaction networks. Similar to previous in-
teraction networks, they make use of protein protein interactions but also of genetic
interactions, information on domain-domain interactions and GO annotations [113].
Since in contrast to the previously mentioned methods they want to predict path-
ways and not functional modules, they want to limit the genetic interactions that
occur in a pathway. Thus, genetic interactions are assigned a weight of 0. All other
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kind of interactions are assigned a score of 1. By investigating the GO annotations
for genes applying a method proposed by Wang et al. [141] (explained in more detail
in Section 3.4.2, pages 64 ﬀ.), they calculate a similarity score for pairs of gene prod-
ucts. Thus, for each pair of proteins, Zhang et al. derive scores based on diﬀerent
kinds of interactions as well as the GO-similarity score. Taking the average of the
scores for each pair of proteins results in the ﬁnal weight for the edge connecting
these two proteins in the interaction network. A cutoﬀ is applied to this score and
only edges passing that cutoﬀ are used to predict biological pathways in yeast.
The prediction is based on network topology. Topological similarity is calculated
using the Jaccard coeﬃcient [142] for neighboring proteins. Similar proteins are
summarized to pathways.
2.3.12 Conclusion
Table 2.1 gives an overview of diﬀerent characteristics for the methods brieﬂy re-
viewed in this section.
Apart from ToPNet and Pandora, all methods described in this section focus on
the detection of gene modules that are enriched in deregulated genes. Since nu-
merous processes are regulated by, for example, post-transcriptional modiﬁcations
one objective of this thesis is to expand the analysis beyond the transcriptional
level. Most important when analyzing mode of action is the biological interplay of
proteins. Therefore, we also want to incorporate further evidence with respect to
common biological mechanisms.
ToPNet [128, 129], as an example, allows to query for GO annotations of the
molecules contained in the network. Based on these queries, subnets are detected.
ToPNet oﬀers the possibility to perform speciﬁc queries that make it possible to in-
tegrate previous knowledge. To be able to formulate such queries, knowledge about
what is interesting and possibly even some knowledge on the biological process of
interest is needed. Thus, de novo analyses of mode of action and especially identiﬁca-
tion of oﬀ-target eﬀects is probably diﬃcult to perform using ToPNet. Further, only
very speciﬁc questions are answered and it seems impossible to answer a question
like what are the oﬀ-target eﬀects of the compound under investigation? Apart
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from that, ToPNet seems to be no longer available.
Some methods like those described in Sections 2.3.3, pages 31 f. and 2.3.9 try
to derive only one huge module to explain the biological process reﬂected by the
expression data. Further, Gu et al. state As observed in previous studies and in our
analysis, a big module usually dominates the responsive process [48, 49] [139]. We
argue that mode of action is induced by several processes that in general inﬂuence
each other. Even if an analysis results in multiple networks, it is easily possible
that more than one process, i.e. the on- and several oﬀ-target eﬀects, are covered by
one larger module. Thus, the individual eﬀects are diﬃcult to detect and interpret.
By deriving small modules, it is more likely to be able to separate diﬀerent eﬀects
represented in the biological system under investigation. Otherwise, it is impossible
to understand the biological processes taking place and how they relate to each other.
Most of the existing approaches focus on protein/gene interaction in combina-
tion with expression data. Approaches that go beyond this and integrate further
data rarely exist. Pandora integrates diﬀerent kinds of data but at the same time
does not make use of expression values. This is due to the fact that the purpose
of the method is to detect complete pathways or networks like for example present
in KEGG, but not to derive small modules explaining processes present in a gene
expression experiment. GiGA does integrate expression data, protein interactions
and GO annotations. But still the integrated GO information is only translated to
edges in a network for which the methods still tries to derive modules solely based
on deregulated genes.
The major drawback of the present methods is that they focus on diﬀerentially
expressed genes. They neglect the vast amount of biological data that could be
used to support the analyses especially with respect to the fact that not all genes
are regulated on the transcriptional level. Thus, I aim at developing a method
that constitutes a combination of approaches like jActiveModule, making use of
protein interaction data and gene expression data, and Pandora, that integrates
additional data sources. By doing so, it will be possible to extract small modules
that help revealing the eﬀects present in the expression experiment. This method will
exemplarily be applied to a gene expression experiment conducted for the analyses
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of compounds' mode of action.
2.4 Analyzing Groups of Genes
Given the outcome of a biological experiment like gene expression measurements,
we are interested in the biological processes that are related to the experiment. One
of the most prominent approaches to interpret such data is to make use of prede-
ﬁned gene groups. Such gene groups provide more biological knowledge compared
to looking at individual genes, thereby oﬀering the possibility of a more meaning-
ful interpretation in the biological context. Groups of genes can be deﬁned based
on diﬀerent sources, e.g., based on pathways as deﬁned by KEGG, Reactome, or
BioCarta. A second source are Gene Ontology terms. Here, groups of genes can
be determined by genes annotated with the respective term or any of its children
in the hierarchy (explained in more detail on pages 44 ﬀ.). Further possibilities are,
e.g. groups based on the chromosomal region in which the genes are located, genes
associated with a special disease, or groups deﬁned based on literature relevant to
the biological research question under investigation.
By identifying predeﬁned groups of genes aﬀected by the gene expression ex-
periment it is possible to relate the underlying experiment to a biological process
like the signaling cascades of a potential oﬀ-target. In Section 2.4.1 I focus on over-
representation analyses conducted using Fisher's exact test [130], GSEA [40,41], and
topGO [43]. Further, I provide a brief introduction into more holistic approaches
that do not separate the analysis of diﬀerential expression from gene set analysis in
Section 2.4.2.
2.4.1 Gene Set Enrichment
The basic idea of gene set enrichment analyses is to ﬁrst deﬁne a measure for in-
teresting genes. This could be for example fold changes and/or p-values for genes
analyzed in an expression experiment. In a second step, these interesting genes are
compared to predeﬁned groups of genes related to a certain biological process. If
interesting genes are over-represented in a special predeﬁned group, the related pro-
cess will very likely be relevant for the underlying expression experiment.
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One of the simplest tests to investigate over-representation is Fisher's exact
test [143], which has been widely used with respect to gene expression analy-
ses [43, 144, 145]. Fisher's exact test is a count-based method as it solely is based
on a count of genes meeting a speciﬁc criterion. Given a set of K genes identiﬁed
as interesting, for example genes exceeding a certain threshold of a gene-associated
score; Fisher's exact test calculates the signiﬁcance of the overlap between a prede-
ﬁned group of genes of size M and the K interesting genes with respect to the total
number of genes N . A more detailed explanation is given in Section 3.6.2 (page 75.
Count based approaches require that a set of genes is selected by some deﬁnite
criterion (hard thresholding). Thus, any information on the genes outside of this
set is not used. In contrast, methods utilizing all gene scores or gene ranks derived
based on an experiment exist. One of the most prominent ones possibly is GSEA, the
Gene Set Enrichment Analysis as ﬁrst applied by Mootha et al. [40] and described
in detail by Subramanian et al. [41]. GSEA can be divided into two steps. First,
gene-wise measures like diﬀerential expression are calculated for all N measured
genes and respective genes gi are ranked accordingly to form L = (g1, g2, ..., gN). In
their publication, Subramanian et al. [41] rank genes according to their correlation
rj to a proﬁle of interest. Second, labels are assigned to genes gj indicating whether
they belong to a gene group of interest S or not, i.e. gj ∈ S or gj ∈ S¯ = N \ S,
respectively. Walking down the ranked list L, two running enrichment scores (ES)
are calculated:
ESS(l) =
∑
gj∈S
j≤l
|rj|p
NS
, where NS =
∑
gj∈S
|rj|p
ESS¯(l) =
∑
gj∈S¯
j≤l
1
N −m , where m = |S|
The authors propose to set p = 1. If one wants to penalize sets of genes S for lack
of coherence, p < 1 could be appropriate. The ﬁnal ES is deﬁned as the maximum
deviation of ESS(l) − ESS¯(l) from 0, i.e., ES = max |ESS(l)− ESS¯(l)|. If the
maximum value for ES is higher than expected randomly, the group is enriched
with interesting genes. The signiﬁcance is calculated based on a phenotype-based
permutation test. This is essentially a test for deviation from a uniform distribution.
Drawback of permutation tests is their low power.
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topGO is a Bioconductor package implemented by Alexa et al. [43]. They propose
a gene set enrichment framework especially applicable to ontology structures like the
Gene Ontology (GO) [113]. Figure 2.4 displays a small part of the GO hierarchy
which is explained in the following.
Deﬁnition 2.4.1. Directed acyclic graph (DAG).
A directed acyclic graph (DAG) is a graph G = (V,E) with directed
edges eu→v = (u, v) that contains no path that starts and ends at the
same vertex. The root nodes R ∈ V of a DAG are deﬁned as the
nodes where no edge starts, R = {r ∈ V |@ v ∈ V : er→v}. The leave
nodes L ∈ V of a DAG are deﬁned as all nodes where no edge ends,
L = {l ∈ V |@ v ∈ V : ev→l}.
Deﬁnition 2.4.2. Ontology.
An ontology is a set of deﬁned terms or vocabularies that are given hier-
archical relationships to one another. It can be represented as a directed
acyclic graph (DAG). GO, for instance, provides a set of terms to de-
scribe the properties of proteins.
In the case of GO, the terms are used to describe and annotate proteins with
respect to their molecular function (MF), the biological processes (BP) they are
involved in, and the cellular component (CC) they occur in. Each of these three
classes, MF, BP and CC, builds a separate DAG exactly containing one root node
r. Genes associated with special attributes are assigned to the respective ontology
term which in turn is represented by a vertex/node in the DAG. The ontologies
resemble a hierarchy, ancestor terms (Deﬁnition 2.4.3) are less specialized than their
descendants (Deﬁnition 2.4.4). With respect to GO, whenever we refer to a term
of the ontology, we refer to a node/vertex in the respective DAG. In an ontology,
each gene/protein which is associated with a term is also mapped to all its ancestor
terms.
Deﬁnition 2.4.3. Ancestors of node v.
For a DAG G = (V,E), the ancestor set Vancestor(v) ⊆ V of any node
v consists of all nodes vi that are reachable from v via a directed path
P = (ev→v1 , ev1→v2 , ..., evi−1→vi). That is, all nodes on any path to the
root node of the DAG are ancestors of v.
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Figure 2.4: DAG representing parts of the Gene Ontology. Displayed is
a DAG (Deﬁnition 2.4.1, page 44) representing a small part of the Biological Process
hierarchy of the Gene Ontology. The node highlighted in red indicates the root node
(Deﬁnition 2.4.1, page 44), blue nodes are the leaf nodes (Deﬁnition 2.4.1, page 44), and
the node highlighted in orange is the lowest common ancestor (Deﬁnition 2.4.7, page 46)
of, e.g. the nodes High Density Lipoprotein Mediated Signaling and Cellular Response
to Hormone Stimulus, two of the leaf nodes. At the same time, it is a parent node
(Deﬁnition 2.4.6, page 46) of the leaf nodes Cellular Response to Epidermal Growth
Factor Stimulus, Cellular Response to Hormone Stimulus, and Cellular Response to
TGF-β Stimulus as well as of the node Cellular Response to Lipoprotein Stimulus.
Analogous to an ancestor, we deﬁne the term descendant:
Deﬁnition 2.4.4. Descendants of node v.
For a DAG G = (V,E) the descendant set Vdescendant(v) ⊆ V of any node
v consists of all nodes vi that v is an ancestor of. That is, all nodes on
any path leading from the leaves to v are descendants of v.
A more speciﬁc set of descendants is referred to as children:
Deﬁnition 2.4.5. Children of node v.
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For a DAG G = (V,E) the set of children Vchildren(v) for a node v ∈ V
consists of all nodes vi ∈ V of which v is a direct ancestor. That is,
Vchildren(v) = {vi ∈ V |evi→v ∈ E}.
Analogous, parent term is deﬁned:
Deﬁnition 2.4.6. Parent of node v.
For a DAG G = (V,E) the set of parents Vparent(v) of a node v ∈ V
consists of all nodes vi ∈ V of which v is direct descendant. That is,
Vparent(v) = {vi ∈ V |ev→vi ∈ E}.
In later sections, the term lowest common ancestor is used in the context of DAGs
representing ontologies:
Deﬁnition 2.4.7. Lowest common ancestor (LCA).
The lowest common ancestor of two nodes u, v in a DAG G = (V,E) is
denoted as LCA(u, v). It is deﬁned as the node with the maximum path
length from the root, i.e., the lowest node in G that has both u and v as
descendants (u or v are allowed to be a descendant of itself).
Not every gene is necessarily annotated to a leave node in the ontology. Due to
the interleaved structure of ontologies, calculation of enrichment is statistically even
more sophisticated than for other gene sets. In their proposed methods, Alexa et al.
consider this special structure to ﬁnd those terms in an ontology that show an
enrichment in signiﬁcant genes. Besides count-based tests like the Fisher's exact
test and tests based on gene scores or ranks of genes like GSEA, they additionally
implemented a test that is directly based on the gene expression data. Such tests are
sometimes referred to as holistic approaches. In contrast to tests like Fisher's exact
test or GSEA which at least require two separate steps, the gene-wise calculation of
a score and the test for over-representation, holistic approaches perform the whole
analyses in one go.
2.4.2 Holistic approaches
Methods that combine the analysis of diﬀerential expression and detection of en-
riched gene sets in one step are globaltest and GlobalANCOVA. These methods
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are therefore also referred to as holistic approaches. Applying these methods, it is
possible to consider small but consistent changes in expression. The methods try
to answer the question whether the global expression pattern X of a group of genes
signiﬁcantly relates to some clinical variable of interest Y like disease status or sur-
vival taking into account covariates C like time, dose, age or sex.
globaltest has been proposed by Goeman et al. [42,44]. This test was developed
for predicting clinical outcomes Y based on the expression pattern of a group of
genes X and covariates C. The hypothesis
H0 : P (Y |X,C) = P (Y |C)
is tested to decide whether gene expression X does improve the prediction for the
phenotype Y .
GlobalANCOVA has been introduced by Mansmann and Meister [45,146] and fur-
ther developed by Hummel et al. [46, 47]. In contrast to globaltest, it tries to
uncover the inﬂuence of the observed phenotype Y on the gene expression X:
H0 : P (X|Y,C) = P (X|C).
2.4.3 Conclusion
Several methods exist that are capable to reveal biological processes related to a
gene expression experiment. Except for Fisher's exact test, all methods are based
on a measure/score present for each individual gene. The most prominent one prob-
ably is GSEA. Holistic approaches directly combine the analysis of expression with
the detection of enriched gene sets. In contrast to other methods, they are capable
of considering small but consistent changes in expression.
Changes in gene expression are not necessarily the only indicator to infer mode of
action and, thus, should be considered in conjunction with further biological criteria.
Processes mediated through protein interactions as for example frequently present
in signaling cascades are essentially neglected by all enrichment methods. These
methods treat networks with potentially complex topology as an unstructured set of
genes. Further, they do not take into account feedback by transcriptional regulation.
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Such feedback can for example also be represented by protein interactions. Existing
knowledge about proteins and their relation to one another is disregarded.
Chapter 3
Methods
3.1 TGF-β Gene Expression Data
All laboratory work described in this section has been conducted by Dr. Patrick
Baum in the scope of his PhD thesis [52]. It is described here for completeness,
more details can be found in [52]. Primary data analysis has been performed in a
cooperative manner. Further, he kindly provided the experimental data to validate
the new methods developed in the present work.
3.1.1 Cell Culture and NCE Treatment
HaCaT cells were cultured under standard conditions [147]. Cells were seeded in
24-well plates and grown overnight to a conﬂuence of approximately 70%. Cells
were starved for 3 hours in DMEM without addition of fetal calf serum (FCS).
Five BI compounds, in the following referred to as BI1 to BI5, and two competitor
substances, Ex1 and Ex2, with inhibitory potency towards TGF-βR1 kinase were
used as NCE. Details about the synthesis, design, and structure of the molecules can
be found in Roth et al. [1]. BI1 to BI5 belong to the chemical class of indolinones,
Ex1 and Ex2 to the class of pyridopyrimidinones. Cells were pre-incubated with
increasing NCE concentrations (0.0032, 0.016, 0.08, 0.4, 2, 10µM) for 15 min and
subsequently stimulated with 5 ng/ml of TGFβ1 (R&D Systems) and incubated
for 2, 4, or 12 hours. As controls, cells where either left untreated or treated with
DMSO (solvent of compounds) and either stimulated with 5ng/ml of TGF-β1 or not
stimulated and incubated for 2, 4, or 12 hours. NCE treatments were conducted in
triplicates, respective controls in quadruples.
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3.1.2 RNA Extraction
RNA isolation was carried out using a MagMAXTMExpress-96 Magnetic Parti-
cle Processor and the MagMAXTM-96 Total RNA Isolation Kit according to the
manufacturer's protocol. Total RNA concentration was quantiﬁed by ﬂuorescence
measurement using SYBR Green II (Invitrogen) and a Synergy HT reader (BioTek)
as previously described [148]. The RNA quality was characterized by the quotient
of the 28S to 18S ribosomal RNA electropherogram peak using an Agilent 2100
bioanalyzer and the RNA Nano Chip (Agilent).
3.1.3 BeadChip Hybridization of RNA Samples
Illumina TotalPrep RNA Ampliﬁcation Kit (Ambion) was used to transcribe 200ng
total RNA according to the manufacturer's recommendation. A total of 700ng of
cRNA was hybridized at 58◦C for 16 hours to Illumina HumanHT-12 v3 Expres-
sion BeadChips (Illumina). BeadChips were scanned using an Illumina BeadArray
Reader and the BeadScan Software (Illumina). On the HumanHT-12 v3 each gene
of the human genome is represented by at least one probe. The raw data is accessible
as MIAME compliant entry at Array Express [149] (E-MTAB-265).
3.1.4 qRT-PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted for
eight genes (CDKN1A, CDKN2B, HAND1, JUNB, LINCR, RPTN, SERPINE1,
and TSC22D1) known to be deregulated at at least one time point by TGF-β stim-
ulation. mRNA expression levels of the eight genes were determined by qRT-PCR
analysis using a 7900HT Fast Real Time PCR System (Applied Biosystems) and the
Universal Probe Library System (Roche). Gene speciﬁc forward and reverse primer
sequences were designed using the Universal Probe Library Assay Design Center
(Roche). Total RNA was transcribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's
instructions. qRT-PCR was carried out in a ﬁnal volume of 1µl in three replicates
for each cDNA sample. Levels of RNA polymerase II were used for normalization
of the data. The ∆∆CT method [150] was used to relatively quantify mRNA levels
of samples stimulated with TGF-β1 compared to untreated controls.
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3.2 Normalization
For gene expression measurements using microarrays, normalization of the data has
to be performed in order to minimize systematic eﬀects that are not constant be-
tween diﬀerent samples of an experiment and that are not due to the factors under
investigation (e.g. treatment, time). Optimal selection of a normalization method
depends on the nature of the experiment. Factors that inﬂuence the choice are for
example the array technology used (e.g. one/two color, oligo or cDNA probes), the
design of the experiment (e.g number of replicates or experimental conditions) and
whether accuracy or stability is an issue (bias/variance trade-oﬀ). In this regard
factors like comparability and quality of single runs play a major role. It has been
shown that the normalization method used may inﬂuence further downstream anal-
ysis to a great extend [39], and thus has to be carefully chosen based on the actual
experiment.
In this section, we describe the methods used to select an optimal normalization
procedure for the TGF-β gene expression data described in the previous section.
Respective results are presented in Section 4.1 and discussed in Section 5.1. This
part of my thesis has been published in BMC Genomics [53].
3.2.1 Data Processing
Data has been processed with BeadStudio version 3.0 and the R Language and En-
vironment for Statistical Computing (R) 2.7.0 [151, 152] in combination with Bio-
conductor 2.2 [153]. The Bioconductor lumi package [154] has been used for quality
control. Twenty-ﬁve combinations of background correction, transformation, and
normalization methods were calculated either with methods oﬀered by BeadStudio,
with methods available in the lumi package, or with a combination of BeadStudio
and lumi methods. Table 3.1 on page 53 summarizes the individual pre-processing
steps for each of the combinations investigated. The following two paragraphs give
some details on the availability of the diﬀerent methods.
BeadStudio Pre-Processing
The normalizations executed by Illumina BeadStudio were applied to the expres-
sion values on the original scale. In cases where background adjustment has been
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performed, the standard background normalization oﬀered by Bead-Studio (indi-
cated by bg_∗) which may lead to negative values has been used. noBg_noNorm
and bg_noNorm refer to the raw and to the background corrected data, respectively.
Cubic Spline, Rank Invariant, and Average methods were used for normalization
and are referred to as ∗_cubicSpline, ∗_rankInvariant, and ∗_Average, respec-
tively. Details about these normalization methods can be found in the BeadStudio
Gene Expression Module User Guide [155]. Finally, expression values were log2-
transformed.
R Pre-Processing
To be able to log2-transform the expression data, negative values which can re-
sult from BeadStudio background normalization have to be transformed to pos-
itive scale. This is achieved by forcePositive (forcePos) [154] or rma back-
ground adjustment [156] available through the lumiB() function of the lumi package
(bgAdjust.affy) [154]. In case the lumiT() function is used for log2 transfor-
mation, forcePos is automatically conducted to transform negative values. noBg
implies that the background normalization available in BeadStudio has not been
applied. For transforming the data, a simple log2-tranformation (log) or variance-
stabilizing transformation (vst) [157] was used. The latter applies a function that
is asymptotically identical to log2(x), but has been shown to keep variance con-
stant under reasonable error models [157]. Data was normalized using quantile
normalization (quantile) [158], robust spline normalization (rsn) [154], local re-
gression (loess) [159], or variance stabilization and normalization (vsn) [160]. vst
as well as vsn can handle negative values in the data. Thus, neither forcePos nor
rma was applied as pre-processing for any of those two methods to not unnecessarily
modify the values. All methods used are implemented in the R packages affy [161],
vsn [160], or lumi [154].
3.2.2 Statistical Measures
In the following, the statistical measures used to select an appropriate normalization
method as described in Section 4.1 are brieﬂy summarized. Unless otherwise noted,
all statistical calculations were performed using R.
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Table 3.1: Summary of pre-processing steps used for the 25 diﬀerent nor-
malization procedures. For background correction BeadStudio's background normaliza-
tion was applied [162]. This can lead to negative values. To be able to log2-transform the data,
background-correction of rma [156] or forcePos [154] is used to shift the data to positive scale.
Alternatively, data was transformed using (vst) [157] which is capable of dealing with negative val-
ues. Data was normalized using quantile, loess, or rsn [154]. vsn [160] renders transformation
of the data unnecessary.
Name Background Correction Transformation Normalization
bg_average BeadStudio log2 average
bg_cubicSpline BeadStudio log2 cubicSpline
bg_forcePos_log_loess BeadStudio + forcePos log2 loess
bg_forcePos_log_quantile BeadStudio + forcePos log2 quantile
bg_forcePos_log_rsn BeadStudio + forcePos log2 rsn
bg_noNorm BeadStudio + forcePos log2 -
bg_rankInvariant BeadStudio log2 rankInvariant
bg_rma_log_loess BeadStudio+rma log2 loess
bg_rma_log_quantile BeadStudio+rma log2 quantile
bg_rma_log_rsn BeadStudio+rma log2 rsn
bg_vsn BeadStudio - vsn
bg_vst_loess BeadStudio vst loess
bg_vst_quantile BeadStudio vst quantile
bg_vst_rsn BeadStudio vst rsn
noBg_average - log2 average
noBg_cubicSpline - log2 cubicSpline
noBg_log_loess - log2 loess
noBg_log_quantile - log2 quantile
noBg_log_rsn - log2 rsn
noBg_noNorm - log2 -
noBg_rankInvariant - log2 rankInvariant
noBg_vsn - - vsn
noBg_vst_loess - vst loess
noBg_vst_quantile - vst quantile
noBg_vst_rsn - vst rsn
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Signal-to-Noise Ratios
One aim of normalization is to minimize, for each gene, the within-group variability
while maximizing the between-group variability, also referred to as mean sum of
squares within (MSQwithin):
MSQwithin =
1
N − k
k∑
i=1
ni∑
j=1
(xij − x¯i)2 (3.1)
and mean sum of squares between (MSQbetween):
MSQbetween =
1
k − 1
k∑
i=1
ni(x¯i − x¯)2, (3.2)
respectively. Here, k represents, for a given gene, the number of groups, ni the size
of group i, x¯i the mean expression level of group i, x¯ the total mean, N the total
number of observations, and xij the jth value in group i. The aim is to maximize
MSQbetween
MSQwithin
(3.3)
which follows an F-statistic with (k−1;N−k) degrees of freedom. This test has been
used to derive results described in Section 4.1.1 (Figures 4.1 - 4.4, pages 82 ﬀ.). As a
reference, artiﬁcial group means x¯ = 6, x¯ = 6, and x¯ = 7, k = 3, n1 = n2 = n3 = 4,
and x¯ = (x¯1+x¯2+x¯3)
3
were used. This results in an MSQbetween of 1.33 which is in-
dicated in Figures 4.3 and 4.4 by a grey dashed line. The FDR-corrected [163]
p-values for the F-statistic were summarized using their empirical cumulative dis-
tribution function (Figure 4.1, page 83).
Pseudo-ROC Curves
One of the main uses of expression arrays is the identiﬁcation of genes that are
diﬀerentially expressed under various experimental conditions. A typical identiﬁca-
tion rule ﬁlters genes with p-values and/or fold change exceeding a given threshold.
Given a set of known true positives (TP) and false positives (FP), receiver opera-
tor characteristic (ROC) curves oﬀer a graphical representation of both speciﬁcity
and sensitivity for such a detection rule. ROC curves are created by plotting the
true positive rate (sensitivity) against false positive rate (1-speciﬁcity) obtained at
each possible threshold value. Since we are only sure about TPs, we made use
of so-called pseudo-ROC curves [164]. 20 genes that are known to be deregulated
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by TGF-β were selected as TPs (SERPINE1, SERPINE2, CDKN1A, CDKN2B,
SMAD7, VASN, JUNB, BAMBI, CTGF, SOX18, TGM2, MMP10, MMP2, THBS1,
TGFBI, IGFBP7, IL1R1, ACTN1, MYC, NOTCH1). True negatives (TNs) were
randomly sampled from the set of transcripts remaining when subtracting the TPs
from all transcripts. As threshold values, we used FDR-adjusted p-values [163] of an
F-statistic (Eq. 3.3) based on the sample groups for untreated and TGF-β stimulated
HaCaT cells at 2 hours.
log2 Ratios, Residual Standard Deviation, and p-Values
log2 ratios, respective residual standard deviation, and p-values used in Chapter 4
were calculated using linear models in combination with the moderated t-statistic
as supplied by the limma package [165].
Regression Analysis of Fold Change values and qRT-PCR Measurements
To get an overall impression of the goodness-of-ﬁt of the fold change levels detected
using the diﬀerent normalization methods, an orthogonal regression, i.e. total least
squares, was applied. This method is appropriate since both variables, the normal-
ized and the qRT-PCR results, depend on each other; it is not possible to categorize
them as dependent and independent variable as it would be necessary for stan-
dard linear regression. For the two dimensional case, with the normalized and the
qRT-PCR results being the two dimensions, the orthogonal regression can be calcu-
lated using the princomp() function as available in the basic R environment. This
method is applied in Section 4.1.2, pages 96 f..
3.3 Diﬀerential Expression Analysis and Gene Set
Enrichment
In this section, I describe the methods used in analysis of diﬀerential gene expression
data.
3.3.1 Diﬀerential Expression
Based on the results of Section 4.1 the data has been log2-transformed and nor-
malized using robust spline normalization (rsn) referred to as log_rsn. Details
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are described in Section 3.2.1, pages 51 f.. Linear models (Bioconductor package
limma) [165] were used to calculate log2 ratios, the resulting p-values were FDR-
corrected [163].
3.3.2 TGF-β Signature
To deﬁne genes deregulated by TGF-β signaling, three sequential ﬁltering steps were
applied to the log2 transformed expression values of each time point separately:
i) The ﬁrst ﬁltering is based on the comparison of TGF-β-stimulated cells against
untreated cells using linear models as described in Section 3.3.1 (FDR-corrected
p-value < 0.01 and |log2 ratio| ≥ 0.5).
ii) A linear model was applied to the dose groups of each compound to extract
all genes which are signiﬁcantly deregulated (FDR-corrected p-value < 0.01)
by at least one concentration compared to the respective control (cells treated
with TGF-β and DMSO but no compound). Here, concentrations are treated
as categorical variables.
iii) To detect genes with a dose-dependent deregulation, the likelihood ratio test
statistic for monotonicity (R package IsoGene [166]) was used. Treating concen-
trations as ordinal variables, IsoGene performs an isotonic regression based on
the replicates for each concentration resulting in regression values µ1, µ2, ..., µ6
for each gene and each compound treatment. Only genes that are signiﬁcantly
regulated by at least one compound with |µ1 − µ6| ≥ 1 and an FDR-corrected
p-value < 0.01 for monotonicity were included in further analysis. Additionally,
µ1− µ6 has to be > 0 if TGF-β treatment induced down-regulation, and < 0 if
TGF-β treatment induced up-regulation. Thereby, those genes that are most
likely deregulated in a dose dependent manner are selected.
For each time point the genes that passed all three ﬁlters constitute the ﬁnal TGF-β
signature.
3.3.3 Inferring the Oﬀ-Target Signature
In order to detect transcripts that are deregulated due to oﬀ-target eﬀects of the com-
pounds, unstimulated cells (wotgf class) as well as TGF-β-stimulated cells (tgf
class) were considered. Since the IC50 of all NCEs lies between 0.08µM and 2µM,
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Figure 3.1: Comparisons used to infer the oﬀ-target signatures. Expression
intensities for an arbitrary gene are indicated by ∗ for compound concentrations of 0µM ,
0.08µM , and 2µM . Horizontal dotted lines are used to indicate the diﬀerent expression
intensities. The woftg class comparisons d11, d12, and δ1 are calculated based on com-
parisons of the indicated expression intensities (red dashed lines). Comparisons for the
TGF class are calculated accordingly.
these two concentrations were considered for oﬀ-target analysis. For the wotgf
class, the NCE-treated samples at 0.08µM as well as at 2µM were compared to
untreated cells. Additionally, the 2µM samples were compared to the respective
0.08µM samples. These comparisons are denoted by d11, d12, and δ1, respectively
(Figure 3.1). The same comparisons were made based on the tgf class and are
denoted by d21, d22 and δ2, respectively. Signiﬁcant up- and down-regulation was
deﬁned based on FDR-corrected [163] p-value (p.adj) < 0.01 and |log2ratio| ≥ 1,
where p-values and log2ratios were calculated using linear models [165]. Based on
these nomenclatures and values, the following boolean variables are deﬁned:
dxy,up =
{
1 , if log2ratio(dxy) ≥ 1 and p.adj(dxy) < 0.01
0 , else
,
dxy,down =
{
1 , if log2ratio(dxy) ≤ −1 and p.adj(dxy) < 0.01
0 , else
,
dxy,sig =
{
1 , if |log2ratio(dxy)| ≥ 1 and p.adj(dxy) < 0.01
0 , else
,
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δ1,up 
1 δ1,down 
d12,up d11,down 
0 d11,up 
1 d12,down 
0 log2ratio(δ1)>-1 
1 0 
d12,down 
0 
log2ratio(δ1) ≥1 
d12,up 
1 0 
 δ1,up=1 
 1 
d12,down 
d12,up 
0 
log2ratio(δ1)≥1 
1 0 log2ratio(δ1)>-1 
1 0 
         yes 
         no 
Figure 3.2: Decision tree to calculate wotgfup. Displayed is the decision tree to
decide whether a gene belongs to the wotgfup-class or not. d11, d12, and δ1 are calculated
as described in Figure 3.1 and Eq. 3.4. A mathematical representation of the decision
tree for wotgfup is given in Eq. 3.5. wotgfdown, tgfup, and tgfdown are calculated
accordingly (compare Eq. 3.6, 3.7, and 3.8, respectively).
δx,up =
{
1 , if log2ratio(δx) ≥ 1 and p.adj(δx) < 0.01
0 , else
,
δx,down =
{
1 , if log2ratio(δx) ≤ −1 and p.adj(δx) < 0.01
0 , else
. (3.4)
where x, y ∈ {1, 2}. x = 1 refers to the wotgf class, x = 2 to the tgf class,
y = 1 refers to the comparison of 0.08µM to 0µM , and y = 2 to the comparison of
2µM to 0µM . Figure 3.1 indicates the comparisons based on exemplary expression
intensities for an arbitrary gene.
Transcripts that are up- or down-regulated by compound treatment (wotgfup
and wotgfdown, respectively) or by TGF-β stimulation together with compound
treatment (tgfup and tgfdown, respectively) were detected based on the described
comparisons as follows: a transcript belongs to the class wotgfup if either δ1 in-
dicates signiﬁcant up-regulation (δ1,up == 1) or if it does not indicate signiﬁcant
down-regulation (δ¯1,down == 1) but d11, d12, and δ1 indicate an increasing course of
expression intensity for higher compound concentrations. That is, if δ¯1,down holds
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true, ﬁve diﬀerent trends render up-regulation:
1. d11 and d12 both indicate signiﬁcant up-regulation (d11,up == d12,up == 1);
2. d11 indicates signiﬁcant down-regulation but log2ratio(δ1) ≥ 1, thereby show-
ing an increasing trend of expression for increasing compound concentrations;
3. d11 indicates signiﬁcant up-regulated and log2ratio(δ1) > −1, allowing for a
small but not signiﬁcant decreasing trend for increasing compound concentra-
tion;
4. d12 indicates signiﬁcant down-regulated and log2ratio(δ1) ≥ 1;
5. d12 indicates signiﬁcant up-regulated and log2ratio(δ1) > −1.
On the one hand, as soon as one of d11 or d12 indicates signiﬁcant up-regulation
(cases 3 and 5), a small amount of noise, i.e. a small trend towards down-regulation,
was allowed by claiming log2ratio(δ1) > −1. On the other hand, as soon as one of
d11 or d12 indicate down-regulation (cases 2 and 4), we are more strict by claiming
log2ratio(δ1) ≥ 1 to call a transcript as being up-regulated.
In a more formal fashion, transcripts up-regulated within the wotgf class are
deﬁned as follows:
wotgfup =

δ1,up ∨
[δ¯1,down ∧ ((d11,up ∧ d12,up)
∨ (d11,down ∧ d¯12,sig ∧ log2ratio(δ1) ≥ 1)
∨ (d11,up ∧ d¯12,sig ∧ log2ratio(δ1) > −1)
∨ (d¯11,sig ∧ d12,down ∧ log2ratio(δ1) ≥ 1)
∨ (d¯11,sig ∧ d12,up ∧ log2ratio(δ1) > −1))]

(3.5)
The mirrored method was used to detect wotgfdown and the analogous methods
are used to detect tgfup and tgfdown based on the cells stimulated with TGF-β.
Figure 3.2 shows an exemplary decision tree based on which it is possible to de-
cide whether a gene belongs to class wotgfup. Analgous trees can be derived for
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wotgfdown, tgfup, and tgfdown based on the following formulas:
wotgfdown =

δ1,down ∨
[δ¯1,up ∧ ((d11,down ∧ d12,down)
∨ (d11,down ∧ d¯12,sig ∧ log2ratio(δ1) < 1)
∨ (d11,up ∧ d¯12,sig ∧ log2ratio(δ1) ≤ −1)
∨ (d¯11,sig ∧ d12,down ∧ log2ratio(δ1) < 1)
∨ (d¯11,sig ∧ d12,up ∧ log2ratio(δ1) ≤ −1))]

(3.6)
tgfup =

δ2,up ∨
[δ¯2,down ∧ ((d21,up ∧ d22,up)
∨ (d21,down ∧ d¯22,sig ∧ log2ratio(δ2) ≥ 1)
∨ (d21,up ∧ d¯22,sig ∧ log2ratio(δ2) > −1)
∨ (d¯21,sig ∧ d22,down ∧ log2ratio(δ2) ≥ 1)
∨ (d¯21,sig ∧ d22,up ∧ log2ratio(δ2) > −1))]

(3.7)
tgfdown =

δ2,down ∨
[δ¯2,up ∧ ((d21,down ∧ d22,down)
∨ (d21,down ∧ d¯22,sig ∧ log2ratio(δ2) < 1)
∨ (d21,up ∧ d¯22,sig ∧ log2ratio(δ2) ≤ −1)
∨ (d¯21,sig ∧ d22,down ∧ log2ratio(δ2) < 1)
∨ (d¯21,sig ∧ d22,up ∧ log2ratio(δ2) ≤ −1))]

(3.8)
The ﬁnal oﬀ-target signature was deﬁned based transcripts for which the following
formula holds true:
(tgfup ∧wotgfup) ∨ (tgfdown ∧wotgfdown)∨
(tgfup ∧wotgfdown) ∨ (tgfdown ∧wotgfup). (3.9)
The proﬁles of the respective transcripts can be assigned to diﬀerent categories:
TGFup ∧WOTGFup: additive or bipolar on- and oﬀ-target eﬀect or common oﬀ-
target eﬀect,
TGFdown ∧WOTGFdown: additive or bipolar on- and oﬀ-target eﬀect or common
oﬀ-target eﬀect,
TGFup ∧WOTGFdown: inverse or bipolar on- and oﬀ-target eﬀect, and
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TGFdown ∧WOTGFup: inverse or bipolar on- and oﬀ-target eﬀect.
Bipolar on- and oﬀ-target eﬀects describe gene expression proﬁles for which the
direction of regulation depends on the concentration range, i.e. it is possible that
a compound induces expression at lower concentrations whereas expression again
decreases at higher concentrations or vice versa.
3.3.4 Gene Set Enrichment Analysis
Based on the on- and oﬀ-target signatures, standard Ingenuity Pathway Analyses
(IPAs) [144] were conducted. In these analyses, gene sets deﬁned by the Ingenuity
Knowledge Base are tested for enrichment of deregulated genes using Fisher's ex-
act test. Additionally, gene sets deﬁned by KEGG pathways as annotated by the
Bioconductor package KEGG.db version 2.2.11 were tested for enrichment of genes
contained in the TGF-β signature (Section 3.3.2). As KEGG is not freely available
to the pharmaceutical industry, no compound related analyses were conducted using
KEGG. The gene sets were hierarchically clustered based on the calculated p-values
using manhattan distance and complete linkage as distance measures between gene
sets and clusters. Results are presented in Section 4.2.3 pages 106 ﬀ..
3.4 A New Approach for Data Integration
In this section, I describe the individual evidence that has been used to calculate
edge weights ω(vi, vj) for PPI networks (Deﬁnition 2.2.2). Respective networks are
used in Sections 4.3 and 4.4. How individual measures are weighted is highly ﬂexible
and should be chosen according to the research objective and in close cooperation
with biologists familiar with the experimental setting and background.
3.4.1 Protein Interaction Data
iRefIndex
The protein interaction network was generated based on iRefIndex [22]. PSI-MITAB
formatted interactions for human were taken from the publicly available version of
release 5 (9606.mitab.06042009.txt.zip), which consolidates information taken from
six diﬀerent Protein interaction databases (BIND [33,34], BioGRID [35,36], IntAct
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[37], MINT [38], MPPI [39] and OPHID [40]). For generating the underlying protein
interaction network, all binary interactions were used. This resulted in a network of
10, 321 nodes and 57, 811 edges. The respective proteins were represented by their
UniProt Accessions.
3.4.2 Scoring Similarity of Genes Based on Gene Ontology
(GO)
In contrast to most previous approaches as described in Section 2.3, our method
takes into account the similarity of the GO annotation of two nodes that are adja-
cent in a protein interaction network. Similarity scores described in this section are
calculated based on the directed acyclic graph representing the ontology. Details
on GO have been given in Section 2.4.1, Deﬁnitions 2.4.2 - 2.4.4, and Figure 2.4 on
pages 44 ﬀ..
To our knowledge, Wu et al. [167] ﬁrst integrated GO annotations to derive func-
tional modules. Using a Bayesian approach, they combine results for the analyses
of phylogenetic proﬁles, gene neighborhoods, and GO annotations. The combined
information is used to measure the strength of gene functional relationship based on
which functional modules present in Escherichia coli were predicted.
Let us assume two genes/proteins, g1 and g2 represented by nodes in an inter-
action graph are annotated by two sets of GO terms, GO1 and GO2, respectively.
Below, I ﬁrst describe several approaches to derive similarity scores sim(go1, go2)
for a pair of GO-terms go1 ∈ GO1 and go2 ∈ GO2 (pages 62 ﬀ.). In a second
step, I introduce diﬀerent possibilities to calculate the similarity of two sets of GO-
term, sim(GO1, GO2), based on the similarity calculated for a pair of GO-terms
sim(go1, go2). sim(GO1, GO2) can be used as a score for the similarity of two
genes/proteins Sim(g1, g2) (pages 65 f.).
Resnik's Measure [168,169]
Resnik proposes a similarity score that is based on the information content (IC).
The IC takes into account the frequency of occurrence of any ontology term in
the ontology, i.e. how often the respective term is annotated to a gene/protein
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compared to the maximum possible usage of that term. The more frequent a term
occurs, the lower its information content is. Thus, in case of a unique root of the
ontology tree, p(root) = 1. The respective information content ICroot is deﬁned as
−log p(root) = 0. Analogous, for any other term go, ICgo = −log p(go). Based on
the IC, the similarity of two terms go1, go2 is calculated. The more information two
terms share, the higher is their similarity sim(go1, go2):
simResnik(go1, go2) = maxgo∈S(go1,go2)(−log p(go)), (3.10)
where S(go1, go2) is the set of common ancestors of terms go1 and go2. Thus,
the information content of their lowest common ancestor (LCA, Deﬁnition 2.4.7)
quantiﬁes the similarity of two terms:
simResnik(go1, go2) = −log p(LCA(go1, go2)). (3.11)
Lin's Measure [170]
The measure proposed by Lin is also based on the IC. In contrast to Resnik's deﬁ-
nition of similarity, Lin normalizes the similarity of two terms go1, go2 with respect
to the sum of the IC of the individual terms:
simLin(go1, go2) = maxgo∈S(go1,go2)
2 · log p(go)
log p(go1) + log p(go2)
(3.12)
Rel [171]
Rel, the similarity measure proposed by Schlicker et al. additionally weights the mea-
sure proposed by Lin according to its relevance. The relevance of a term decreases
with increasing frequency of occurrences, the similarity is weighted with 1− p(go):
simRel(go1, go2) = maxgo∈S(go1,go2)
(
2 · log p(go)
log p(go1) + log p(go2)
· (1− p(go))
)
(3.13)
Jiang's and Conrath's Measure [172]
Jiang and Conrath deﬁne a semantic distance
Dist(go1, go2) = IC(go1) + IC(go2)− 2 · IC(LCA(go1, go2)). (3.14)
The distance is an inversion of the similarity, thus, Yu [173] implements the similarity
as
simJC(go1, go2) = 1−min(1, d(go1, go2)), (3.15)
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where
d(go1, go2) = log p(go1) + log p(go2)− 2 · log p(LCA(go1, go2)). (3.16)
GOViz
GoViz was implemented by Andreas Bonertz with support from Dr. Benedikt Brors
in the course of a trainee at the Computational Biology group of the former The-
oretical Bioinformatics department at the DKFZ. The R-package was provided by
Dr. Benedikt Brors. Making use of the GOstats package, similarity of the GO an-
notations of two genes is calculated as the path length of the intersection graphs
induced by the annotations [174]. GoViz does not take into account the semantic
similarity of the GO terms assigned to a pair of genes but only the depth of the
common annotations.
Wang's Measure [141]
Wang et al. state that the methods described so far were developed for natural lan-
guage taxonomies [168170,172]. All these methods base their similarity scoring on
the information content present in a term. They neglect that the speciﬁcity of a
GO term is determined by the information inherited from its ancestors, thus, the
location within the GO graph has to be taken into account. That is why they pro-
pose a new method to measure the semantic similarity of a GO term. Based on the
calculated semantic similarity scores, they developed a new algorithm to measure
the similarity of genes with respect to their GO annotation.
DAGgo = (Tgo, Ego) represent the GO term go. Tgo is the set of GO terms, i.e.
nodes, in DAGgo containing go as well as all its ancestor terms; Ego refers to all
edges induced by Tgo. To calculate the semantic value of go, the authors deﬁne a
so-called S-value calculated for any term t ∈ Tgo in the ontology:
Sgo(t) =
{
1 : t = go
max{γet→t′ · Sgo(t′)|t′ ∈ Vchildren(t)} : t ∈ Tgo, t 6= go
, (3.17)
where γet→t′ is the semantic contribution factor for edge et′→t ∈ EA linking term t′
with its parent term t. Based on the S-values, the semantic value of GO term go is
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given by
SV (go) =
∑
t∈Tgo
Sgo(t). (3.18)
The semantic similarity of GO terms go1 and go2 which induceDAGgo1 = (Tgo1 , Ego1)
and DAGgo2 = (Tgo2 , Ego2), respectively is then calculated by
simWang(go1, go2) =
∑
t∈Tgo1∩Tgo2 (Sgo1(t) + Sgo2(t))
SV (go1) + SV (go2)
. (3.19)
Calculate the similarity of genes based on their GO annotations
Similarity of genes based on GO annotations can either be calculated with respect
to the cellular component (CC) in which the proteins encoded by the genes are lo-
cated in, with respect to the biological process (BP) in which the genes/proteins are
involved in, or with respect to the molecular function (MF) of the encoded proteins.
CC, BP, and MF are described by three separate DAGs in the GO.
Wang et al. propose the following formula to calculate the semantic similarity
sim(go,GO) between GO term go and a set of GO terms GO = {go1, go2, ..., gok}
sim(go,GO) = max1≤i≤k(SGO(go, goi)). (3.20)
Now, given genes g1, g2 annotated by GO term sets GO1 = {go11, go12, ..., go1m} and
GO2 = {go21, go22, ..., go2n}, respectively, their similarity Sim(g1, g2) is deﬁned as
sim(GO1, GO2), i.e. the similarity of GO1 and GO2. Wang et al. [141] propose the
following formula to calculate Sim(g1, g2)
sim(GO1, GO2) =
∑
1≤i≤m(sim(go1i, GO2)) +
∑
1≤i≤n(sim(go2i, GO1))
m+ n
(3.21)
This method is used in the Bioconductor package GOSemSim [173].
Schlicker et al. propose similar methods:
SimAvg(g1, g2) =
1
2
(∑
1≤i≤m(sim(go1i, GO2))
m
+
∑
1≤i≤n(sim(go2i, GO1))
n
)
(3.22)
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SimMax(g1, g2) = max
(∑
1≤i≤m(sim(go1i, GO2))
m
,
∑
1≤i≤n(sim(go2i, GO1))
n
)
(3.23)
In cases were the GO annotation for one gene product only matches a subset of
the GO annotations of the second gene product, SimMax is superior to SimAvg
for similar gene products. Since GO1 and GO2 are not necessarily equal in length
and generally diﬀer in terms,
∑
1≤i≤m(sim(go1i,GO2))
m
and
∑
1≤i≤n(sim(go2i,GO1))
n
are not
necessarily equal. In case one of the gene products g1 or g2 is annotated incom-
pletely, this could lead to artiﬁcially low
∑
1≤i≤m(sim(go1i,GO2))
m
or
∑
1≤i≤n(sim(go2i,GO1))
n
.
Taking the average as in SimAvg(g1, g2) would then lead to a lower value than us-
ing SimMax(g1, g2). Such situations can occur if the annotation for the ﬁrst gene
product are not complete or if the second gene product is multi-functional [171].
SimMax is, for example, implemented in the R-package GOSim [175].
Implementations of GO Similarity Scores
R packages GOSemSim [173], GOSim [175], and GOstats [176] were used to weight the
protein pairs according to their GO annotations. First, I made use of the mgoSim
function implemented in the GOSemSim package [173], retrieved the GO annotations
of the proteins using biomaRt [177] and ﬁltered them by ignoring GO terms with ev-
idence codes NAS, IEA, ND (non-traceable author statement, inferred from electronic
annotation and no biological data available, respectively) and those which had not
assigned any evidence code. Similarities for the annotations were calculated based
on the methods proposed by Resnik (Eqs. 3.10 and 3.11, page 63) [178], Jiang and
Conrath (Eqs. 3.14-3.16, pages 63 f.) [172], Lin (Eq. 3.12, page 63) [170], Schlicker
(Eq. 3.13, page 63) [171], and Wang (Eqs. 3.17-3.19, pages 64 f.) [141]. The similarity
of two genes based on their GO-annotations is calculated using Eq. 3.21.
Next, I made use of the method mgeneSim, also implemented in the GOSemSim
package. Swiss-Prot Identiﬁers were mapped to EntrezGene IDs using the pack-
age org.Hs.eg.db, and similarities were calculated using the methods proposed by
Resnik (Eqs. 3.10 and 3.11, page 63) and Wang (Eqs. 3.17-3.19, pages 64 f.) without
ﬁltering for speciﬁc evidence codes. Again, the similarity of two genes based on their
GO-annotations is calculated using Eq. 3.21.
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According to Smialowski [179], I utilized the GOSim package [175] which, amongst
others, also implements the method from Resnik (Eqs. 3.10 and 3.11, page 63) but
oﬀers diﬀerent options for comparing and summarizing GO-Terms. To compute the
similarity of a pair of proteins, the method getGeneSim was used with default pa-
rameters but setting similarityTerm = Resnik. Thereby, Eq. 3.23 (page 66) is
applied to calculate the similarity of two genes based on their GO annotations.
Finally, I used GOViz [174] that calculates the similarity score as the length of
the longest path in the intersection graph induced by the GO annotations of the
two genes under consideration (page 64).
3.4.3 Scoring Similarity of Genes Based on Promoter Regions
Information on transcription factor binding sites was taken from the ElDorado
database using the Gene2Promoter large scale analysis [180] which is part of the
Genomatix Genome Analyzer (GGA) [181]. Based on the binding site motif (weight
matrix) of transcription factor TF and the sequence of the promoter region of gene
G, a matrix similarity score scoreTF (G) was calculated using MatInspector [182,183].
A perfect match of the transcription factor's binding site motif to a region in the
promoter gets a score of 1.0, a good match usually has a score > 0.8 [180].
A score, scoreTF (X, Y ), is calculated based on the set of transcription factors
TF(X) and TF(Y ) predicted to regulate the protein-coding genes X and Y , re-
spectively. The higher this score, the more similar are the promoter regions of X
and Y . Using a Tanimoto-based approach, diﬀerent possibilities were implemented
to calculate scoreTF (X, Y ):
1. Calculation of the score is based on the sum over the matrix similarity scores
predicted for transcription factors regulating both, gene X and gene Y . This
sum is divided by the sum over the scores for the union of the predicted
transcription factor binding sites of both genes:
scoreTF,1(X, Y ) =
∑
TF∈(TF(X)∩TF(Y ))(scoreTF (X) + scoreTF (Y ))∑
TF∈(TF(X)∪TF(Y ))(scoreTF (X) + scoreTF (Y ))
(3.24)
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2. scoreTF,1(X, Y ) is multiplied by the number of common transcription factors:
scoreTF,2(X, Y ) = |TF(X) ∩TF(Y )| · scoreTF,1(X, Y ) (3.25)
Results based on using all predicted transcription factor binding sites were com-
pared to those that are predicted with a matrix similarity score > 0.8 referred to as
cutoﬀ_08. This ﬁnally results in four possibilities to calculate scoreTF (X, Y ).
3.4.4 Scoring Similarity of Genes Based on Literature
For each recorded protein interaction iRefIndex provides a conﬁdence score. This
score is based on the number of PubMed publications supporting the respective
interaction. Within iRefIndex the conﬁdence scores are given in the following format:
lpr|hpr|np. lpr refers to the lowest number of distinct interactions that any PubMed
reference supporting the respective protein interaction contains. That is, a small
value of lpr indicates a low throughput experiment for validating an interaction,
whereas larger values of lpr indicate high throughput experiments; hpr refers to the
highest number of interactions that any PubMed reference supporting the respective
protein interaction contains; np is the total number of references supporting the
respective interaction. For details I refer the reader to the original publication [96]
and to the README for iRefIndex MITAB 4.0. Since we want to give higher
conﬁdence to interactions that are supported by a low-throughput experiment and
more publications, the calculation of the conﬁdence score is based on lpr and np.
The following formula was used to calculate a conﬁdence for the edge representing
the interaction in our network:
scoreconf (X, Y ) =
√
np
lpr
(3.26)
Since np and lpr are only available for protein interactions present in iRefIndex,
scoreconf (X, Y ) was only applied to iRefIndex-based but not to the STRING-based
networks.
3.4.5 Scoring Similarity of Genes Based on Expression Data
In Sections 4.3.1 (pages 111 ﬀ.) and 4.3.2 (pages 114 f.), I make use of the gene
expression data derived from TGF-β1-stimulated as well as unstimulated cells mea-
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sured in four biological replicates at 2, 4 and 12 hours after stimulation. In Sec-
tion 4.3.3 (pages 116 f.), I considered data derived from untreated as well as treated
cells. For the treated cells, I focused on cells stimulated with TGF-β1 and ei-
ther treated with diﬀerent concentrations of BI1 or BI4, or not treated with any
compound. By applying the methods described in this section together with the
algorithm described in Section 3.5 to compound-treated cells, I demonstrate how
these methods can support the analysis of compounds' mode of action.
For each edge e{X,Y } in the protein interaction network G = (V,E) connect-
ing protein coding genes X and Y a score scoreexp(X, Y ) is calculated based on
the underlying gene expression experiment. I compared 9 diﬀerent possibilities for
weighting the interactions. They are either based on correlation or on co-variance
(as for example also used by Guo [49]) of vectors x and y. x and y contain values
derived based on two conditions either looking at three diﬀerent time points (2, 4,
12 hours) or for one timepoint (2 hours). In Sections 4.3.1 (pages 111 ﬀ.) and 4.3.2
(pages 114 f.) the two conditions are TGF-β1-stimulated and unstimulated cells, in
Section 4.3.3 (pages 116 f.) data derived from untreated as well as compound-treated
cells is considered.
1. Weighting based on correlation (cor): Pearson correlation is calculated based
on the
(a) log2 ratios of two conditions,
(b) mean of replicate values for the normalized expression values of both
conditions, or
(c) normalized expression values of both conditions for all replicates
at the diﬀerent time points measured (2, 4, 12 hours):
scoreexp(X, Y ) = cor(x, y) (3.27)
2. Weighting based on covariance (cov): The covariance is calculated based on
the
(a) log2 ratios of the two conditions for the respective gene pair (X,Y) at the
diﬀerent time points measured (2, 4, 12 hours),
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(b) mean of the replicate values of the normalized expression values of both
conditions at the diﬀerent time points measured (2, 4, 12 hours), or
(c) normalized expression values of both conditions for all replicates at the
diﬀerent time points measured (2, 4, 12 hours) and at 2 hours.
scoreexp(X, Y ) = cov(x, y) = cor(x, y) · sd(x) · sd(y) (3.28)
Since a negative covariance/correlation could hint at pairs of proteins exhibiting
related biological contexts (e.g. inhibitor and activator), the absolute value of the
correlation/covariance was taken.
The score may be weighted by a factor ωexp:
scoreexp,weighted(X, Y ) = ωexp · scoreexp(X, Y ) (3.29)
Two diﬀerent approaches have been applied to calculate 3.29: scoreexp(X, Y ) was
calculated based on method (1a) and two diﬀerent possibilities to calculate ωexp were
considered:
3. For focusing on changes occurring at a speciﬁc time point ωexp is set to the
average of |log2ratios| at the time point of interest (in our case 2 hours, since
this is the time frame for which expression changes directly induced through
TGF-β-signaling are observed).
4. To assign higher weights to genes that show a change in diﬀerential expression
over time, ωexp is set to the average of the standard deviations of log2 ratios
across all time points (in our case 2,4, and 12 hours) for X and Y .
To test the weighted scoring, we applied (3) and (4) using the correlation of log2
ratios across the three time points as scoreexp(X, Y ).
In total, nine diﬀerent ways of calculating scoreexp were compared: Three of them
are based on correlation (1a-c), four are based on covariance (2a-c, 2c was applied
for measures at all 3 time points as well as for measured at 2hours), and two are
based on weighting scoreexp (Eq. 3.29).
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3.4.6 Combining the Individual Similarity Scores
For each edge, a linear combination over all individual scores is calculated to make
up the ﬁnal edge score:
scoreedge =
n∑
i=1
aisi, with (3.30)
ai ∈ [0,∞) and si ∈ {scoreGO, scoreTF , scoreconf , scoreexp, ...}.
Since this weighting function is highly ﬂexible, additional information can easily be
added. All scores but those obtained based on the gene expression experiment are
normalized between 0 and 1. To weight all evidence equally, ai = 1 ∀ i. With four
diﬀerent methods used for scoring the transcription factors, nine diﬀerent methods
scoring gene expression data, and ten diﬀerent methods to score GO, 360 combina-
tions of methods are considered. In Section 4.3.1 (pages 111 ﬀ.), I describe how one
of the possible combinations was selected. Based on this combination all further
analyses presented in this thesis have been conducted. In principle, the weighting
factors ai can be adjusted according to the research objective and in close coop-
eration with biologists. More important scores should be given a higher weight.
3.5 modEx - A New Approach for Extraction of
Protein Modules
Based on the methods presented in the previous sections, diﬀerent data types are
integrated into a protein interaction network to obtain an edge- and node-weighted
graph G = (V,E). The log2 ratios or fold changes of a gene expression experiment
are assigned as node weights. By the methods presented in Section 3.4, information
on biological processes, molecular functions, cellular components, transcription fac-
tor binding sites, literature and on correlation or covariance of the gene expression
is translated to edge weights scoreedge as described by Eq. 3.30 on page 71.
In Section 3.5.1, I deﬁne some graph-theoretical problems that can be posed by
networks weighted as described in the previous paragraph. Solving the problems on
this basis, it is possible to shed some light on the underlying biology, like for example
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the mode of action of compounds. In Section 4.5.2 (pages 134 ﬀ.) the NP-hardness
of these problems is proven.
In Section 3.5.2 (pages 73 f.) I propose a heuristic, modEx, that could be used
to solve the previously deﬁned problems. After validation on a biological basis in
Section 4.3.2, this method is applied in Section 4.3.3 to identify modules that help to
elucidate the biological processes aﬀected in the gene expression experiments under
investigation (pages 114 f.).
3.5.1 Formal Problem Deﬁnitions
In the following, I introduce some graph-theoretical problems that could be posed to
resolve biological questions based on edge weighted graphs. All problem deﬁnitions
are constrained with respect to a set of vertices that have to be part of the solution
and/or to the number of vertices contained in the solution. Generally speaking, all
objective functions aim at maximizing the edge weight of the solution:
Deﬁnition 3.5.1. The vertex Constrained Maximum Edge weight Con-
nected Graph (vCMECG) problem.
Input: An undirected graph G = (V,E) with weight function ω : E → [0,∞),
and a positive integer s.
Task: Find a connected subgraph G′ = (V ′, E ′) with |V ′| = s such that
Ω(G′) =
∑
e∈E′
ω(e) (3.31)
is maximized.
Deﬁnition 3.5.2. The k-vertex Constrained Maximum Edge-Weight Con-
nected Graph (k-vCMECG) problem.
Input: An undirected graph G = (V,E) with weight function ω : E → [0,∞),
Vk ⊆ V with |Vk| = k, and a positive integer s.
Task: Find a connected subgraph G′ = (V ′, E ′) with Vk ⊆ V ′ and
|V ′| = s such that
Ω(G′) =
∑
e∈E′ ω(e)
|V ′| (3.32)
is maximized.
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Considering a network scored as described in Section 3.4.6, Vk could for example
be chosen based on the set of k strongest deregulated genes observed in the un-
derlying gene expression experiment. As a solution for k-vCMECG, the subgraph
G′ = (V ′, E ′) could then help to explain and understand the biological context of
the k deregulated genes. In general, any set of genes for which the biological context
is in question could be used as Vk.
Deﬁnition 3.5.3. The k-vertex/edge Constrained Maximum Edge-Weight
Connected Graph (k-veCMECG) problem.
Input: An undirected graph G = (V,E) with weight function ω : E → [0,∞),
and Vk ⊆ V with |Vk| = k and a positive integer s.
Task: Find a connected subgraph G′ = (V ′, E ′) such that Vk ⊆ V ′,
|V ′| = s, and
Ω(G′) =
∑
e∈E′ ω(e)
|E ′| (3.33)
is maximized.
Since we are not only interested in identifying one module but in detecting as
many modules as are necessary to investigate the underlying processes, we consider
a special case of the k-vCMECG problem, namely the 1-vCMECG problem:
Deﬁnition 3.5.4. The 1-vertex Constrained Maximum Edge-Weight Con-
nected Graph (1-vCMECG) problem.
Input: An undirected graph G = (V,E) with weight function ω : E → [0,∞),
a seed vertex vi ∈ V , and a positive integer s.
Task: Find a connected subgraph G′i = (V
′, E ′) with vi ∈ V ′ and |V ′| = s
such that
Ω(G′i) =
∑
e∈E′ ω(e)
|V ′| (3.34)
is maximized.
3.5.2 Heuristic Approaches to Solve the 1-vCMECG Problem
modEx starts with seed nodes selected on the basis of the gene expression ex-
periment to analyze. Out of the signiﬁcantly deregulated genes (FDR-adjusted
p-value < 0.01), the i mostly deregulated are selected as seed nodes. Starting
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at those nodes, the networks are expanded in the direction of the heaviest edge.
Depending on whether one is interested in sparse or dense networks, either only the
heaviest edges are returned or the subgraph induced by the selected nodes (Deﬁni-
tion 2.3.2, page 28) is extracted. The modules extracted in this work all represent
induced subgraphs.
A number of variations with respect to how the extraction of graph G′i around
the i-th seed node (Deﬁnition 3.5.4) is performed and how the algorithm terminates
can be applied. Following procedures were investigated:
(1) Apply greedy search and stop after a pre-deﬁned number of nodes have been
extracted.
(2) Apply greedy search and stop as soon as an optimum for Ω(G′i) is reached.
(3) Use simulated annealing optimizing Ω(G′i).
(4) Reapply (1), (2) or (3), starting with diﬀerent seed nodes until a pre-deﬁned
number of connected components is extracted.
If necessary, methods (2) and (3) can be combined with (1) in order to avoid
extracting undesired large networks. The results presented in this work are all
based on (3) combined with (1) by stopping simulated annealing as soon as more
than 50 nodes were extracted. Details on this decision are given in Section 5.3 on
page 142.
3.6 Statistical Measures Used
3.6.1 Quantiﬁcation of Extracted Modules
To quantitatively compare the modules extracted from the protein interaction graphs,
we compared them to modules extracted from randomized graphs. Nodes of the
network were permuted 500 times and edge weights were recalculated based on
these permutations. Based on the permuted graphs, modules were extracted by
applying approach (3) combined with (1) using 50 nodes as the limit for module
sizes (page 74). For each of the 500 modules, Ω(G′i) (Eq. 3.34, page 73), in connec-
tion with the random graphs referred to as Ω(G′i,rand), was calculated.
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P-Value Calculation Based on Z-Score Transformation
Assuming a normal distribution for the Ω(G′i,rand) values obtained by the ran-
dom networks, the corresponding parameters µrand and σrand were estimated by
mean(Ω(G′i,rand)) and sd(Ω(G
′
i,rand)). Given that Ω(G
′
i) of the real network follows
the same distribution, a z-score transformation is performed:
zi =
Ω(G′i)− µrand
σrand
(3.35)
Then, zi follows a N(0, 1) distribution. Based on this, the probability P (x ≥ Ω(G′i))
of randomly observing network scores ≥ Ω(G′i) can be calculated for the extracted
modules. In the following, I refer to this probability as z-score based p-value.
P-Value Calculation Based on Approximative Permutation Tests
As the Ω(G′i,rand) values not strictly follow a normal distribution, p-values were
additionally calculated using an approximation-based approach. The probability of
randomly observing a score ≥ Ω(G′i) is calculated as the relative frequency of how
often Ω(G′i,rand) ≥ Ω(G′i) is observed, referred to as approximative permutation test
based p-value.
3.6.2 Gene Set Enrichment Using Fisher's Exact Test
Fisher's Exact Test
Given N as the total number of genes as, for example, available on a microarray or
all genes present in an organism. M is the number of genes in the gene group to test
for enrichment. We are interested in how probable it is to have x genes of the K
most interesting genes in this group. This can be displayed in a 2 × 2 contingency
table.
Table 3.2: 2× 2 contingency table.
∈ gene group /∈ gene group
∈ genes of interest x K-x K
/∈ genes of interest M-x (N-M)-(K-x) N-K
M N-M N
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Fisher showed that the probability of obtaining such a set of values under the
null hypothesis is given by the hypergeometric distribution
P (X = x|N,M,K) =
(
M
x
)
+
(
N−M
K−x
)(
N
K
)
Thus, the p-value for the enrichment is obtained by
P (X ≥ x|N,M,K)
In Section 4.4 (pages 124 f.) and 4.4.1 (pages 124 f.), gene sets are ranked according
to p-values and inverse ranks of TGF-β signaling are used to compare diﬀerent
results.
3.7 Comparison to Existing Approaches
jActiveModule
jActiveModule [48] is a Cytoscape plugin aiming at the identiﬁcation of modules
(subnetworks) exhibiting signiﬁcant changes in diﬀerential gene expression experi-
ments (see Section 2.3.1, pages 28 ﬀ.). It oﬀers a greedy search as well as a simu-
lated annealing approach to detect these modules. To achieve results that can be
compared to results derived by our approach, we utilized the FDR-adjusted p-values
obtained by comparing the TGF-β-stimulated HaCaT cells to the unstimulated cells
after 2, 4, and 12 hours. Not all proteins contained in the network are represented
by probes on the microarray used to measure gene expression. In case the protein
coding gene is not represented, three diﬀerent options have been investigated:
1. No p-values are assigned (no-pval).
2. 1 is assigned as p-value, 0 as log2 ratio (def-pval).
3. Only the subnet of the iRefIndex-based network is kept that contains proteins
for which genes are represented on the chip (sub-net).
Labels in parenthesis are used in Section 4.4.2 (pages 126 f.) and Section 4.4.3
(pages 127 ﬀ.) to refer to these diﬀerent approaches.
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STRING Based Protein Interaction Network
STRING [55, 121, 184] is a database of known and predicted protein interactions.
The interactions include direct (physical) and indirect (functional) associations; they
are derived from four sources: Genomic context, high-throughput experiments, co-
expression, and previous knowledge. STRING quantitatively integrates interaction
data from these sources for a large number of organisms, and transfers information
between these organisms where applicable. STRING version 8.3 covers 2, 590, 259
proteins from 630 organisms. Since the gene expression experiment under consid-
eration is based on a human cell line (Section 3.1), I only made use of associations
for human (taxonID: 9606) resulting in a network composed of 17, 078 nodes and
1, 236, 215 edges. Associations stored in STRING have diﬀerent conﬁdence scores
ranging from 0-1000. Based on ﬁlters applied to these conﬁdence scores, three sep-
arate analyses were conducted. Using protein associations with a conﬁdence score
≥ 400 results in a network containing 15, 858 nodes and 408, 619 edges, using only
highly conﬁdent associations with a score > 700 in 12, 692 nodes and 176, 595 edges,
and applying a ﬁlter with a score ≥ 848 in 10, 331 nodes and 120, 337 edges. Us-
ing our scoring method, we recalculated the scores for the edges contained in the
STRING-based networks. They are referred to as STRINGmod. Networks based
on the original scoring are referred to as STRINGorg. Since a cutoﬀ of 848 ap-
proximates the size of the iRefIndex-based network, results presented in Section 4.4
are all based on this cutoﬀ. For easier readability, in the main text of this thesis,
STRINGorg refers to the original STRING network with 848 applied as cutoﬀ for
the edge scores; analogous, STRINGmod refers to the same network but with edge
weights recalculated using the scoring method introduced in Section 3.4.6 (Eq.3.29,
page 70). In the Appendix, we explicitly state the results for diﬀerent cutoﬀs used
for STRINGorg and STRINGmod.

Chapter 4
Results
This study is based on gene expression analyses described in Section 3.1. An opti-
mal normalization method was selected for the expression data to be able to derive
the TGF-β signature as well as the NCE's oﬀ-target eﬀects. To reveal the biologi-
cal context of the signatures, the gene expression proﬁles have been clustered, and
gene set enrichment analyses were performed. Further, I applied the approaches
developed in the scope of this thesis to derive compounds' mode of action. De-
rived in silico results were validated by cell biological experiments. The results are
presented in [5254], and I refer the reader to these references; here, I address the
methodological aspects of this work.
This chapter is structured as follows: In Section 4.1, I describe how the optimal
normalization method for our data set has been selected. This has been published
in Schmid and Baum et al. [53]. Based on the normalized data, I describe the in sil-
ico analyses using state-of-the-art methods in Section 4.2. This section is part of
a PLoS One publication by Baum and Schmid et al. [54] and of the PhD thesis of
Dr. Patrick Baum [52]. In Section 4.3, I apply the new data integration method,
introduced in Section 3.4, in combination with modEx, introduced in Section 3.5,
to suggest the mode of action (MoA) of given compounds. In short, interaction
evidence from gene expression measurements, transcription factor binding sites and
information from GO annotation is integrated. This information translates into edge
weighted graphs, which allow the extraction of subnetworks based on protein inter-
actions exhibiting high conﬁdence. Applying this approach I generated hypotheses
on mechanism-related actions of compounds inhibiting TGFβ-R1. In silico gen-
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erated hypotheses about modulation of certain signaling pathways by selected in-
hibitors could be conﬁrmed by cell biological experiments. Finally, in Section 4.4, we
compare our newly proposed approaches to others and show that they beneﬁcially
complement these.
4.1 Selecting an Appropriate Normalization Method
A plethora of diﬀerent normalization methods has been proposed for microarray
experiments [154, 156162]. Diﬀerent microarray technologies require diﬀerent nor-
malization procedures, and even for the same technology, diﬀerent methods are
employed depending on the number of genes being diﬀerently expressed and on the
extent of their changes.
To estimate the performance of a normalization method, and to compare com-
peting methods, one measures both, their inﬂuence on the variance of the data, e. g.
the degree of heteroscedasticity or the ability to discriminate between known groups,
and the bias, i. e. how far a given measure like fold change (ratio of expression in
condition 2 over expression in condition 1) deviates from the truth. Typically, this
is a trade-oﬀ, so methods that yield nearly unbiased estimates of the fold changes
have high variance on this estimation, and vice versa.
Scores that give a measure of either variance or bias require a gold standard, i. e.
that the truth on expression of certain genes or their fold change is exactly known.
This can be obtained by orthogonal methods of gene expression measures, e. g.
quantitative real-time polymerase chain reaction (qRT-PCR). Since it is not possi-
ble to obtain this truth for all genes, or even a signiﬁcant fraction of those present
on a microarray, assumptions have to be made with regard to diﬀerential expression.
In Section 4.1.1 diﬀerent pre-processing methods were evaluated by analyzing the
variance of the resulting gene expression intensities via various statistical measures:
• Plot of ANOVA p-values versus MSQbetween (page 84),
• Boxplots of mean sum of squares (MSQs) between and within groups (pages 85 ﬀ.),
• Density functions of MSQs between and within groups (pages 87 ﬀ.),
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• Volcano plots for pairwise group comparisons (pages 89 f.),
• Residuals versus mean or minimal expression levels (pages 90 ﬀ.),
• Scatterplots of pairwise replicate expression levels (pages 92 f.), and
• Pseudo-ROC curves (pages 93 f.).
Some of these have already been used in other studies [185].
In addition to the variance, in Section 4.1.2 bias of the expression intensities is
investigated. Fold changes derived from resulting gene expression intensities were
compared to fold changes based on quantitative measurements of RNA abundance
as determined by qRT-PCR. Thereby, it is possible to evaluate the pre-processing
methods with respect to their bias. To compare diﬀerent normalization methods,
the following scores are employed:
• Correlation of fold changes based on expression intensities and fold changes
based on qRT-PCR measures (pages 95 f.) and
• Slope of regression between fold changes based on expression intensities and
fold changes based on qRT-PCR measures(pages 96 f.).
Normalization corrects for two diﬀerent eﬀects: background and scaling. Back-
ground means a global (or sometimes local) signal that adds to each value and is
due to light scattering, auto-ﬂuorescence or cross-hybridization. Scaling is neces-
sary since the amount of RNA used for hybridization, labeling rate and quantum
yield cannot be as precisely controlled as required. However, all these factors re-
duce (or amplify) the signal by a linear factor that can be estimated. In addition,
some normalization methods (e. g. variance-stabilizing-normalization (vsn) [160] or
variance-stabilizing-transformation (vst) [157]) employ a variance-stabilizing trans-
formation that will make the variance constant across the entire range of intensities,
provided that the underlying model of variance-intensity relationship holds true.
Since the total setup of the expression experiment is relatively complex, the analy-
sis has been focused on the TGF-β-stimulated and control samples measured at three
time points (2 hours, 4 hours, 12 hours) in four replicates. Thereby, a consistent sub-
set is used as representative for the whole data set based on which a normalization
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method has been selected. Twenty-ﬁve diﬀerent ways of pre-processing the expres-
sion data have been investigated. For a detailed overview of the normalization proce-
dures I refer the reader to Section 3.2 and Table 3.1 on page 53. In brief, ﬁrst either
background normalization from BeadStudio [162] (bg_∗) or no background modiﬁca-
tion (noBg_∗) has been applied. In a next step, the data was transformed using either
log2-transformation (log) or variance-stabilizing transformation (vst) [157]. Since
BeadStudio's background normalization can lead to negative values, the data had to
be transformed to contain only positive values by using either the background correc-
tion of rma [156] or forcePos [154] to be able to apply log2-transformation. In a last
step, the data was normalized using quantile, loess, or rsn [154] normalization.
Alternatively, the transformation steps were skipped and vsn [160] or the normal-
ization methods supplied by BeadStudio (average, rankInvariant, cubicSpline)
were used for normalization.
Pre-processing methods were scored from −2 to 2 based on how well they match
the required criteria for the diﬀerent analyses described in this section. A com-
plete overview of the scores assigned and the ﬁnal ranking is given in Section 4.1.3,
Figure 4.12.
4.1.1 Analyses of Variance Based on Expression Intensities
One basic assumption of gene expression pre-processing methods is that the majority
of genes do not change their expression under diﬀerent conditions. Additionally,
expression intensities of replicates should be very similar in contrast to the expression
of transcripts between diﬀerently treated sample groups. Based on these principles,
we looked at diﬀerent statistical measures to identify the method best suited for our
dataset with respect to variance.
Distribution of F-test Statistics
A good normalization method should minimize the variation within a biological con-
dition, i. e. within a group of replicates. Furthermore, the variation within a group
should be smaller than the variation between groups. The F-statistic measures the
variation between replicates in comparison to the variation between conditions or
groups [186, 187] (Eq. 3.3, page 54). Results for the F-statistic based on the gene
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Figure 4.1: Cumulative Distribution Functions of F-test p-values. Cumula-
tive Distribution Functions (CDFs) of FDR-corrected F-test p-values (Eq. 3.3, page 54)
were calculated based on the gene expression measured for untreated HaCaT cells cultured
for 2, 4, and 12 hours. Each of the three groups is composed of four replicates. Displayed
are the results obtained for the diﬀerent pre-processing methods used. The vertical red
dashed line indicates the commonly chosen p-value cut-oﬀ of 0.05. The insert displays
the obtained results over the whole range of values from 0 to 1 on both axes. Assuming
that only few genes are diﬀerentially expressed across the diﬀerent time points bg_noNorm
(orange dashed line) outperforms the other normalization procedures.
expression measured for the untreated HaCaT cells cultured for 2 hours, 4 hours,
and 12 hours are displayed in Figure 4.1.
Four BeadStudio normalization methods (noBg_average, noBg_rankInvariant,
bg_rankInvariant, bg_average) show cumulative distribution functions that are
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clearly above those obtained based on all other pre-processing methods. Apply-
ing neither background correction nor any normalization method (noBg_noNorm,
Figure 4.1, light gray dashed line) results in a data set producing less transcripts
with adjusted p-values < 0.02 than other pre-processing methods. With decreasing
signiﬁcance of the adjusted p-values, more pre-processing methods produce fewer
p-values of higher signiﬁcance than noBg_noNorm. Based on the data set used, we
expect only a small subset of the transcripts to be signiﬁcantly deregulated. Since
for bg_noNorm (Figure 4.1, orange dashed line) compared to other pre-processing
methods the fewest genes would be detected as being diﬀerentially expressed, i. e.
showing a relatively high variation between compared to within group variability,
this method seems to provide the best results. The remaining pre-processing meth-
ods for which the CDFs are running between that of bg_noNorm and bg_average
perform relatively similar and equally well.
P-Values versus MSQbetween
Assuming a stable variance over the within group measurements, the higher the vari-
ance between the groups (Eq. 3.2, page 54) compared to the within group variance
(Eq. 3.1, page 54), the higher the respective −log10(p − value) should be. When
plotting these parameters, an appropriate normalization method should result in
smoothly increasing values with not much scattering around the ﬁtted curve. Fig-
ure 4.2 displays the −log10(p − value) against the respective variance between the
control groups at time points 2 hours, 4 hours, and 12 hours for three of the pre-
processing methods, an overview of all results is given in [53].
Normalizations reﬂecting the described properties are for example noBg_vsn,
noBg_cubicSpline, noBg_log_rsn, and noBg_vst_rsn. All of the normalizations
performed on rma background corrected data as well as bg_vsn display a relatively
high −log10(p−value) for a relatively high proportion of low between group variabil-
ity values leading to a high scattering of observations in these regions. Using, for
example, the rank invariant normalization of BeadStudio (noBg_rankInvariant)
the p-values for the low between group variability tend to be relatively small. This
could lead to an overestimation of diﬀerentially expressed genes when ﬁltering solely
based on p-values.
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Figure 4.2: −log10(p−values) againstMSQbetween whereMSQbetween ≤ 5.
MSQbetween (mean sum of squares between groups, Eq. 3.2, page 3.2) was calculated based
on the gene expression measured for the three control groups, namely untreated HaCaT
cells cultured for 2, 4, and 12 hours. Each of the groups had been measured in four repli-
cates. Results of three exemplary pre-processing methods of diﬀerent quality are shown.
bg_rma_log_loess exhibits the most unfavorable behavior of the three. The p-values show
a high variability over the whole range of MSQbetween and even for small MSQbetween val-
ues there are many relatively high −log10(p − values). Though for noBg_rankInvariant
the p-values show less variability in general, especially for small MSQbetween values there
are more as well as higher −log10(p − values). In contrast, noBg_log_rsn exhibits less
varying p-values and does not assign as many small p-values to low MSQbetween regions.
The blue line represents a loess-curve ﬁtted to the values. This curve takes uniformly larger
values for noBg_rankInvariant and noBg_log_rsn than for bg_rma_log_loess indicating,
on average, smaller p-values for the same MSQbetween value. Thus, quality values of −1,
0, and 2 are assigned to bg_rma_log_loess, noBg_rankInvariant, and noBg_log_rsn, re-
spectively. For an overview of all diﬀerent normalization methods and their quality scores,
see Figure 4.12 and [53].
Boxplots of MSQbetween and MSQwithin
Distributions of between- (MSQbetween, Eq. 3.2) and within-group (MSQwithin,
Eq. 3.1) variances and their relation to each other are further indications for normal-
ization performance. If genes are not diﬀerentially expressed, MSQbetween should be
comparable to MSQwithin. For genes that are diﬀerentially expressed, MSQbetween
is supposed to be higher than MSQwithin. Figure 4.3 displays the boxplots for
MSQbetween (red) and MSQwithin (blue) values. Since we expect some genes to
be diﬀerentially deregulated across the diﬀerent time points under consideration,
quantiles of MSQwithin values should lie below the corresponding quantiles of the
4. Results 86
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Figure 4.3: Boxplots of MSQwithin (blue) and MSQbetween (red). Mean sum
of squares (MSQs) were calculated based on the gene expression measured for the three
sample groups analyzed, namely untreated HaCaT cells cultured for 2, 4, and 12 hours
(Eqs. 3.1 and 3.2, page 54). Results obtained for the diﬀerent pre-processing methods used
are displayed. The gray dashed line indicates the expected value for the MSQbetween of
1.33 based on 6, 6, and 7 as measurements for the group means of four replicates for three
time points (Eq. 3.2, page 54).
MSQbetween values. For the diﬀerentially expressed genes, within group variance
should be smaller than between group variance, whereas for the genes not diﬀeren-
tially expressed, the respective MSQbetween and MSQwithin values should show no
great diﬀerence. Small interquartile ranges (IQRs) of MSQwithin are indicative for
a comparable variability between genes.
To judge the distributions, MSQbetween was calculated for artiﬁcial group means
of log2 expression values for three time points based on four replicates. The group
means used were (6, 6, 7) which resulted in anMSQbetween of 1.33 (Eq. 3.2, page 54),
indicated by a dashed gray line in Figure 4.3. The mean expression values of the
artiﬁcial groups have been chosen such that they exhibit a log2 ratio of 1 when
group 3 is compared to group 1 or group 2, reﬂecting a relevant diﬀerence between
those groups. A good normalization method should result in similar expression
values for replicates and thus in small MSQwithin values hardly crossing this arti-
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ﬁcial MSQbetween. Additionally, since we limited the whole data set to expressions
measured for untreated HaCaT cells across time, we expect only few genes to be dif-
ferentially expressed. Thus, only a few genes are assumed to result in anMSQbetween
above the artiﬁcial threshold of MSQbetween = 1.33.
Almost all boxplots representing MSQwithin of background normalized data
(bg_*) result in outliers crossing the artiﬁcial MSQbetween, only those trans-
formed using vst do stay below. Compared to other pre-processing methods,
noBg_vst_loess, noBg_log_loess, and bg_vst_loess show a relatively wide IQR
for both, MSQbetween and MSQwithin. Methods that meet the described be-
havior are bg_vst_quantile, bg_vst_rsn, noBg_log_quantile, noBg_log_rsn,
noBg_noNorm, noBg_vsn, noBg_vst_quantile, and noBg_vst_rsn. They show a
low within group variability for which the quantiles generally exhibit lower values
than the quantiles of the between group variabilities.
Density Functions of MSQbetween and MSQwithin
Density functions of MSQbetween and MSQwithin should exhibit clear diﬀerences.
This fact renders density functions of MSQbetween and MSQwithin an additional op-
tion for investigating these values. Within group variability should be smaller than
between group variability and most of the genes should show a between group vari-
ability similar to the within group variability, i. e. are not diﬀerentially expressed.
Thus, the mode of MSQwithin should be smaller than the mode of MSQbetween and
the peak of the function for MSQwithin is supposed to be higher than the peak
for MSQbetween. Lean MSQwithin functions, on the one hand, reﬂect a comparable
within group variability for many genes. On the other hand, broader MSQbetween
functions indicate that at least some of the genes, i. e. the diﬀerentially expressed
ones, show a higher between than within group variability. Ideal characteristics of
density functions as described here are very similar to the characteristics of ideal
boxplots mentioned in the previous section. In contrast to density functions, box-
plots give a very rough idea about the distribution of the values, also depicting
outliers. Density functions deliver a more detailed view of how the values are dis-
tributed across diﬀerent ranges.
Figure 4.4 displays density functions of MSQwithin (blue) and MSQbetween (red)
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Figure 4.4: Density plots ofMSQwithin (blue) andMSQbetween (red). Mean
sum of squares were calculated based on the gene expression measured for the three
sample groups analyzed, namely untreated HaCaT cells cultured for 2, 4, and 12 hours
(Eqs. 3.1 and 3.2, page 54). Each of the groups is composed of four replicates. The gray
dashed line indicates the expected value for the MSQbetween of 1.33 based on 6, 6, and
7 as measurements for the group means of four replicates for three time points. Three
examples of diﬀerent quality are shown. Based on the noBg_vst_loess pre-processing
the MSQwithin values show a strong bimodal distribution, for the bg_rma_log_rsn pre-
processing the distribution is highly skewed. The distributions for noBg_log_rsn based
values reﬂect the desired behavior. The quality values assigned are −2, 0, and 2, for
noBg_vst_loess, bg_rma_log_rsn, and noBg_log_rsn, respectively. For an overview of
the distributions for all pre-processing methods and their respective plots, see [53] or Ap-
pendix B Figure B.1.
for three of the pre-processing methods, a complete overview is given in [53]. In par-
ticular density plots representing the normalization methods noBg_log_quantile,
noBg_log_rsn, and noBg_vsn come close to the desired behavior. Unexpectedly the
density functions of MSQwithin generated by bg_vst_loess, noBG_log_loess, and
noBg_vst_loess are bimodal. One reason for bimodal density functions could be a
group of transcripts exhibiting higher variability compared to other transcripts. In
general, it is expected that the data shows a consistent variability. Having the oppor-
tunity to choose between normalization methods resulting in unimodal or bimodal
density functions for MSQwithin, normalization methods leading to a unimodal dis-
tribution should be favored. A small overlap of the functions like for the values
generated by the noBg_average normalization (Appendix B Figure B.1) would in-
dicate the unlikely event that most of the genes show a higher between than within
group variability, i. e. are diﬀerentially expressed. Under the assumption of constant
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expression of most transcripts, this normalization method is not adequate.
Volcano Plots
Volcano plots are a standard visualisation of results for microarray diﬀerential ex-
pression analysis. They are generated by plotting −log10(p − value) versus the
respective log2 ratios. The former measures the signiﬁcance of the change, while the
latter (ratio of mean intensity in group 1 over mean intensity in group 2) measures
the extent of this change. Due to the tendency of larger log2 ratios being connected
to more signiﬁcant −log10(p − values) a volcano like shape is generated. Again
using untreated HaCaT cells cultured for 2, 4, and 12 hours, pairwise comparisons
(4 hours compared to 2 hours, 12 hours compared to 2 hours, and 12 hours com-
pared to 4 hours) using a moderated t-statistic were performed to calculate log2
ratios and p-values (Section 3.2.2, page 55, [165]). Our aim is to detect normal-
ization procedures yielding as correct estimates of log2 ratios as possible combined
with as informative p-values as possible. As mentioned above, higher log2 ratios
should tend to have higher −log10(p − value). The loess ﬁts of the log2 ratios and
−log10(p− value) pairs (black curves) of the volcano plots shown in Figure 4.5 shall
neither be too ﬂat nor too narrow and the scatter of the p-values for speciﬁc log2
ratios should not be too large.
All volcano plots based on rma background corrected data show undesired char-
acteristics. The ﬁtted curves are rather ﬂat, i. e. even for high absolute log2 ratios
the −log10(p − value) are relatively low. Additionally, the −log10(p − value) for
similar log2 ratios tend to scatter extremely. Some plots, e.g. for bg_average,
bg_noNorm, bg_rankInvariant, and noBg_rankInvariant, show an asymmetri-
cal relation between p-values for negative and positive log2 ratios. Especially
noBg_rankInvariant exhibits a bias towards small negative log2 ratios for which
the respective −log10(p − value) seems to be relatively high. In this region the
ﬁtted curve shows a very steep, linear course. Volcano plots generated for all
other methods are similar to what would be expected. Still they diﬀer in the vari-
ance of the p-values and in that some of the ﬁtted curves show a ﬂatter shape
than others. This reﬂects the fact that some normalization methods generate
a smaller variance than others, resulting in lower fold changes but more signif-
icant p-values. Ultimately, a method with a reasonable trade-oﬀ between fold
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Figure 4.5: Volcano plots. log2 ratios and p-values for the comparison of untreated
HaCaT cells at 4 hours compared to 2 hours, 12 hours compared to 2 hours, and 12 hours
compared to 4 hours were calculated based on the gene expression measured. Three ex-
amples of diﬀerent qualities are displayed showing the −log10(p− value) against log2 ratio
comparing 4 hours to 2 hours. The black line represents a loess-curve ﬁtted to the values.
Quality values assigned to bg_rma_log_rsn, noBg_log_loess, and noBg_log_rsn are −2,
0, and 2, respectively. Pre-processing using bg_rma_log_rsn yields a very ﬂat volcano like
shape with p-values exhibiting a high degree of scattering, i. e. log2 ratios are overesti-
mated and at the same time p-values are not very accurate. In contrast, noBg_log_loess
better represents the expected range of log2 ratios (not many genes are assumed to heavily
change their expression between the diﬀerent time points), but compared to noBg_log_rsn
p-values still are not very accurate, i. e. show a high degree of scattering for equivalent log2
ratios. For a complete overview of all methods and all comparisons, see [53].
change and variance has to be chosen, and cut-oﬀ parameters for interesting genes
have to be deﬁned accordingly. Volcano plots that best reﬂect the desired prop-
erties in the context of our experiment were generated by noBg_log_quantile,
noBg_log_rsn, and noBg_vsn. They show the least scattering of values around
the ﬁtted curves, but, as indicated by the steep ﬁtted curves, they probably un-
derestimate fold changes. Plots produced by noBg_cubicSpline, noBg_log_loess,
noBg_vst_loess, noBg_vst_quantile, noBg_vst_rsn, bg_forcePos_log_loess,
bg_forcePos_log_quantile, bg_forcePos_log_rsn, bg_vst_quantile, and
bg_vst_rsn also fulﬁll the above mentioned criteria, but show more scattering.
Residual Standard Deviation Against Mean and Minimum of Gene Ex-
pression Levels
In an optimally normalized experiment the residual standard deviation of ﬁtted gene
expression intensities should be low and independent of the expression levels, i. e.
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Figure 4.6: Residual standard deviation against expression intensities. Stan-
dard deviation of the residuals (residual sd) observed for gene expression intensities are plot-
ted against minimum (upper row) and mean (lower row) expression intensity of each tran-
script. The blue line represents a loess-curve ﬁtted to the values. bg_rma_log_quantile
exhibits very high deviation of residuals in ranges of lower expression intensities, whereas
noBg_vst_rsn shows homogeneous and low deviations of residuals over the whole range
of expression intensities. Compared to noBg_vst_rsn, residual standard deviations tend
to be a bit higher and less homogeneous in small ranges of expression intensities when
noBg_cubicSpline is used for pre-processing. Thus, scores of -2, 0, and 2 are assigned
for bg_rma_log_quantile, noBg_cubicSpline, and noBg_vst_rsn, respectively. For an
overview of all methods, see [53].
the variance over the diﬀerent expression levels should be stable. This is prerequi-
site for many statistical methods, like for example linear model ﬁtting and moderate
t-statistics [165], that are utilized for analyzing gene expression data.
As indicated in Figure 4.6, all of the methods without background normalization
(noBg_*) show a moderate or low variance in regions of no or hardly-to-measure
expression. In contrast, nearly all of the background corrected methods (bg_*) re-
sult in high and, compared to the other methods, instable variance in the range of
low intensity values. Extreme examples especially are rma background corrections
and bg_vsn normalization procedures. An exception are those methods that use
background normalization in conjunction with variance-stabilizing transformation
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Figure 4.7: Scatterplots between replicates. After application of diﬀerent nor-
malization methods, expression values for the respective replicates at 12 hours are plotted
against each other. bg_vsn as well as noBg_vst_rsn display a symmetrical distribution
of expression values around the main diagonal (orange line), with bg_vsn exhibiting more
scattering values especially obvious in regions of low expression. The scatterplot based
on bg_vst_loess is slightly bended towards the upper diagonal based on a bias to higher
values in the expression values for replicate 4. Scores of −2, 1, and 2 are assigned to
the scatterplots based on bg_vsn, bg_vst_loess, and noBg_vst_rsn, respectively. For an
overview of all methods, I refer the reader to [53].
(bg_vst_*), which in contrast to other procedures using background corrections per-
form especially well. Methods which perform best with respect to variance stabiliza-
tion across all expression levels are bg_vst_loess, bg_vst_quantile, bg_vst_rsn,
noBg_vst_loess, noBg_vst_quantile, and noBg_vst_rsn.
Scatterplots of Expression Values
Scatterplots are an easy and straightforward visualisation tool for judging the com-
parability of replicates. They clearly show whether high variances are to be expected
and, if this is the case, in which range of the expression data. Figure 4.7 displays
the expression values of replicates plotted against each other. The results con-
ﬁrm our previous ﬁndings. Some of the methods, for example bg_rma_log_loess,
bg_rma_log_quantile, bg_rma_log_rsn, and bg_vsn, show high variance espe-
cially in the range of lower expression. Plots generated based on these proce-
dures exhibit high variability between replicates. Some of the methods like for
example bg_noNorm, bg_vst_loess, and noBg_average lead to asymmetric scat-
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terplots indicating a bias in the expression values and a higher variability between
replicates. Methods that perform well in stabilizing the variance across diﬀerent
expression levels, for example bg_vst_quantile, bg_vst_rsn, noBg_vst_loess,
noBg_vst_quantile, and noBg_vst_rsn, could also be conﬁrmed by the scatter-
plots. Additionally to those, noBg_cubicSpline and noBg_rankInvariant exhibit
symmetric scatterplots with a very low degree of variance between replicates.
Pseudo-ROC Curves
In order to compensate for missing spike-in and dilution data, a pseudo-ROC ap-
proach [164] mimicking the presence of true negatives has been conducted. True
positives were selected from bona ﬁde target genes of TGF-β, thus they are ex-
pected to change in expression upon stimulation of TGF-β signaling (Section 3.2.2,
page 54). The pseudo-ROC curve for each normalization method is a linear trans-
formation of the true ROC curve. Common single number summaries used to score
and compare ROC curves - the area under the curve (AUC) or the sensitivity at
a given false positive rate - are area or distance based. They are reduced by this
transformation, but to the same degree for every curve. Aiming at the validation
of normalization methods with respect to their ability to generate data exhibiting
a good sensitivity to speciﬁcity ratio, expression intensities derived from TGF-β-
treated versus untreated cells at 2 hours were compared. Based on the AUC of the
pseudo-ROC curves (Figure 4.8), all normalization methods perform relatively well
in delivering values suited for separating true positives from true negatives. To as-
sign quality values to the ROC curves, the AUC values were sorted and subsequently
allocated to three bins of sizes 5, 18, and 2. Finally the bins were assigned qual-
ity values of −1, 0, and 1, respectively (Figure 4.12). bg_rankInvariant performs
best with an AUC of 0.9102, whilst bg_vst_loess performs worst with an AUC of
0.8403.
4.1.2 Analyses of Bias Based on qRT-PCR
qRT-PCR has been performed for mRNAs from eight genes that are known to be
deregulated by TGF-β signaling to a varying degree, namely CDKN1A, CDKN2B,
HAND1, JUNB, LINCR, RPTN, SERPINE1, and TSC22D1. By this means, it is
possible to compare the results of the normalization methods to values that reﬂect
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Figure 4.8: Pseudo-ROC curves based on adjusted p-values. Pseudo-ROC
curves were calculated for the diﬀerent pre-processing methods. FDR-adjusted p-values
[163] of an F-statistic (Eq. 3.3, page 3.35) comparing the expression intensities measured
for untreated and TGF-β-stimulated HaCaT cells cultured for 2 hours were used. Each of
the two groups is composed of four replicates. (TPR: true positive rate, FPR: false positive
rate, AUC: area under the curve).
the real abundance of the respective mRNA in the cells. Thus, it was possible to
evaluate the accuracy of the diﬀerent pre-processing methods with respect to their
bias. To guarantee that the comparisons of the normalization methods are not
biased towards certain intensities, the mRNAs used in qRT-PCR experiments were
chosen such that the respective signals on the chips cover a broad range of expression
intensities.
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Figure 4.9: Pearson correlation of log2 ratios for diﬀerent normalization
methods and qRT-PCR. Correlations of log2 ratios were calculated for diﬀerently pre-
processed gene expression data from BeadChip arrays and qRT-PCR based results. On the
x-axis, pre-processing methods are ranked according to their correlation to qRT-PCR. The
dashed red lines indicate the cut-oﬀs used for assigning quality score between −2 (≤ 0.9)
and 2 (≥ 0.96).
Correlation Analysis of Fold Changes
Based on the diﬀerent normalization procedures for the gene expression experiment
and based on the qRT-PCR measurements, Pearson correlations of the respective
fold changes measured for TGF-β-stimulated versus untreated cells at 2, 4, and
12 hours were calculated. Figure 4.9 displays the ranked correlation coeﬃcients de-
scribing the relation between the diﬀerent normalization methods and the qRT-PCR
results. Quality values were assigned based on correlation cutoﬀs. A value of 2 is
assigned to correlation coeﬃcients ≥ 0.96, a value of 1 to coeﬃcients between 0.96
and 0.94, a value of 0 to coeﬃcients ≤ 0.94 and ≥ 0.92, a value of −1 to coef-
ﬁcients between 0.92 and 0.9, and a value of −2 to correlation coeﬃcients ≤ 0.9
(Figure 4.12).
Values derived from most of the methods not utilizing background correction
(noBg_*) show a lower correlation to the qRT-PCR results than expression intensities
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Figure 4.10: Orthogonal regression between qRT-PCR and normalization
based log2 ratios. Regression of log2 ratios was conducted based on diﬀerent normaliza-
tion methods (y-axis) against qRT-PCR (x-axis). Equations and the respective regression
lines are displayed in red. The gray dashed line indicates the main diagonal. Compared to
qRT-PCR, log2 ratios as calculated based on noBg_rankInvariant and noBg_log_loess
pre-processing are overestimated in the lower and underestimated in higher ranges of log2
ratios. This over- and underestimation is more extreme for noBg_rankInvariant (intercept
= 0.177, slope = 0.542) than for noBg_log_loess (intercept = 0.109, slope = 0.658). Data
pre-processed using bg_rma_log_loess hardly over- or underestimates the data (intercept
= −0.276, slope = 0.965). This results in scores of −2, 0, and 2 for noBg_rankInvariant,
noBg_log_loess, and bg_rma_log_loess, respectively. An overview of the results for all
pre-processing methods is given in [53].
that are background corrected (bg_*). An exception in this regard are methods that
are based on vst transformation (bg_vst_*). These three methods are amongst
the six methods resulting in the lowest correlation coeﬃcient values. Correlation
coeﬃcients exhibiting high values are delivered by methods introducing BeadStudio's
background correction combined with either rma background correction and log2-
transformation (bg_rma_log_*), cubic spline normalization (bg_cubicSpline), or
variance stabilizing normalization (bg_vsn).
Regression Analysis
To investigate the linear relationship between fold changes as determined by gene
expression data and qRT-PCR, a linear regression analysis was performed by min-
imizing the sum of squares of the Euclidean distance of points to the ﬁtted line
(orthogonal regression, Figure 4.10). This method was chosen because there is no
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Figure 4.11: Results of orthogonal regression. Ranking of slope (A) and inter-
cept (B) of the orthogonal regression lines as exemplary displayed in Figure 4.10. For the
slope, quality scores are assigned from −2 to 2 as indicated by the red dashed lines.
clear assignment of dependent and independent variables (Section 3.2.2, page 55).
Figure 4.11 displays the ranking of the diﬀerent methods according to the slopes of
the orthogonal regressions. Following rules apply for results of these analyses: The
closer the slope is to 1, the better the respective normalization method reﬂects the
qRT-PCR results in a linear manner. In this situation the deviation of the inter-
cept from 0 indicates a constant under- or overestimation of the change of mRNA
abundance across the whole range of fold changes. An intercept < 0 stands for
an underestimation and an intercept > 0 for an overestimation of fold changes. In
the case that the slope deviates from 1 the diﬀerence between qRT-PCR based fold
changes and normalized expression based fold changes depends on the size of the
fold change. Here, on the one hand, an intercept near 0 implies a continuous over-
(slope > 1) or underestimation (slope < 1). Depending on the slope, an intercept
deviating from 0, on the other hand, indicates overestimation for a certain range of
values and underestimation for another range of values. Regardless of the intercept,
the most relevant point in our case is that the scatterplots are generally linear, with
low variability and a slope close to 1.
In accordance to previous results, all expression values that are transformed using
vst together with noBG_rankInvariant result in slopes that exhibit the largest
deviation from 1. Fold changes calculated based on rma background correction and
log2-transformation (bg_rma_log_*) best ﬁt the qRT-PCR results (Figure 4.11).
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Figure 4.12: Heatmap of quality scores assigned for the diﬀerent pre-
processing methods. Displayed are the quality scores for the diﬀerent pre-processing
methods given for the analyses conducted. Quality scores range from −2 (bad) to 2 (good).
The values in parentheses display the sum over the single quality scores for the respective
pre-processing procedures. Based on this sum, the pre-processing method ﬁnally used to
normalize the expression data has been chosen. Manhattan distance and complete link-
age algorithm were used for clustering. Methods evaluating the bias (slope of regression,
correlation to qRT-PCR) are clearly separated from methods evaluating the variance. Pre-
processing procedures that perform best based on the sum over quality scores are located
at the top of the heatmap.
4.1.3 Summary
After evaluating each of the twenty-ﬁve normalization procedures and assigning
scores ranging from -2 to 2, the methods were clustered based on the scores as-
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signed for the considered quality measures. Methods evaluating the bias (slope of
regression, correlation to qRT-PCR) are clearly separated from methods evaluating
the variance. Pre-processing procedures that perform best based on the sum over
quality scores are located at the top of the heatmap (Figure 4.12). The bottom part
of the heatmap is dominated by background normalized data sets which, on average,
score worse than those that have not been background normalized. Based on the
sum over the individual scores, the pre-processing method used to normalize the
expression data has been chosen. As can be seen in Figure 4.12, noBg_log_rsn and
noBg_log_quantile achieve the same overall score. Based on the results presented
in this section, noBg_log_rsn was selected as the ﬁnal normalization method for
further analysis. A detailed discussion on this decision is given in Section 5.1.
4.2 Evaluating New Chemical Entities by State-of-
the-Art Approaches
In this section, I describe how the expression data for the seven NCEs (Section 3.1.1)
can be analyzed by applying state of the art approaches. Five BI compounds, BI1
to BI5, belonging to the chemical class of indolinones, and two competitor sub-
stances, Ex1 and Ex2, belonging to the chemical class of pyridopyrimidinones, with
inhibitory potency towards TGF-βR1 kinase have been used. As we are interested
in revealing MoA of the NCEs, two eﬀects are of interest, the on- and the oﬀ-target
eﬀect. On-targets are those proteins, that are intended to be hit, i. e. in our case
inhibited, by the compound. The compounds used in this study bind to the ATP
pocket of the TGF-βR1 kinase domain. Thereby binding of ATP as well as phos-
phorylation of proteins downstream in the signaling cascade is prevented and, thus,
signal transduction is inhibited. In contrast to on-targets, oﬀ-targets are all those
proteins that are hit/modulated by the compound in addition to the intended tar-
get. ATP pockets are domains highly conserved among kinases, leading to a high
potential of oﬀ-target activities [8789]. Eﬀects caused by on- and oﬀ-target activi-
ties of compounds are referred to as on- and oﬀ-target eﬀects, respectively.
In Section 4.2.1 the on-target signature is derived. As the NCEs under investiga-
tion were designed to inhibit TGF-βR1, the on-target signature refers to those genes
that are deregulated by TGF-β signaling. The degree of deregulation should depend
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on compound treatment in a dose dependent manner. Genes of this signature should
further be regulated in opposite directions for TGF-β-stimulated cells compared to
unstimulated cells and compound treated plus TGF-β-stimulated cells compared to
TGF-β-stimulated cells. Based on the genes contained in this signature, KEGG
pathways are checked for enrichment of those genes.
In Section 4.2.2 an oﬀ-target signature is derived for each of the seven NCEs. An
NCE's oﬀ-target signature is composed of that set of genes that is deregulated due
to oﬀ-targets of the respective NCE. Diﬀerent gene sets were checked for enrichment
of oﬀ-target signature genes in Section 4.2.3.
4.2.1 Eﬀects Related to TGF-β Signaling - On-Target Signa-
ture
In order to gain a deeper insight into the TGF-β biology we ﬁrst identiﬁed genes that
are diﬀerentially expressed comparing TGF-β1-stimulated to unstimulated HaCaT
cells. To unravel the time-dependent eﬀects of TGF-β treatment, HaCaT cells were
stimulated with TGF-β1 for 2, 4, and 12 hours. While immediate early genes that
are directly regulated by the TGF-β pathway are detected at 2 hours post stimu-
lation, more and more secondary eﬀects linked to TGF-β signaling are found after
4 and/or 12 hours. Additionally, genes that are directly linked to TGF-β signaling
pathway should be regulated in a dose dependent manner with respect to compound
treatment. Thus, to avoid arbitrary fold change cut-oﬀs we do not only make use
of the TGF-β1-stimulated compared to untreated cells, but also consider the com-
pound treated cells to derive a TGF-β signature.
Two criteria were applied to identify TGF-β signature genes (Section 3.3.2): First,
genes that were signiﬁcantly deregulated (p-value ≤ 0.01) in a basic comparison of
TGF-β-stimulated versus unstimulated cells were selected for further analysis (Sec-
tion 3.3.2: i, page 56). 1046, 1949 and 5725 genes (6525 non-redundant genes) were
found to be regulated 2, 4 and 12 hours after stimulation. In a second step, these
genes were proven to be aﬀected in a dose-dependent manner in the opposite direc-
tion to the TGF-β-eﬀect by NCE treatment after TGF-β stimulation using a like-
lihood ratio test statistic for monotonicity [166] (Section 3.3.2: ii+iii, page 56). By
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Figure 4.13: Venn diagram for the on-target TGF-β signature The list of
genes 446, 772 and 1,932 genes were identiﬁed as the NCE-dependent on-target TGF-β
signature 2, 4, and 12 hours after NCE treatment and TGF-β stimulation.
this means these genes can be separated from potential compound related oﬀ-target
eﬀects. All transcripts identiﬁed for each NCE were merged to a common signature
of TGF-β dependent genes (Section 3.3.2, page 56). Thereby, the identiﬁcation of
a common on-target signature focused on minimizing the amount of false positive
and false negative genes. The Venn diagram displayed in Figure 4.13 depicts the
number of genes that were identiﬁed 2, 4, and 12 hours after stimulation: 446 genes
(2 hours), 772 genes (4 hours) and 1932 genes (12 hours), respectively. A compre-
hensive list of genes assigned to the TGF-β signature, i. e. the on-target signature,
can be found in [54].
Subsequently, the genes comprising the TGF-β signature were checked for en-
richment in certain gene sets. Gene sets from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [114, 188] corresponding to 201 diﬀerent pathways were used.
Applying Fisher's exact test resulted in 16 diﬀerent signaling pathways which were
signiﬁcantly enriched by genes that are deregulated upon TGF-β stimulation. By
clustering the respective p-values these 16 pathways could be divided into four groups
that correspond to the time frame of aﬀectedness (Figure 4.14).
Not surprisingly, the TGF-β signaling pathway itself as well as directly aﬀected
pathways like WNT and p53 signaling were signiﬁcantly regulated by the treatment
of TGF-β (cluster 1). In cluster 2, signaling by MAPK, cytokines, ErbB, Shh, as well
as apoptosis are strongly aﬀected immediately early upon TGF-β stimulation. The
modulation is reduced at later time points (4 and 12 hours), when more secondary
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Figure 4.14: Gene set enrichment analysis using KEGG pathways. En-
richment analysis using Fisher's exact test resulted in 16 signiﬁcantly aﬀected gene
sets/signaling pathways. Clustering of −log10 p-values using complete linkage and man-
hattan distance resulted in four major clusters: immediate early aﬀected pathways (cluster
2), permanently aﬀected pathways with emphases at early (cluster 1) and late time points
(cluster 4) or late established events (cluster 3). The color code deﬁnes the signiﬁcance
determined by Fisher's exact test.
eﬀects, such as DNA polymerase, actin cytoskeleton, amino acid metabolism, gap
junction, and tight junction signaling become apparent (cluster 3). The activation
of these pathways in combination with the modulation of the cell cycle and cell
communication activity (cluster 4) seem to relate to phenotypic consequences of
TGF-β stimulation.
4.2.2 Inferring the Oﬀ-Target Eﬀects
After the identiﬁcation of the TGF-β signature (on-target signature) as well as the
related pathways, we tried to identify the NCEs' oﬀ-target eﬀects. This was done
by ﬁrst deriving an oﬀ-target signature solely based on gene expression as described
in Section 3.3.3. Second, the genes of the respective signatures were checked for
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enrichment within gene sets describing molecular functions and canonical pathways
as deﬁned by Ingenuity Pathway Analysis software [144].
Each compound treatment resulted in a unique gene expression signature of regu-
lated genes. These signatures are composed of the cellular response to two diﬀerent
stimuli, i. e. TGF-β1 and NCE stimulation. Thereby, elucidating the eﬀects based
on NCE treatment is more demanding since both TGF-β, i. e. on-target as well as
oﬀ-target eﬀects occur. We also observed interaction eﬀects of the vehicle (DMSO)
with the NCEs. The eﬀects of the diﬀerent stimuli overlap and also interfere with
each other constraining a clear signature resolution. The proﬁle of a given gene may
therefore be dependent on which eﬀect prevails and thus, dose-dependency might
no longer be observed [52, 54]. That is why we had to come up with a deﬁnition
of the oﬀ-target signature that allows a certain degree of variability by avoiding a
stringent cutoﬀ. Details on how the ﬁnal oﬀ-target signature is derived are described
in Section 3.3.3. By applying the described strategy, we empirically observed a good
trade-oﬀ between false positives and false negatives in the oﬀ-target signatures.
In a ﬁrst approximation, the NCE treatment phenotypes were determined as
the total of all regulated genes (p-value < 0.01 and |log2ratio| ≥ 1) comparing
NCE-treated and TGF-β-stimulated cells to DMSO control-treated and TGF-β-
stimulated cells. This analysis was done separately for each of the tested compounds
at each concentration. Subsequently, the diﬀerent phenotypes obtained after 2 hours
NCE treatment were clustered to unravel similarities between the diﬀerent signa-
tures (Figure 4.15). The early time point allowed focusing on primary aﬀected genes
that were altered as direct response to the treatment. Hierarchical clustering clearly
revealed two major clusters separating the group of indolinones (BI1 to BI5) from
the pyridopyrimidinones (Ex1 & Ex2). Thus, the classical concept of chemotypes
determining biological proﬁles of NCEs holds true in this case. More details about
the inﬂuence of chemotypes and diﬀerent side chains are given [52]. Additional to
the separation based on chemotypes, clusters also depend on high and low dose of
the compound.
Identifying a particular oﬀ-target based on this approach is diﬃcult. Further anal-
yses were therefore performed to separate the compounds' oﬀ-target eﬀects from the
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Figure 4.15: Hierarchical clustering of genes diﬀerentially expressed due
to NCE treatment. 4,314 genes were found to be signiﬁcantly deregulated (|LR| ≥ 1
and p − value < 0.01) by at least one NCE. The diﬀerent treatment groups were hier-
archically clustered according to the correlation coeﬃcients of the respective genes using
complete linkage. The ﬁve indolinones (BI1-BI5) are grouped and separated from the two
pyridopyrimidinones (Ex1 & Ex2). Additionally, clusters show grouping by high vs. low
dose treatment. The indolinone BI1 separates from the other class members.
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treatment signatures. As mentioned above, not all oﬀ-target eﬀects can be identiﬁed
through dose dependent correlation. Reasons for this are overlapping, inverse, and
additive eﬀects [54]. Hence, oﬀ-targets can only be identiﬁed based on NCE-treated
samples in presence and absence of the TGF-β stimulus. In brief, all regulated genes
(p-value < 0.01 and |log2ratio| ≥ 1) identiﬁed by comparing compound-treated cells
(either 0.08µM or 2µM) to DMSO-treated controls were selected. Genes were con-
sidered once the regulation was observed during compound treatment upon TGF-β
stimulation as well as without TGF-β stimulation. Thereby, it was ensured to select
only drug oﬀ-target and TGF-β independent alterations. A more detailed descrip-
tion on how these genes are identiﬁed is given in Section 3.3.3 on pages 56 ﬀ.. All
genes that matched the described criteria were allocated to the oﬀ-target signature
of the respective NCE after 2, 4, and 12 hours. Based on this analysis, huge diﬀer-
ences in the amount of oﬀ-target genes were observed. While treatment with BI1
deregulated 2, 752 genes at all time points, BI3 deregulated only 973 genes. Slightly
more oﬀ-target genes were identiﬁed for the indolinones BI2, BI4 and BI5 (1, 050,
1, 064 and 1, 100, respectively). The pyridopyrimidinones regulated 1, 347 (Ex1) and
1, 306 (Ex2) genes. The largest oﬀ-target increase over time was seen for Ex1 and
Ex2 with almost four times more genes being regulated comparing the 12 hours to
the 2 hours time point. In contrast, the amount of oﬀ-targets for the ﬁve indolinones
was at a maximum doubled within this period.
In summary, looking at the oﬀ-target signatures in general, the indolinones except
for BI1 appear more favorable compared to the pyridopyrimidinones at later points
in time. Among the indolinones, BI2 to BI5 deregulate fewer genes than BI1 at
all points in time. This also conﬁrms diﬀerences in structure-activity relationships
observed by Roth et al. [1] for diﬀerences in substitution positions of certain residues
of BI1 compared to BI2 to BI5. They demonstrate that indolinones such as BI1
showed a less favorable selectivity proﬁle compared to indolinones such as BI2 to
BI5. Among the indolinones, BI3 appears to be the most attractive compound when
merely looking at the oﬀ-target analysis.
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Figure 4.16: Compound proﬁles. Every circle represents one of the seven proﬁled
compounds. The size of each circle corresponds to the number of oﬀ-target genes (in
red). The relative amount of on-target gene numbers are shown in blue. As described
in Section 4.2.1 and displayed in Figure 4.13, the on-target signature is composed of 446,
772, and 1,932 genes at 2, 4 and 12 hours, respectively. The relative amount of on- and
oﬀ-target genes can easily be seen. Whereas BI1 has both, the highest net amount of
oﬀ-targets as well as the highest relation of oﬀ- compared to on-targets, Ex1 and Ex2 lie
between BI1 and BI2 to BI5. BI2 to BI5 constitute the better compounds with respect to
both, number of oﬀ-targets, which should be low, as well as relation between number of
oﬀ- compared to number of on-targets.
4.2.3 Mode of Action Analysis Using Existing Approaches
Diﬀerent in silico strategies can be applied to analyze the oﬀ-target signatures of
the compounds in order to generate hypothesis about their mode of action. As
diﬀerent criteria have been combined to derive the oﬀ-target signature, there is no
homogeneous and consistent value/measure assigned to the genes contained in this
signature that is appropriate to conduct enrichment analysis which rely on measures
assigned for each individual gene (see Section 2.4.1). Thus, we decided to conduct
enrichment analysis based on Fisher's exact test which does not depend on any
measures assigned to the genes but is purely count-based (Section 3.6.2).
Gene Set Enrichment
Initially, the genes from the 12 hours oﬀ-target signatures were assigned to their
molecular function using Ingenuity Pathway Analysis. Since we were interested in
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-log10(p-value)
Figure 4.17: Clustering of gene set enrichment results for oﬀ-target genes
of all seven NCEs after 12 hours treatment. Using Fisher's exact test, an
enrichment test was conducted based on the molecular function gene sets as deﬁned by the
Ingenuity Knowledge Base [144]. For each gene set, a p-value was obtained. Displayed is
the clustering of gene sets signiﬁcant for oﬀ-targets of at least one compound. Clustering
was calculated based on the −log10(p − values) using complete linkage and manhattan
distance.
long term events, this analysis was focused on a late time point. Hierarchical cluster-
ing of the functions based on the respective −log10(p-values) resulted in one major
cluster for both pyridopyrimidinones and in one for the indolinones (Figure 4.17).
The genes regulated by the indolinones are distributed in more classes; genes
involved in Vitamin and Mineral Metabolism, Cellular Compromise, Nucleic Acid-
and Amino Acid Metabolism are exclusively regulated by the indolinones. In accor-
dance with the structure-activity ﬁndings mentioned before, within the indolinone
subcluster, BI1 stands apart from the four other indolinones and BI2 and BI3 as
well as BI4 and BI5 are grouped in one cluster, respectively. The genes additionally
regulated by BI1 are involved in RNA Post-Transcriptional Modiﬁcation, Energy
Production, Cellular Response to Therapeutics and in RNA Traﬃcking. Half of
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the molecular functional classes identiﬁed are regulated by all compounds. How-
ever, this does not necessarily mean that the same genes are regulated since the
categories are rather generally deﬁned, such as Cell Cycle or Cellular Growth and
Proliferation. Furthermore, diﬀerent NCEs reach far higher signiﬁcance scores for
some categories than others caused by the higher amount of regulated genes in the
respective biological process, e.g. both pyridopyrimidinones regulate a huge amount
of genes involved in Cell Death and Cellular Growth and Proliferation.
In order to get a better understanding of the compounds' MoA Ingenuity Path-
way Analysis was used to further analyze the oﬀ-target signatures. We found
39 (2 hours), 38 (4 hours) and 51 (12 hours) canonical signaling pathways signiﬁ-
cantly enriched with oﬀ-target genes of at least one of the NCEs (Fisher's exact test,
−log10(p − value) > 2). While immediate early aﬀected processes can be found 2
hours after compound treatment, the eﬀect of the compounds manifests during late
phases. A hierarchical clustering of the pathway analysis representing the 12 hours
results is displayed in Figure 4.18. Again the indolinones are separated from the
pyridopyrimidinones, indicating that both compound classes share not only a com-
mon mode of action like TGF-β inhibition, but also generate a distinct aﬀection of
other pathways by their speciﬁc oﬀ-target function. BI1 results in 5 signiﬁcantly
ranked pathways and the smallest overlap among the indolinones. BI3 aﬀects 15
signaling pathways almost exclusively involved in diﬀerent cancer pathways. This
could hint at carcerogenicity of this NCE. The indolinones BI2 and BI4 regulated
genes that are signiﬁcantly enriched in only 4 (BI2) and 2 (BI4) signaling pathways,
respectively. However, pathways such as the Aryl Hydrocarbon Receptor Signaling
and the LPS/IL-1 mediated inhibition of RXR function are also signiﬁcantly ranked
high for up to six compounds at all three time points, indicating a more general eﬀect
like a xenobiotic response to NCE treatment rather than a true compound speciﬁc
eﬀect. The highest numbers of signiﬁcantly aﬀected pathways are found for the two
pyridopyrimidinones with 24 (Ex1) and 28 (Ex2). Additionally, genes involved in 29
out of the 51 signaling pathways are exclusively regulated by Ex1 or Ex2 treatment.
Conﬁrming previous ﬁndings, 12 out of the 51 identiﬁed pathways are related to tox-
icity and cell death. These 12 pathways reach highest signiﬁcance scores for either
Ex1 or Ex2 with 8 being solely aﬀected by the two pyridopyrimidinones indicating
a cytotoxic mode of action for both of them. Besides cytotoxicity, these two NCEs
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deregulate genes involved in inﬂammatory processes like IL6 signaling, ERK/MAPK
signaling and p38 MAPK signaling. A more detailed discussion also considering de-
velopment of pathway signiﬁcance over time is given in Baum and Schmid et al. [54].
Experimental Validation
Results from in silico analyses strongly implied diﬀerent induced phenotypes after
treatment with speciﬁc NCEs. The accuracy of the gene set enrichment based ﬁnd-
ings were experimentally validated. Results can be found in [52,54].
4.3 A New Approach for the in Silico Analyses of
Mode of Action
In Sections 3.4 and 3.5 I introduced a new method to score the protein interac-
tions in a network along with a new module extraction method called modEx. As
more and more information on genes and proteins becomes available, it is impor-
tant to integrate and combine this knowledge in biological network-based analyses.
By this means supporting evidence for real interactions is accumulated. At the
same time the shared biological context and the functional association of a pair of
molecules will be highlighted. The results presented in this section are based on
iRefIndex (Section 3.4.1) as an underlying network. In addition to deriving mod-
ules or subnetworks solely based on diﬀerential expression, the proposed knowledge
mining approach enables us to identify modules relevant for the experimental con-
ditions under investigation including proteins that are not necessarily regulated on
the mRNA level. The relevance of proteins is based on their biological relatedness
which is reﬂected by a weighting scheme. Information on Gene Ontology annota-
tion (Section 3.4.2) and predictions of common transcription factor binding sites
(Section 3.4.3) are integrated for weighting the edges between pairs of proteins (Sec-
tion 3.4.6). For iRefIndex-based networks, additionally a conﬁdence score based on
literature was used (Section 3.4.4) to appropriately increase the edge weights. To
transfer the network into the biological context of interest, the expression experi-
ments introduced in Section 3.1 were exemplary used as anchoring points for the
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Figure 4.18: Results of gene set enrichment based on canonical pathways as
deﬁned by the Ingenuity Knowledge Base. Ingenuity pathway analysis (Fisher's
exact test) was conducted for the oﬀ-target genes of all seven NCEs after 12 hours. Result-
ing −log10(p − values) for the 51 signiﬁcantly ranked canonical signaling pathways were
clustered using complete linkage and manhattan distance. Oﬀ-target genes of BI3 show
strong enrichment in 10 cancer signaling pathways (red arrows). Ex1 and Ex2 oﬀ-target
genes play a role in 12 pathways involved in cytotoxicity or cell death (gray arrows) and
in 5 pathways involved in inﬂammation (green arrows).
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analyses as described in Section 3.4.5.
This section is structured as follows: As there are several options to score the
diﬀerent measures used to calculate edge weights, in Section 4.3.1 an optimal com-
bination of evidence is selected. IUsing these results, in Section 4.3.2 the proposed
data mining approach together with modEx is evaluated on a biological basis. In
Section 4.3.3, I apply the newly proposed approaches to analyze compounds' mode
of action with respect to on- and oﬀ-target eﬀects. The analyses are based on ex-
pression data for BI1 and BI4. To show the beneﬁts of my approach in contrast to
approaches only incorporating gene expression data, I compare it to jActiveMod-
ule 2.3.1 in Section 4.4. In the same Section, I additionally compare how diﬀerent
networks used as input aﬀect the results obtained by modEx.
4.3.1 Choosing a Reasonable Combination of Evidence
In Section 3.4, in total 360 possible combinations were proposed that could be used
to calculate an edge weight (Section 3.4.6, page 71). Since conﬁdence scores based
on literature are only available for iRefIndex based networks, the best combination
of methods was selected independent of this measure. To decide which method is
best suited for integration a ROC curve based approach was used. The main idea
is to identify that combination of scoring methods that best distinguishes biologi-
cally more related pairs of proteins from less related ones. One would assume that
proteins which physically interact are more likely biologically related than randomly
sampled pairs of proteins. As true positives (TPs), i. e. biologically related proteins,
all proteins that interact based on the iRefIndex network were used. As true neg-
atives (TNs), i. e. less likely and less probable biologically related pairs of proteins,
randomly sampled pairs of proteins of the iRefIndex network that were not con-
nected by an edge were selected. This approach is comparable to a pseudo-ROC
approach [53, 164]. The pseudo-ROC curve for each of the 360 combinations of
scoring methods is a linear transformation of the true ROC curve. Common single
number summaries used to score and compare ROC curves - the area under the
curve (AUC) or the sensitivity at a given false positive rate - are area or distance
based, and thus reduced by this transformation, but to the same degree for every
curve. Thus, even if there are pairs selected as TN though they are TP this artifact
occurs in each of the pseudo-ROC curves and it is still possible to compare them
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Figure 4.19: Results of the pseudo-ROC analysis for diﬀerent combinations
of evidence. Displayed are the values of the top ten Area Under the Curve (AUC) re-
sults for the comparison of the real to a node permuted iRefIndex graph based on diﬀerent
combinations of evidence (Section 3.4). The combination of methods that best separate
scores for TP (real) from TN (random) edges and, thus, yields the highest AUC, is given
by scoreexp(2c2/4/12h), scoreTF (2cutoff08), scoreGO. It is obtained by combining the covari-
ance of the replicates across the three time points (scoreexp(2c2/4/12h), Method 2c, page 70),
the calculation of scoreTF using Eq. 3.25 (page 68) only considering matrix scores > 0.8
(scoreTF (2cutoff08)), and scoreGO by using the Resnik method (page 62) as implemented in
the GOSemSim package without ﬁltering GO annotations for evidence codes (page 66). Fol-
lowing abbreviations are used for remaining individual measures used: scoreexp(2b2/4/12h):
covariance across the three time points, Method 2b, page 70; scoreTF (2): calculated us-
ing Eq. 3.25, page 68, considering all matrix scores; scoreexp(2a2/4/12h): covariance of the
log2ratios of the two conditions, i. e. TGF-β-stimulated compared to untreated cells, across
the three time points, Method 2a, page 2; scoreexp(2c2h): covariance of the replicates
across measured 2 hours after stimulation, Method 2c, page 70; scoreTF (1): calculated
using Eq. 3.24, page 67, considering all matrix scores.
based on their AUC. Based on the measures given in the previous section and anal-
ogous to the TPs, edge scores, scoreedge, for the TNs were calculated for each of the
360 combinations. Next, the AUC for the pseudo-ROC curves for the real (TP) and
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Figure 4.20: Density distribution and boxplots of edge scores. Comparison of
edge scores as obtained for the TP (real) compared to the TN (random) edges using the
best combination of methods based on the AUCs displayed in Figure 4.19. According to
the density functions and boxplots, scores for the real protein interactions are, on average,
higher than those for the random interactions.
random (TN) edges for each of the possible 360 combinations were calculated. Based
on the ranking of the AUC values for the pseudo-ROC curves, the combination used
for the ﬁnal analysis was chosen.
Figure 4.19 displays AUC values for the ten highest ranking combinations of meth-
ods. The best AUC is obtained for scores based on the covariance of the expression
values for the replicates over all time points (Method 2c, page 70) in combination
with GOSemSim Resnik without ﬁltering for evidence codes (Section 3.4.2, page 66)
and applying scoreTF,2 only considering matrix scores > 0.8 for transcription factor
weighting (Eq. 3.25, page 68). A comparison of edge score distributions and boxplots
for the TP (real) and TN (random) edge scores as given in Figure 4.20 clearly shows
higher scores obtained for real protein interactions in contrast to random pairs of
proteins.
4. Results 114
Figure 4.21: Result of gene set enrichment based on Fisher's exact test.
Based on gene expression for TGF-β1-stimulated cells, modEx was used to extract 10
modules. Fisher's exact test was conducted on gene sets as obtained by Reactome pathways
for the union of these modules. Signiﬁcantly enriched gene sets showing p-values < 1 ·10−7
are displayed. Detected pathways show a clear link to TGF-β signaling.
4.3.2 Biological Evaluation by TGF-β Stimulation Experi-
ment
In order to show the principle applicability of our approach, I ﬁrst utilized an easy to
interpret gene expression experiment comparing TGF-β-stimulated against unstim-
ulated HaCaT cells at 2, 4, and 12 hours after stimulation [54]. Brieﬂy speaking, an
iReﬁndex based network was scored using the best combination of evidence selected
in the previous section, with covariance for adjacent proteins calculated based on
gene expression values for the two conditions (TGF-β-stimulated and unstimulated)
across the three time points. Based on the weighted PPI network, ten networks were
extracted using modEx (Section 3.5.2) and selecting the 10 strongest deregulated,
signiﬁcant genes as seed nodes (adjusted p − value < 0.01). Table 4.1 displays the
probabilities for obtaining these networks by chance calculated by the statistical
measures described in Section 3.6.1. For biological evaluation, gene set enrichment
analysis by Fisher's exact test [143] was conducted based on the nodes (proteins)
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Table 4.1: Overview of modules extracted based on TGF-β stimulation
experiment. Displayed are diﬀerent measures for modules extracted based on TGF-β-
stimulated cells compared to unstimulated cells using modEx (Section 3.5.2). The p-values
indicate the probability of observing the respective score Ω(G′i) or a higher one for the i-th
extracted module of the random graphs. The module ranking column indicates the order
for the extracted modules according to z-score based p-values and Ω(G′i).
Net
No. i
Seed node log2 ratio
#
Module
ranking
Ω(G′i)
§ z-score
p-value+
approx.
p-value+
1 VASN 5.4 10 2.203 0.032 0.044
2 SERPINE1 5.34 4 2.76 0.001 0.01
3 CTGF 3.94 9 2.258 0.029 0.036
4 JUN 3.48 2 3.159 <0.001 0
5 TGM2 3.39 8 2.233 0.025 0.04
6 FOSB 3.13 3 3.022 <0.001 0
7 BHLHE40 3.06 7 2.53 0.006 0.016
8 CDKN2B 3 1 4.533 <0.001 0
9 SMAD7 2.87 5 2.658 0.004 0.004
10 SOX18 2.85 6 2.507 0.006 0.014
Union∗ 2.786 <0.001 0
#log2 ratio comparing TGF-β-stimulated cells to unstimulated cells after 2 hours.
§ Ω(G′i) is calculated using Eq. 3.34.
+Approximative permutation test (approx.) and z-score based p-values refer to the probabilities
calculated based on 500 random graphs (Section 3.6.1).
∗Union refers to the network as obtained by the union of the ten individual nets extracted.
contained in the union graph of the ten networks extracted. Results are displayed
in Figure 4.21. Proteins contained in the extracted networks show a signiﬁcant en-
richment in gene sets related to TGF-β signaling. It is well known that TGF-β
signaling plays a major role in controlling the cell cycle as well as reorganization of
the extracellular matrix. Additionally, our ﬁndings are conﬁrmed by a signiﬁcant
enrichment in BMP-signaling, a signaling pathway induced by the BMP receptor
which also belongs to the TGF-β receptor superfamily, and TGF-β signaling itself.
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4.3.3 Analyses of Compounds' On- and Oﬀ-Target Eﬀects
To investigate whether it is possible to detect on- and oﬀ-target eﬀects of compounds
based on the proposed method, I used expression data derived from human HaCaT
cells treated with inhibitors of TGFBR1 [54]. In what follows, I focus on two com-
pounds which are referred to as BI1 and BI4. HaCaT cells were stimulated with
TGF-β and either treated with 2µM (lowest concentration above IC50, [1,54]) of the
respective compound or not treated with compound. Gene expression of stimulated
and compound-treated HaCaT cells was compared to the gene expression of TGF-
β-stimulated cells after a time span of 2 hours. Out of the genes with FDR-adjusted
p values < 0.01, ten seed nodes were chosen based on log2 ratios. In contrast to
the covariance used above, covariance between the expression proﬁles of two genes
was calculated across 2, 4 and 12 hours for ﬁve diﬀerent compound concentrations
(0.0032, 0.016, 0.08, 0.4, 2µM) measured in triplicates and the control group mea-
sured in quadruples. Remaining scores were calculated as described for the TGF-β
stimulation experiment. By applying modEx, modules were extracted based on the
ten seed nodes selected.
On-Target Eﬀects
Considering the union of the ten modules, connected components were identiﬁed.
Figure 4.22 displays one connected component extracted based on TGF-β-stimulated
compared to unstimulated cells (Figure 4.22 A) and one connected component ex-
tracted based on TGF-β-stimulated cell compared to cells stimulated with TGF-β
and treated with BI4 (Figure 4.22 B). Seed nodes that led to the connected com-
ponents displayed were JUN and FOSB (Figure 4.22 A) or FOSB, JUN, and JUNB
(Figure 4.22 B). As displayed in Tables 4.1 and 4.2, the individual extracted modules
based on these seed nodes had a p-value ≤ 0.002, i. e. modules with the respective
scores are very unlikely to be observed by chance. An on-target eﬀect of compounds
can be detected by inversion of the TGF-β eﬀect. This is the case for networks
extracted based on BI4 treatment (Figure 4.22). Genes that are up-regulated by
TGF-β stimulation (red) are down-regulated by compound treatment (green).
Networks extracted based on BI1 treatment do not exhibit as strong on-target
eﬀects (Figure 4.23). Compared to results obtained for BI4 (Figure 4.22), for BI1
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Figure 4.22: modEx results demonstrating on-target eﬀect of BI 4.Compari-
son of networks extracted based on TGF-β-stimulated compared to unstimulated (A) and
BI4-treated and TGF-β-stimulated compared to TGF-β-stimulated (B) cells. Red indi-
cates up-, green down-regulation of the respective genes, diamond-shaped nodes indicate
seed nodes. The on-target eﬀect of BI4 inverting the TGF-β stimulation can directly be
seen by the opposite regulation of many of the genes contained in the extracted modules.
an as clear inversion of the direction of deregulation cannot be observed. For BI4,
two nearly identical modules have been extracted basesd on TGF-β-stimulated (Fig-
ure 4.22A) and based on compound treatment (Figure 4.22B). For BI1, the module
displayed in Figures 4.24A and 4.24B shows the densest enrichment in genes which
due to their direction of deregulation hint at on-target eﬀects. But at the same time
it contains genes that are neither strong nor signiﬁcantly deregulated but are direct
oﬀ-targets of BI1 (Appendix F). Figure 4.24C displays the module extracted based
on TGF-β1-stimulation that exhibits the greatest overlap to the latter module with
respect to the proteins contained. Compared to BI4 (Figure 4.22), the overlap of
Figures 4.24A and 4.24C is not as striking with regard to on-target eﬀects.
Oﬀ-Target Eﬀects
For investigating oﬀ-target eﬀects, ﬁrst, results obtained for expression data as mea-
sured based on BI1-treated and TGF-β1-stimulated cells were analyzed. In a sec-
ond step, the same analysis was done using data from BI4-treated and TGF-β1-
stimulated cells. To focus the analysis towards oﬀ-target eﬀects, only those seed
nodes were used that are not signiﬁcantly de-regulated (FDR-adjusted p-value≥ 0.01)
in the opposite direction when comparing TGF-β-stimulated to unstimulated cells
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Table 4.2: Overview of modules extracted based on BI4 treatment. Dif-
ferent Measures for modules extracted based on BI4-treated and TGF-β-stimulated cells
compared to just TGF-β-stimulated cells using modEx (Section 3.5.2) are summarized.
The p-values indicate the probability of observing the respective average edge score Ω(G′i)
or a higher one for the i-th extracted module of the random graphs.
Net
No. i
Seed node log2 ratio
# Ω(G′i)
§ z-score
p-value+
approx.
p-value+
1 SERPINE1 -4.43 2.06 0.031 0.038
2 VASN -3.88 1.955 0.074 0.072
3 FOSB -3.29 2.41 0.004 0.016
4 CTGF -3.23 2.034 0.045 0.044
5 JUN -3.15 3.57 <0.001 0
6 CYR61 -3.08 2.025 0.041 0.038
7 SCGB1A1 2.87 2.428 0.003 0.01
8 SKIL -2.76 2.372 0.003 0.006
9 KRT1 2.71 1.649 0.238 0.178
10 JUNB -2.67 3.089 <0.001 0.002
Union∗ 2.359 <0.001 0
#log2 ratio comparing BI4-treated and TGF-β1-stimulated cells to TGF-β1-stimulated cells after
2 hours.
§ Ω(G′i) is calculated using Eq. 3.34.
+Approximative permutation test (approx.) and z-score based p-values refer to the probabilities
calculated based on 500 random graphs. (Section 3.6.1)
∗Union refers to the network as obtained by the union of the ten individual nets extracted.
after 2 hours.
Table 4.3 summarizes the results obtained for the ﬁrst ten extracted networks
based on the BI1 data, i. e. based on the comparisons of BI1- and TGF-β1-treated
compared to TGF-β1-treated cells; Figure 4.25 displays the results of Fisher's exact
test conducted for one of the most signiﬁcant networks extracted (Net No. 8). In
contrast to the results described in the analysis of on-target eﬀects (pages 116 f.)
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A: Nodes are colored according to log2 ratios of expression
values based on BI1 and TGF-β1 treatment compared to
the respective control.
B: Nodes are colored according to log2 ratios of expression
values based on TGF-β-treated compared to untreated cells
Figure 4.23: Union graph extracted based on BI1 treatment. Displayed is
the union graph of the 10 graphs extracted based on the mostly deregulated genes in BI1-
treated and TGF-β1-stimulated compared to TGF-β1-stimulated cells. Diamond-shaped
nodes represent the seed nodes. Triangular purple-framed nodes represent wet-lab validated
direct oﬀ-targets of BI1. Green indicates down-, red up-regulation. The more intense the
colors, the stronger the respective genes are deregulated. In contrast to Figure 4.22 which is
based on BI4, for BI1 we can not see an as obvious inversion of the direction of deregulation
when comparing Subﬁgure A and Subﬁgure B.
the results for BI1 do not show any direct connection to TGF-β signaling. Instead,
the modules detected by modEx method are enriched in diﬀerent signaling cascades
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A: Nodes are colored ac-
cording to log2 ratios of
expression values based on
BI1- plus TGF-β1-treated
cells compared to the re-
spective control.
B: Nodes are colored ac-
cording to log2 ratios of
expression values based on
TGF-β1-treated compared
to untreated cells.
C: Nodes are colored
according to log2 ra-
tios of expression val-
ues based on TGF-β1-
treated compared to un-
treated cells.
Figure 4.24: Subgraph of union graphs extracted based on BI1 treat-
ment (A&B) or TGF-β (C) stimulation. Subﬁgure A displays the connected
component out of the union graph in Figure 4.23 that contains most of the direct oﬀ-
targets of BI1 and at the same time best could be linked to on-target eﬀects compared
to other connected components. Diamond-shaped nodes represent the seed nodes. Tri-
angular purple-framed nodes in A&B represent wet-lab validated direct oﬀ-targets of BI1
(Appendix F. Green indicates down-, red up-regulation. The more intense the colors, the
more the respective genes are deregulated. Subﬁgure B depicts the same subgraph but
with nodes colored according to the deregulation observed in TGF-β-treated compared to
untreated cells. In contrast to Figure 4.22 which is based on BI4, for BI1 we can not see an
as obvious inversion of the direction of deregulation. Subﬁgure C shows one connected
component of the union graph derived based on expression data for TGF-β1-treated com-
pared to untreated cells. Out of all components in the union graph this component yields
the highest overlap with genes in Subﬁgure A.
triggered by kinases which could be conﬁrmed as direct BI1 oﬀ-targets in wet-lab
experiments (Figure 4.25, Appendix Tables F.1-F.3, pages 170 ﬀ.) [54]. It could be
shown that BI1 inhibits all three FGF receptor kinases. In line with this observa-
tion highest signiﬁcant scores are obtained for gene sets describing FGFR signaling.
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Figure 4.25: Result of gene set enrichment based on Fisher's exact test.
Based on gene expression for BI1-treated and TGF-β1-stimulated cells, modEx was used
to extract 10 modules. One of the most signiﬁcant modules (Net No. 8, Table 4.3) was used
in the enrichment analysis. Fisher's exact test was conducted based on gene sets as ob-
tained by Reactome pathways for genes contained in Net No. 8. Displayed are signiﬁcantly
enriched gene sets with p-values < 2 · 10−6. Compared to random networks, the network
extracted using our method is very unlikely to be observed randomly (p-value < 0.001, Ta-
ble 4.3). Additionally, it shows highly signiﬁcant enrichment for genes related to signaling
pathways regulated by various oﬀ-target kinases such as FGFR signaling (Appendix Ta-
bles F.1-F.3, pages 170 ﬀ.) [54].
Furthermore BI1 inhibits the neurotrophic tyrosine kinase, receptor 1 (NTRK1 also
referred to as TRKA). Again gene sets involved in TRKA signaling itself as well
as its ligand NGF were identiﬁed. In addition the signaling pathway component
GAB1, a known activator of PI3 kinase signaling [189], was detected by our analy-
sis. Finally, BI1 inhibits MEK1 (MAP2K1) that acts as a mitogen-activated protein
(MAP) kinase kinase and is involved in the integration of multiple biochemical sig-
nals including insulin receptor signaling (IRS) and epidermal growth factor receptor
(EGFR) signaling [190]. Both related gene sets were identiﬁed by our approach.
Compared to BI1, for BI4 oﬀ-target eﬀects are not as evident. Again, seed
nodes for modEx have been chosen such they do not exhibit an inverse deregula-
tion compared to TGF-β1-stimulated cells. Figure 4.26 displays the results for the
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Table 4.3: Overview of modules extracted for the oﬀ-target analysis of BI1.
Displayed are results for modules extracted based on BI1-treated and TGF-β1-stimulated
cells compared to TGF-β1-stimulated cells using modEx (Section 3.5.2). The p-values
indicate the probability of observing the respective average edge score Ω(G′i) score or a
higher one for the i-th extracted module of the random graphs.
Net
No. i
Seed node log2 ratio
# Ω(G′i)
§ z-score
p-value+
approx.
p-value+
1 KRT1 3.59 1.71 0.208 0.149
2 VWF 3.52 2.78 <0.001 0.016
3 SCGB1A1 3.44 1.969 0.06 0.101
4 PLA2G10 3.12 1.814 0.124 0.112
5 HSP90AA1 -3.07 3.105 <0.001 0
6 GBP2 2.9 2.187 0.031 0.053
7 TRIM31 2.78 2.104 0.049 0.037
8 ABP1 2.77 2.987 <0.001 0
9 RGS2 -2.75 2.181 0.025 0.027
10 ARL4A -2.75 5.043 <0.001 0
Union∗ 2.588 <0.001 0
#log2 ratio comparing BI1-treated and TGF-β1-stimulated cells to TGF-β1-stimulated cells after
2 hours.
§ Ω(G′i) is calculated using Eq. 3.34.
+Approximative permutation test (approx.) and z-score based p-values refer to the probabilities
calculated based on 500 random graphs. (Section 3.6.1)
∗Union refers to the network as obtained by the union of the ten individual nets extracted.
Fisher's exact test conducted based on proteins contained in the module extracted
for SCGB1A1. This module is one of the most signiﬁcant ones (approximative p-
value = 0.01, Table 4.2, page 118) as well as one of the few ones for which gene sets
could be linked to direct oﬀ-targets of BI4. The respective gene sets hint at PDGF
and MAPK related signaling events, PDGF as well as diﬀerent MAP-kinases could
be conﬁrmed as direct BI4 oﬀ-targets (Appendix F, Table F.5, page 174). Looking
at the union graphs extracted based on BI1 and BI4, enriched gene sets for BI1 hint
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Figure 4.26: Oﬀ-target eﬀects observed for BI4. Fisher's exact test was conducted
based on gene sets as obtained by Reactome pathways for genes contained in a network
extracted using SCGB1A1 (P11684) as seed node (p-value = 0.003, Table 4.2). Displayed
are signiﬁcantly enriched gene sets with p-values < 0.05, page 118. Compared to BI1, for
BI4 gene sets hinting at oﬀ-target eﬀects are much rarer to observe. Genes contained in
the subnetwork extracted show enrichment in PDGF and MAPK related signaling events.
These kinases have been conﬁrmed as direct oﬀ-targets of BI4 (Appendix F, Table F.5,
page 174).
at more oﬀ-target eﬀects than those detected for BI4. For BI4, TGF-β-signaling is
even the fourth most signiﬁcant. In summary, this all hints at compound BI4 being
much cleaner, i. e. being more speciﬁc for TGF-βR1, than compound BI1. This
could be conﬁrmed by the kinase screen exhibiting much more direct oﬀ-targets for
BI1 than for BI4 (Appendix F, pages 169 ﬀ.).
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4.4 Comparison to Existing Approaches
Results derived using the proposed approach do not only depend on the extraction
procedure, modEx, but also on the underlying network and the edge scoring. Thus,
to further evaluate the method, I ﬁrst conducted analyses based on three diﬀerent
protein networks, namely iRefIndex, STRING, which I refer to as STRINGorg, and
STRING with recalculated edge weights (Eq. 3.30, page 71), which I refer to as
STRINGmod (see Secion 3.7, page 77 for details). Second, I compared the modules
derived using our approach to modules derived using jActiveModule [48] (see Sec-
tion 3.7, page 76, for more details).
To compare the results based on diﬀerent networks and scoring methods, gene ex-
pression data derived from cells stimulated with TGF-β1 compared to unstimulated
cells was used. Thus, the modules extracted should in the ideal case be enriched in
genes linked to TGF-β signaling. Nodes of jActiveModule instances are weighted
according to the FDR-corrected p-values calculated for the comparisons of TGF-β1-
stimulated compared to unstimulated cells at 2, 4, and 12 hours (see Section 3.3.1,
page 55). Edges of modEx instances are weighted based on the method selected
in Section 4.3.1 as summarized on page 113. Gene expression data of TGF-β1-
stimulated and unstimulated cells across 2, 4, and 12 hours was used to calculate
scoreexp (Eq. 3.28, page 70). log2ratios and FDR-corrected p-values (Section 3.3.1,
page 55) comparing gene expression of TGF-β1-stimulated to unstimulated cells at
2 hours were used to select seed nodes. This setting is equivalent to the setting used
in Section 4.3.2 were this data set was used to evaluate the new approaches.
4.4.1 Comparison Between iRefIndex and STRING
modEx was applied to diﬀerent networks, a complete overview of the results is given
in Appendix C, Tables C.1 - C.3 (pages 157 ﬀ.). Based on the proteins contained in
the extracted modules Fisher's exact test was conducted and gene sets were ranked
according to the respective p-values (Figure 4.27). Results displayed are based on
KEGG gene set. An equivalent analysis has also been conducted using Reactome
gene sets. Results for the latter one are summarized in Appendix Table C.2 on
page 159.
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Figure 4.27: Comparison of STRING and iRefIndex networks. Displayed are
gene set enrichment results for the modules derived when applying modEx to networks with
edges weighted according to the best combination of evidence (Section 4.3.1, Figure 4.19,
page 112) using expression values obtained by a comparison of TGF-β1-stimulated cells to
unstimulated cells after 2, 4 and 12 hours. modEx was applied to iRefIndex, STRINGorg
and STRINGmod. For the iRefIndex network, these modules have already been used in the
scope of the analyses of Section 4.3.2 and are summarized in Table 4.1 on page 115. Based
on KEGG deﬁned gene sets, Fisher's exact test was conducted for the proteins contained
in the extracted modules (indicated by their seed nodes on the x-axis), their union graph
as well as for the maximal connected component (max conComp), i. e. that connected
component of the union graph containing the most nodes. Results of this enrichment
analysis are displayed in Table C.3 on page 160. For comparing the results, the reciprocal
ranks of the TGF-β signaling gene set for the diﬀerent modules were used. The gene
sets were ranked according to p-values. Focusing on networks based on single seed nodes,
STRINGmod is superior to both, iRefIndex as well as STRINGorg. When considering unions
of the individually extracted modules, iRefIndex yields the best results.
On average, the best results are obtained based on STRINGmod. For six of the
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ten extracted networks TGF-β signaling is ranked second when STRINGmod is used
as an underlying network (Figure 4.27, orange bars). Five of them even exceed the
STRINGorg as well as the iRefIndex based results. In only two cases (SERPINE1 and
BHLHE40), the iRefIndex based results (blue bars) clearly outperform the STRING
based results. For three of the ten extracted networks (CDKN2B, SMAD7, SOX18),
iRefIndex slightly outperforms STRINGmod. STRINGorg (green bars) outnumbers
STRINGmod in only one case (SMAD7) and iRefIndex in four cases (VASN, CTGF,
JUN, FOSB). For the union graph as well as for the maximal connected component
of the union graph, STRINGorg yields the worst results. Here, the best results
are obtained by iRefIndex, though it only slightly outperforms STRINGmod for the
union graph (rank two versus rank eight). Thus, when focusing on networks based on
single seed nodes, STRINGmod is superior to both other networks. When considering
unions of the individually extracted modules, iRefIndex yields the best results.
4.4.2 Results for jActiveModule
Since jActiveModule does not make use of any edge scores, I did not compare results
based on diﬀerent scoring methods. As it already has been done for the compari-
son between iRefIndex and STRING, ﬁrst, a module search was performed; second,
Fisher's exact test was conducted based on the proteins contained in the identiﬁed
modules comparing them to predeﬁned gene sets. By this means, it was possible to
compare results obtained for the diﬀerent extraction methods as well as for diﬀer-
ent protein networks. Again, I focus on results as obtained based on KEGG gene
set here. Results for Reactome based analysis are summarized in Appendix Ta-
bles D.2 and D.5 pages 163 f..
jActiveModule oﬀers diﬀerent search options. Using default parameters, greedy
search, simulated annealing, and simulated annealing with hub ﬁnding switched on
were applied. Simulated annealing alone did not return any modules, simulated
annealing with hub ﬁnding returned modules, but none of the returned modules
showed a signiﬁcant enrichment (p-value < 0.01) with genes related to TGF-β sig-
naling (Appendix D, Tables D.2 and D.3, page 163). Thus, in what follows, I focus
on results derived using greedy search (referred to as greedyDef).
When applying jActiveModule, a search for modules active across diﬀerent time
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points was performed, i. e. the method was applied to p-values derived for TGF-β1-
stimulated cells compared to unstimulated cells after 2, 4, and 12 hours. Based on
these p-values, jActiveModule tries to detect modules active at any of these time
points. Since the ﬁve detected modules are only active for the 12 hours expression
data, further analyses exclusively refer to this time point. Modules are ranked from
1 to 5 based on their scores sG′ (Eq. 2.1, page 29).
First, I investigated results of jActiveModule based on diﬀerent networks, namely
STRING and iRefIndex (Figure 4.28, Appendix D Tables D.3 and D.6, pages 163 ﬀ.).
Two of the three highest ranking modules are based on iRefIndex, one is based on
STRINGorg. The TGF-β signaling gene set ranks sixth (module2, sub-net) and
nineth (module5, no-pval) or eighth (module3, def-pval) based on iRefIndex or
STRINGorg, respectively. Even though the best rank is obtained by the iRefIndex
network, the STRINGorg networks more often result in higher ranks. Nevertheless
these ranks are very low with the highest rank of eight for module3 (def-pval) and
all remaining ranks below ﬁfteen. Thus, it is diﬃcult to say which of the networks
is superior to others when using jActiveModule.
4.4.3 Comparison Between modEx and jActiveModule
To get a more detailed impression of the diﬀerence between jActiveModule and
modEx results, I next compared them based on the underlying protein networks.
iRefIndex as well as STRING were used as diﬀerent networks. Additionally, for
STRING diﬀerent cut-oﬀs were applied to the native edge score. A complete
overview of the comprehensive analysis is given in Appendix C, Tables C.1- D.6.
Modules extracted using modEx are ranked from 1 to 5 according to their p-value
and according to ω(G′i) (Table 4.1, page 115, Module ranking column), modules de-
rived using jActiveModule are ranked according to their scores sG′ (Eq. 2.1, page 29).
In the following, I summarize the quintessence of these analysis based on enrichment
analysis conducted using KEGG pre-deﬁned gene sets. A complete overview of the
KEGG-based results is given in Appendix Table C.3, page 160 for modEx and in
Tables D.3 and D.4, pages 163 f. for jActiveModule. Again, the respective results
for Reactome-based analysis can be found in Appendix C, Tables C.2, page 159 for
modEx, and in Appendices D, D.2 and D.5, pages 163 f. for jActiveModule.
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Figure 4.28: Comparison of jActiveModule results for STRING or
iRefIndex networks. Displayed are the results for the individual modules derived
when applying jActiveModule to networks with nodes weighted according to p-values ob-
tained by a comparison of TGF-β1-stimulated cells to unstimulated cells after 2, 4 and 12
hours. To compare jActiveModule derived modules to modEx derived modules the latter
ones are ranked from 1 to 5 according to their p-value and their score ω(G′i) (Table 4.1,
page 115, Module ranking column). In case the protein coding genes are not represented
on the microarray used to measure gene expression either no p-values are assigned to the
respective genes (no-pval, left part of the plot), 1 is assigned as default p-value (def-pval,
middle part of the plot), or only the subnet induced by the genes represented on the mi-
croarray is used in the analysis (sub-net, right part of the plot) (Section 3.7, page 76).
Gene set enrichment results are ranked according to p-values and reciprocal ranks are used
for visualization (y-axis). The best rank is obtained by the iRefIndex network, but the
STRINGorg networks more often result in higher ranks. These ranks are very low with the
highest rank of eight for module3 (dark-green bar, def-pval) and all remaining ranks below
ﬁfteen. Nevertheless, there is no clear evidence for one network being superior to the other
when using jActiveModule.
iRefIndex Used as an Underlying Network
Figure 4.29 displays the comparison of modEx to jActiveModule based on the
iRefIndex. module5 extracted using modEx results in TGF-β signaling being ranked
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Figure 4.29: Comparison of jActiveModule and modEx results based on
iRefIndex networks. Displayed are the results for the individual modules derived
when applying the methods to networks weighted according to a comparison of TGF-β1-
stimulated cells to unstimulated cells after 2, 4, and 12 hours. In case the protein coding
genes are not represented on the microarray used to measure gene expression either no
p-values are assigned to the respective genes (no-pval, left part of plot), 1 is assigned as
default p-value (def-pval, middle part of plot), or only the subnet induced by the genes
represented on the microarray is used in the analysis (sub-net, right part of plot) (Sec-
tion 3.7). Enrichment analysis was conducted for the individual modules extracted and
gene sets ranked according to p-values. For the ﬁve best modules extracted, the reciprocal
ranks for the TGF-β signaling gene set are plotted along the y-axis. This gene set should
be ranked high, as we used expression data from TGF-β1-stimulated cells for which this
signaling pathway is switched on. Since modEx results in TGF-β signaling being ranked
ﬁrst for module5 and since modEx based ranks are consistently higher than jActiveModule
ranks for three of the ﬁve modules, modEx based modules are considered more informative.
ﬁrst. Thus, and since modEx based ranks are higher than jActiveModule ranks in all
cases except of module2 and module3, modEx based modules are considered more
informative.
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STRING used as an underlying network
As it already has been shown in Section 4.4.1 that STRINGmod is superior to
STRINGorg and as the diﬀerence in edge scoring is only relevant for modEx but not
for jActiveModule, STRINGmod was used in this ﬁnal comparison. With STRINGmod
as underlying protein network, the diﬀerences in performance of jActiveModule and
modEx are even clearer (Figure 4.30). Still, for one module, module4 (orange),
jActiveModule outperforms modEx, however the ranks for this module are very low
with 20, 34, and 22 for no-pval, def-pval and sub-net, respectively. Thus, these re-
sults can hardly directly be linked to TGF-β signaling. In all other cases, modEx
performs better than jActiveModule with respect to this signaling pathway. For
three of the modules, module2 (blue), module3 (green), and module5 (purple) the
TGF-β signaling gene set is even ranked second for modEx derived modules. This,
on the one hand, conﬁrms the results of the previous section (Figure 4.27), indicat-
ing that using STRINGmod is superior to using iRefIndex. On the other hand, it
shows that modEx is superior to jActiveModule in cases where we want to derive
modules that are not only enriched with deregulated genes but also are related to
the underlying biological process.
4.5 Complexity Analysis
In Section 3.5.1 I introduced some optimization problems that could be posed in
the analysis of weighted protein-protein interaction networks. In this section, I
will analyze these problems with respect to their computational complexity. The
computational complexity of a problem can be measured by the resources needed
to solve it (see [191193] for more details). In general, computational complexity
theory aims at a classiﬁcation of problems into respective complexity classes. In
the following, I brieﬂy introduce the two complexity classes P and NP from clas-
sical complexity theory. Based on this, I subsequently prove the NP-hardness of
vCMECG, k-vCMECG, k-veCMECG, and 1-vCMECG as introduced in Deﬁ-
nitions 3.5.1 to 3.5.4 on pages 72 f..
The most prominent classes in classical complexity theory are P and NP. P stands
for polynomial time, this class contains all problems that can be solved in polynomial
131 4.5. Complexity Analysis
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Figure 4.30: Comparison of jActiveModule and modEx results based on
STRINGmod network. Displayed are the results for the individual modules derived
when applying the methods to networks weighted according to a comparison of TGF-β1-
stimulated cells to unstimulated cells after 2, 4, and 12 hours. In case the protein coding
genes are not represented on the microarray used to measure gene expression either no
p-values are assigned to the respective genes (no-pval, left part of plot), 1 is assigned as
default p-value (def-pval, middle part of plot), or only the subnet induced by the genes
represented on the microarray is used in the analysis (sub-net, right part of plot) (Sec-
tion 3.7). Enrichment analysis was conducted for the individual modules extracted and
gene sets were ranked according to p-values. For the ﬁve best modules extracted, the
reciprocal ranks for the TGF-β signaling gene set are plotted along the y-axis. As expres-
sion data from TGF-β1-stimulated cells was used, TGF-β signaling should be ranked high.
jActiveModule outperforms modEx for only one module, namely for module4 (orange). As
the ranks for this module are very low with 20, 34, and 22 for no-pval, def-pval and sub-
net, respectively, these results would hardly be directly linked to TGF-β signaling. In all
other cases, modEx performs better than jActiveModule. For three of the modules, mod-
ule2 (blue), module3 (green), and module5 (purple) the TGF-β signaling gene set is even
ranked second for modEx derived modules. Thus, modEx is superior to jActiveModule
using STRINGmod as an underlying network.
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time. NP stands for nondeterministic polynomial time and describes a complexity
class of problems for which it is possible to guess, i. e. nondeterministically ﬁnd a
solution in polynomial time. Given a solution for a problem in NP, it is possible to
test its correctness in polynomial time. It is widely believed that P is not equal to
NP implying that there are problems in NP that are not in P. This leads to NP-hard
problems. Within the considered framework, showing that a problem is at least as
hard as another problem is done by a many-one reduction deﬁned as follows.
Deﬁnition 4.5.1. many-one reduction.
Let A and B denote two problems. The problem A many-one reduces to
B if there is a polynomial-time computable function f such that for an
instance x of problem A denoted as x ∈ A
x ∈ A⇔ f(x) ∈ B.
That means, a many-one reduction is a reduction which converts instances of a
decision problem A into instances of a decision problem B, formally written as
A ≤m B. If A ≤m B, any algorithm that solves instances of B can be applied to
solve instances of A in the time needed for the algorithm to solve B plus the time
needed for the reduction and with the maximum space needed for the algorithm plus
the space needed for the reduction. As A is known to be NP-hard and A ≤m B,
B is NP-hard, otherwise it would contradict A being NP-hard. [192, 194, 195]. A
problem is NP-hard if all problems from NP many-one reduce to it. An NP-hard
problem belonging to NP is NP-complete. Hence, the class of NP-complete problems
comprises a large set of equivalent problems for which presumably no polynomial-
time algorithms exist.
4.5.1 Problems Related to vCMECG
In this section, I introduce some well known graph theoretical problems that are
closely related to the problems I introduced in Section 3.5. These methods provide
the basis for the NP-hardness proof given in Section 4.5.2.
Deﬁnition 4.5.2. Complete Graph.
A complete graph is a graph G = (V,E) where each pair of nodes {vi, vj} ∈ V
is connected by an edge e{vi,vj}.
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Deﬁnition 4.5.3. Clique Problem.
Input: An undirected graph G = (V,E) and a positive integer s.
Task: Is there a complete graph G′ = (V ′, E ′) with V ′ ⊆ V and E ′ ⊆ E
consisting of s vertices.
This problem is well known to be NP-complete [196].
Deﬁnition 4.5.4. Steiner Tree Problem.
Input: An undirected graph G = (V,E), a weight function ω : E → [0,∞),
and a set of terminal nodes R ⊆ V , l ∈ [0,∞).
Task: Find a tree T = (VT , ET ) with R ⊆ VT such that
Ω(T ) =
∑
e∈ET
ω(e) ≤ l
The Steiner Tree Problem is known to be NP-complete [196].
The problems given in Sections 3.5 are all related to the maximum edge-weight
connected graph (MECG) and the constrained maximum edge-weight connected
graph (k-CMECG) problems as described by Li et al. [197]:
Deﬁnition 4.5.5. Maximum edge weight connected graph (MECG).
Input: An undirected graph G = (V,E), a weight function ω : E → [0,∞)
and a positive integer s.
Task: Find a connected subgraph G′ = (V ′, E ′) with |E ′| = s such that
Ω(G′) =
∑
e∈E′
ω(e)
is maximized.
Deﬁnition 4.5.6. k-constrained maximum edge weight connected graph
(k-CMECG).
Input: An undirected graph G = (V,E), a weight function ω : E → [0,∞)
and Ek ⊂ E with |Ek| = k, and a positive integer s.
Task: Find a connected subgraph G′ = (V ′, E ′) with |E ′| = s and
Ek ⊆ E ′ such that
Ω(G′) =
∑
e∈E′
ω(e)
is maximized.
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The authors provide an NP-hardness proof of this problems and propose an integer
linear programming algorithm to solve it.
The main diﬀerence between these and our problem deﬁnitions is that Li et al.
center their analyses around edges only, while we want to incorporate both, edges and
vertices. Instead of s edges (Deﬁnition 4.5.5) we look for s nodes (Deﬁnition 3.5.1,
page 72), instead of ﬁxed edges Ek (Deﬁnition 4.5.6), we consider ﬁxed vertices
Vk (Deﬁnition 3.5.2, page 72), and ﬁnally, instead for optimizing
∑
e∈E′ ω(e) (Def-
inition 4.5.5-4.5.6), we either optimize with respect to the number of edges |E ′|
(Deﬁnition 3.5.3, page 73) or with respect to the number of vertices |V ′| (Deﬁnition
3.5.2, page 72) contained in the subgraph G′. Thus, our problem deﬁnitions are
even more complex than those given by Li et al..
4.5.2 NP-hardness of vCMECG and Related Problems
Using the technique of many-one reduction [198,199], I provide NP-hardness proofs
for vCMECG(Deﬁnition 3.5.1, page 72), k-vCMECG (Deﬁnition 3.5.2, page 72),
k-veCMECG (Deﬁnition 3.5.3, page 73) and 1-vCMECG (Deﬁnition 3.5.4, page 73).
Theorem 4.5.7. vCMECG is NP-hard.
Proof. Clique ≤m vCMECG: Given a Clique instance (G=(V,E),s), construct
an instance of vCMECG by using the same graph with weight one for every edge
and let s also denote the number of vertices of the connected subgraph. Then, G
has a clique of size s if and only if in the new graph there is a connected subgraph
with s vertices and s · (s− 1)/2 edges, that is, with w(G′) = s · (s− 1)/2.
⇒ Clique ≤m vCMECG.
Theorem 4.5.8. k-vCMECG is NP-hard.
Proof. Steiner Tree ≤m k-vCMECG: Given a Steiner Tree instance, G =
(V,E), ω : E → 1, R ⊆ V , and l. Construct an instance of k-vCMECG,
G′ = (V ′, E ′), Vk, and s as follows:
Add a degree-one vertex to every terminal and set the weight of the corresponding
new terminal edge ω(e) to ω(e) = |E| = m. The weights of all remaining edges are
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set to zero. Vk is identiﬁed with R. We obtain G′ = (V ′, E ′) with |V ′| = |V | + |R|,
|E ′| = |E|+ |R|, Vk=R, s = l + |R|.
Now, the following is easy to prove: k-vCMECG instance has a solution of size at
least mk/(l+k+1) if and only if the Steiner Tree instance allows for a Steiner
Tree of size at most l.
Since taking a non-terminal edge to the solution the overall sum is decreased, as
few of these edges are to be taken. Thus, the optimal solution of the k-vCMECG
instance is given by the Steiner Tree of the terminals R plus the new terminal
edges. The denominator of the solution for the k-vCMECG instance resolves to
(l+k+1) as this problem is optimizing the weight of the solution with respect to the
number of nodes which, in trees, is equal to the number of edges + 1. Equally, the
optimal solution for the Steiner Tree is given by the solution for k-vCMECG
by erasing all terminal edges.
⇒ Steiner Tree ≤m k-vCMECG.
Theorem 4.5.9. k-veCMECG is NP-hard.
Proof. Steiner Tree ≤m k-veCMECG: Given a Steiner Tree instance, G =
(V,E), ω : E → 1, R ⊆ V , and l. Construct an instance of k-veCMECG,
G′ = (V ′, E ′), Vk, s as follows:
Add a degree-one vertex to every terminal and set the weight of the corresponding
new terminal edge ω(e) to ω(e) = |E| = m. The weights of all remaining edges are
set to zero. Vk is identiﬁed with R. We obtain G′ = (V ′, E ′) with |V ′| = |V | + |R|,
|E ′| = |E|+ |R|, Vk=R, and s = l + |R|.
Now, the following is easy to prove: k-veCMECG instance has a solution of size
at least mk/(l+ k) if and only if the Steiner Tree instance allows for a Steiner
Tree of size at most l.
Since taking a non-terminal edge to the solution the overall sum is decreased, as few
of these edges are to be taken. Thus, the optimal solution of the k-veCMECG in-
stance is given by Steiner Tree of the terminals R, plus the newly added terminal
edges. The denominator of the solution for the k-veCMECG instance resolves to
(l + k) as this problem is optimizing the weight of the solution with respect to the
number of edges which is given by the size of the solution of the Steiner Tree plus
the number of newly added terminal edges. Equally, the optimal solution for the
Steiner Tree is given by the solution for k-veCMECG by erasing all terminal
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edges.
⇒ Steiner Tree ≤m k-veCMECG.
Theorem 4.5.10. 1-vCMECG is NP-hard.
Proof. Steiner Tree ≤m 1-vCMECG: Given a Steiner Tree instance, G =
(V,E), ω : E → 1, R ⊆ V , and l. Construct an instance of 1-vCMECG,
G′ = (V ′, E ′), V1 = vseed, s as follows:
Set vseed to an arbitrary terminal vertex. Add a degree-one vertex to the terminal
vertex selected as vseed and set the weight of the corresponding new edge ω(e) to
ω(e) = |E| = m. The weight of all remaining edges are set to zero. We obtain
G′ = (V ′, E ′) with |V ′| = |V |+ 1, |E ′| = |E|+ 1, vseed ⊆ R, and s = l + 1.
Now, the following is easy to prove: 1-vCMECG instance has a solution of size
at least m/(l + 1) if and only if the Steiner Tree instance allows for a Steiner
Tree of size at most l.
Since taking a non-terminal edge to the solution the overall sum is decreased, as
few of these edges are to be taken. Thus, the optimal solution of the 1-vCMECG
instance is given by the Steiner Tree of the terminals R plus the new terminal
edge added to vseed, i.e. to one of the terminals out of |R|. The denominator of the
solution for the 1-vCMECG instance resolves to (l+1) as this problem is optimizing
the weight of the solution with respect to the number of nodes which, in trees, is
equal to the number of edges + 1. Equally, the optimal solution of the Steiner
Tree is given by the solution for 1-vCMECG by erasing the terminal edge.
⇒ Steiner Tree ≤m 1-vCMECG.
Chapter 5
Discussion
Based on gene expression data obtained by genome-wide methods, we want to un-
derstand the biological processes aﬀected by TGF-β1 stimulation with or without
simultaneous treatment with inhibitors of the TGFBR1 kinase domain. Present
methods focus on determining diﬀerentially expressed genes. Based on these genes,
gene set enrichment analyses are conducted or small modules are extracted out of
protein interaction networks. Such methods neglect the vast amount of prior bio-
logical knowledge available in the public domain. This data should be used to add
information to the analyses especially with respect to the fact that not all genes
are regulated on the transcriptional level. I presented a method, that combines
approaches like jActiveModule, making use of protein interaction data and gene ex-
pression data, and Pandora, which integrates additional data sources. As a result, I
have been able to extract small modules that helped revealing the eﬀects present in a
given expression experiment. I exemplarily applied this method to a gene expression
experiment conducted for the analyses of compounds' mode of action. Applying my
approach proved useful to reveal oﬀ-target eﬀects, too. The results from my analysis
could be conﬁrmed by wet-lab experiments. I showed that the proposed data inte-
gration method is superior to STRING-based scoring for the biological processes and
genes that are aﬀected in our experiment. Interaction modules derived by modEx
are more informative than the modules derived by jActiveModule. In this chapter,
I will discuss the results presented in Chapter 4.
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5.1 Normalization
In order to put subsequent analyses on a reliable basis, it is important to select
appropriate pre-processing methods for a given data set based on the experimental
setup used [39]. If sample sizes of the diﬀerent groups are relatively small, it is crucial
to achieve a homogeneous variance for the groups. On the contrary, if sample sizes
are large, variances can be estimated reliably and one should focus on calculating
unbiased fold changes. Since the sample sizes for the current data set are rather
small (three to four replicates per group), a stable variance is more important than
an exact representation of the fold change. In general, the data should be normalized
without too much reducing real variations. Figure 4.12 on page 4.12 summarizes
the quality measures for all methods we investigated, demonstrating the background
for the ﬁnal choice. Clustering of the quality scores assigned reveals two major
tendencies based on background normalization.
(i) Background normalized data (bg_*) tend to better reﬂect the real fold changes,
i. e. show less bias.
(ii) Pre-processing without background normalization (noBg_*) leads to a more
homogeneous variance.
This could be explained by accurately deﬁned, constant experimental conditions
across all experiments. As they have been conducted in parallel, this possibly led
to a relatively consistent background level across all samples. Thus, background
correction would introduce additional variation.
Methods combining background normalization with vst (bg_vst_*) constitute
an exception. Here, vst leads to a better stabilization of variance while introduc-
ing more bias. As vst estimates an additional oﬀset for the background based on
the data [157], noBg_vst_* and bg_vst_* pre-processing methods lead to approxi-
mately similar results.
As shown in Section 4.1, there are several pre-processing methods resulting in
nearly equal quality. Therefore, it is not possible to give a well-deﬁned rationale for
using only one speciﬁc method. After excluding the methods that clearly violate
the imposed criteria, the decision is still subjective. It depends, e. g. on whether one
139 5.1. Normalization
would like to account for a good estimate of fold changes or a small and homoge-
neous variance. With the analyses and criteria described here, a recommendation on
the pre-selection of appropriate methods is provided. For the data set under study,
we intended to achieve a low and homogeneous variance. Therefore, I provided
extensive statistics investigating variance. If focus was on a good estimate of fold
change, the researcher should account more for statistics investigating this measure.
Correlation to results from qRT-PCR or slope and intercept of the regression be-
tween qRT-PCR data and gene expression fold changes are examples of analyses that
could be of higher interest in this context (Section 4.1.2, pages 93 ﬀ.). With regard
to variance, best suited for the data set analysed here are noBg_log_quantile and
noBg_log_rsn. Although log2-transformation in combination with quantile normal-
ization has been reported to perform relatively well by Du et al. [154] and Dunning et
al. [200,201], due to my analyses we decided to make use of robust spline normaliza-
tion (rsn). Quantile normalization preserves the rank order of genes but intensities
are transformed discontinuously since intensity values of diﬀerent microarrays are
forced to follow the same distribution. Spline normalization, in contrast, provides a
continuous mapping. rsn combines the positive features of quantile normalization
and spline interpolation. Due to properties of quantile normalization the rank order
of genes is preserved and due to the spline normalization intensities are transformed
in a continuous manner [154, 202]. Surprisingly, the use of vst as recommended
by Dunning et al. [201] and by Du et al. [154, 157, 202] and the combination of
vst with rsn as successfully used by Du et al. [202] did not perform as well as
expected. Reasons for this could be the diﬀerent experimental setups (two repli-
cates per group in the Barnes study [203] used for validation of vst, compared to
three to four replicates in our setup) or the use of a newer Illumina chip technology,
namely HumanHT-12 v3 chips, in our experiment. vst has been validated based on
a pre-released version of the Human-Ref-8 v1 Expression BeadChip that contained
19 (25% quantile) to 30 (75% quantile) beads per probe. On the HumanHT-12 v3
chips an average of only 15 beads per probe is available. Since vst makes use of
those technical replicates, this could lead to a slightly worse performance on the new
chip generation. In general, vst still performs well in stabilizing the variance but is
outperformed by noBg_log_quantile, noBg_log_rsn, and noBg_vsn in reﬂecting
the expression values as measured by qRT-PCR. When restricting to methods im-
plemented in BeadStudio, in accordance with Dunning et al. [200,201] who advised
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against the use of background normalization, I recommend using the cubic spline
method without background normalization (noBg_cubicSpline). As displayed in
Figure 4.12, noBg_cubicSpline outperforms all other BeadStudio normalization
methods. Spike-in or dilution data is frequently used for evaluating diﬀerent nor-
malization methods [157, 185, 200, 201, 204]. If no such data is available for the
microarray chip type used, its advisable to perform qRT-PCR measurements for
genes covering diﬀerent spectra of expression intensities in order to obtain a mea-
sure for judging the quality of pre-processing methods. Thereby, it becomes possible
to determine how well diﬀerent normalization methods are able to reﬂect the real
changes in expression intensities across diﬀerent expression levels.
In summary, we provide statistical measures based on which researchers can de-
cide on the best suited pre-processing scenario for their own experimental design. It
is also possible to estimate the bias of log2 ratios obtained from normalized data. In
conjunction with the measures for the variability of the data the basis for weighing
well measured changes versus low and homogeneous variance is delivered, and by
this means selecting an appropriate normalization method is feasible.
5.2 Data Integration
In Section 3.4, I proposed a scoring function to describe the pairwise relatedness of
proteins, which is both, easy to use and easy to interpret. This score is highly ﬂexible
by allowing integration of prior knowledge and by oﬀering the possibility to diﬀer-
entially weight individual evidence. Prior knowledge of protein interactions (Sec-
tion 3.4.1) is enriched by information on BP, MF, and CC as annotated by the
Gene Ontology (Section 3.4.2) and the similarity of promoter regions (Section 3.4.3).
Literature-based evidence (Section 3.4.4) and gene expression data (Section 3.4.5)
were integrated as well. By these data sets, I claim to obtain more informative edge
scores than STRING (Section 2.2.5), which does neither make use of GO nor of
transcription factor binding site information. Further, neither STRING- nor LLS-
(Section 2.2.6) or Pandora- (Section 2.3.11) based scoring methods oﬀer the pos-
sibility to extend the score for data derived in an experiment, like we exemplarily
did for the gene expression data (Section 3.4.5). Introducing weighting factors ai
(Equation 3.30, page 71) oﬀers a possibility to weight individual evidence accord-
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ing to biological expert knowledge. As I could show in the analyses conducted in
Sections 4.3.2 and 4.3.3 meaningful results are achieved by weighting the individual
scores by setting ai = 1 for all evidences used. Thus, the method can also be used
in an unbiased fashion, if no expert knowledge is available.
I compared diﬀerent options of how the individual evidence could be integrated.
By applying a pseudo-ROC based approach, I decided for the best combination with
respect to a set of known physical protein-protein interactions present in iRefIndex
that are most likely to represent real functional associations of proteins. This ap-
proach suﬀers, however, from the same drawback as all methods referring to a gold
standard like STRING or LLS, namely the still limited biological knowledge (high
number of false negative ﬁndings).
In the presented applications, I claim that our data integration method is supe-
rior to STRING-based scoring. This can be explained by the fact that I integrated
GO, arguably the currently best annotated and most comprehensive annotation of
genes and their products with respect to both, the biological processes they aﬀect
and their function. The ﬁrst to integrate Gene Ontology annotations to derive
functional modules were Wu et al. [167]. Using a Bayesian approach, they combine
results for the analyses of phylogenetic proﬁles, gene neighborhoods and Gene Ontol-
ogy annotations. The combined information is used to measure the strength of gene
functional relationship based on which functional modules present in Escherichia
coli were predicted. The method was not designed to reveal the eﬀects present in
a speciﬁc experiment under investigation. GO is also integrated in Pandora (Sec-
tion 2.3.11) but the aim of Pandora is to derive complete pathways, but not small
modules.
All of the approaches integrating prior knowledge depend on the quantity and
quality of the available knowledge. If this knowledge is limited, their performance
will be limited as well. It thus makes sense to combine diﬀerent sources like STRING
or LLS annotations using the presented integration approach. The scores based on
STRING and LLS could easily be added as a further data source using Equation 3.30.
Alternatively, modEx (Section 3.5) or other available analyses could be performed
based on each of the diﬀerently scored interaction networks, and the results could
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be interpreted separately to help in understanding the underlying biology.
5.3 modEx
Based on the methods presented in Section 3.4, diﬀerent data types are integrated
into a protein interaction network to obtain an edge- and node-weighted graph
G = (V,E). In Section 3.5.1, I deﬁned some graph theoretical problems that could
be posed based on networks weighted using the described approach. Solving the un-
derlying questions on this basis, it is possible to get biological insight, for example
on the mode of action of compounds. By the data integrated, I do not only focus
on deregulated genes but consider the functional relatedness of the proteins based
on additional previous knowledge. In contrast, most other module extraction meth-
ods discussed in Section 2.3 are heavily based on information from gene expression
proﬁling (Table 2.1, page 2.1). In Section 3.5.2 I introduced modEx to heuristi-
cally solve the 1-vertex Constrained Maximum Edge-Weight Connected
Graph (1-vCMECG) problem (Deﬁnition 3.5.4). modEx is applied in Section 4.3.3
to identify modules that help to elucidate the biological processes aﬀected in the
gene expression experiments under investigation. Many of the previously described
methods try to derive one main module that is aﬀected by the deregulated genes.
jActiveModule, for instance, reports the highest scoring component Gw (Figure 2.3)
as signaling or regulatory circuit of high biological interest [48]. I, in contrast,
argue that changes in gene expression could be induced through diﬀerent processes,
thus, we want to look for several modules that could help to elucidate these pro-
cesses. The actual implementation of jActiveModule returns not only the highest
scoring component but all signiﬁcantly active components. Still, these are rather
large and for the comparison analyses conducted, only ﬁve modules were returned
(Section 4.4.2, pages 127 ﬀ.). There, I could show that modEx results are still supe-
rior in linking the biological experiment to the speciﬁc processes. Since we do not
know a priori how many processes are aﬀected by compound treatment (on- as well
as possibly several oﬀ-target eﬀects), we do not know how many subgraphs we are
looking for. Some of the nodes in the protein interaction network may belong to
several processes/modules simultaneously. This has also not been taken into account
by previous approaches. The newly proposed approach looks for dense networks to
more likely derive subnetworks containing proteins/genes (nodes) that are relevant
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in the same biological context. Thus, the score is optimized relative to the num-
ber of nodes and the node-induced subgraph represents our result. To detect all
modules necessary to investigate the underlying processes, modEx solves a special
case of the k-vCMECG problem (Deﬁnition 3.5.2), namely the 1-vCMECG (Def-
inition 3.5.4) problem. By solving this problem for diﬀerent seed nodes, vseed, it is
possible to extract modules that are related to the diﬀerent underlying processes.
In the analyses described in Sections 4.3.2 and 4.3.3, the 10 strongest deregulated
genes of the underlying gene expression experiment were selected as vseeds. Thereby,
it is possible to detect interesting processes that agree with experimental ﬁndings.
It would also be possible to re-apply modEx until all genes that are deﬁned to be
diﬀerentially expressed based on a speciﬁc cutoﬀ are contained in at least one of the
extracted modules. Thereby it is possible to generate a result that very likely covers
all actually aﬀected processes by at least one of the modules.
The optimization problem, as described in the methods section, is related to the
Constrained Maximum Edge-weight Connected Graph Problem, which
has been shown to be NP-hard [197]. By proving the NP-hardness, a theoretical
justiﬁcation for the use of a heuristic is given. Additional to the theoretical jus-
tiﬁcation, seen from a biological point of view, it could be reasonable to solve the
problem in a non-optimal way:
• The theoretical problem would look for one subnetwork that optimizes the
objective function. The biological system under investigation could be aﬀected
in several biological processes which could be independent from each other.
Thus, it is more biologically relevant to look for several subnetworks.
• We do not know all protein interactions, thus, the graph underlying the prob-
lem already suﬀers from incorrectness. Thus, it is to question whether a correct
solution for the incorrect protein interaction network stays correct knowing all
correct protein interactions.
• The correctness of the complete protein interaction network does not only
depend on our biological knowledge but also on the state of the biological
system under consideration. Thus, components of the network may not be
present under a speciﬁc condition, or may change in a time-dependent manner.
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I ﬁrst applied a greedy search as heuristic algorithm. Since the extracted modules
were very small, simulated annealing was used instead. This resulted in modules
of adequate size. Another more empirical reason why simulated annealing could
be beneﬁcial is that missing prior knowledge could lead to artiﬁcial optima. This
could be due to edges that score low based on the lacking knowledge. With com-
plete knowledge they possibly would score high and lead to a higher Ω(G′i) (Deﬁni-
tion 3.5.4). By applying simulated annealing instead of a simple greedy search or
exact algorithms, we have the chance to overcome local optima, while at the same
time tolerating a certain degree of nescience. At the same time, we take the risk
of a fuzzy solution containing proteins that are not closely related to the aﬀected
biological process. Since our current knowledge is rather limited for many biological
areas, I argue that it is better to allow for some false positive proteins than to miss
some important relationships in an optimal solution. False negative relationships are
a greater concern than false positive ﬁndings since false positives can be identiﬁed
in downstream wet-lab validation. False negatives in contrast are more diﬃcult to
detect in follow-up experiments.
5.4 Analysis of Compounds' Mode of Action Using
modEx
I presented the combination of an edge scoring method and an extraction method for
the analysis of biological eﬀects based on gene expression experiments. Using this
approach, it is possible to detect on- as well as potential oﬀ-target eﬀects of com-
pounds. For the TGF-β experiment under consideration, these eﬀects have been
validated by wet-lab experiments [54]. Since we investigated eﬀects mediated by
kinase inhibitors which usually are propagated through direct protein-protein inter-
actions, I decided to use iRefIndex as underlying network for data integration. In
Section 4.4.1 I have shown that it could be beneﬁcial to use STRING with an ad-
justed edge scoring. This could lead to even better results, especially in cases where
the biological eﬀects are not necessarily dependent on direct protein interactions. I
could also demonstrate that for our application modEx is superior to jActiveMod-
ule. The extracted modules show higher relation to the biological process under
investigation. Additionally, the modules are much smaller than the ones found by
jActiveModules. Thus, they can be analyzed in more detail and, if necessary, even
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manually.
By applying the annotation and extraction methods proposed, it was possible
to derive protein interactions that are meaningful in the biological context un-
der consideration. I exemplarily showed this by investigating gene expression of
TGF-β1-stimulated cells compared to unstimulated cells. Modules extracted based
on this experiment should be related to TGF-β signaling. When conducting Fisher's
exact test based on gene sets predeﬁned by Reactome and KEGG, the signiﬁcantly
enriched gene sets obtained by using the newly proposed method can directly be
linked to TGF-β signaling (Figure 4.21).
In addition, I was able to detect on- as well as oﬀ-target eﬀects of TGF-β receptor
1 kinase-inhibiting compounds that could be conﬁrmed by wet-lab kinase-screens.
Networks extracted based on BI4 expression data reveal direct on-target eﬀects
(Section 4.3.3, Figure 4.22). Oﬀ-target eﬀect for BI4 are very rarely observed in the
networks (Figure E.2). In contrast, networks extracted based on data from experi-
ments involving other compounds are enriched with diﬀerent signaling cascades. By
kinase-screens it could be conﬁrmed in wet-lab experiments that kinases triggering
the detected signaling cascades are direct oﬀ-targets of the respective compounds
(Appendix F). Exemplary results for these oﬀ-target eﬀects are shown for BI1 (Sec-
tion 4.3.3, Figures 4.25 and E.1). Looking at the on-target eﬀects of BI1, it is shown
in Figures 4.23 and 4.22 that these are not as pre-dominant as for BI4 (Figure 4.22).
These in silico ﬁndings identify BI1 as the less favorable compound exhibiting more
oﬀ-target eﬀects than BI4. This is reﬂected by the wet-lab ﬁnding [52,54].
The quality of modules derived by the proposed method strongly depends on the
underlying network used. By comparing results derived using diﬀerent networks
as well as diﬀerent edge scores, I could show that STRINGmod outperforms the
iRefIndex based network as well as STRINGorg (Section 4.3, Figure 4.27).
Since diﬀerent methods have been proposed for identifying active modules within
a protein network, I compared modEx to one of the most prominent methods, jAc-
tiveModule. Ad for modEx, ﬁndings indicate that using STRINGmod as input to
jActiveModule is superior to using iRefIndex (Section 4.4.2, Figure 4.28). Further,
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I could show that modEx is superior to jActiveModule in cases were we want to de-
rive modules that are not only enriched with deregulated genes but also are related
to the underlying processes (Section 4.4.3, Figures 4.29 and 4.30). One reason for
this is the fact that not all genes relevant for a biological processes are regulated
on the transcriptional level. Thus, to shed light on the biological process or mecha-
nism of interest, the beneﬁt of my method is the integration of knowledge that goes
beyond diﬀerential expression. Along these lines, the reason for STRING outper-
forming iRefIndex is that STRING not only considers physical protein interactions
but also functionally related proteins. By weighting the resulting edges I introduced
a measure for the likeliness of the relations. One probable reason for my weighting
scheme outperforming the native STRING weighting is that, based on GO biological
process or the cellular component, additional prior knowledge about the relatedness
is integrated. Obviously, I cannot claim that my scoring performs better than the
STRING scoring for processes for which we do not have any additional prior knowl-
edge. For these cases, it could be beneﬁcial to combine the scoring method with
the ﬁnal STRING score by using the latter one as an additional term in the linear
combination (Equation 3.30). The results derived could be used complementarily to
results based on either the original STRING scoring or my scoring, or both. Thus,
modEx could be applied even with limited or no evidence to elucidate the biological
processes under investigation.
One major advantage of the proposed method is its ﬂexibility with respect to
weighting single pieces of evidence. Based on the research objective and in close
cooperation with experts in the biological context, the scores can be individually
weighted and optimized. Furthermore, it is easy to extent the score to further
evidence of relatedness.
The proposed method can also be used to complement other biological analyses.
Identiﬁcation and validation of new drug targets may serve as an example in this
regard. To identify new targets, proteins that are known to be related to the dis-
ease under investigation could serve as seed nodes for modEx. Resulting modules
could then be further analyzed for interesting intervention points. In cases proteins
that are already targets in a diﬀerent indication area are contained in the extracted
modules, target repositioning is an option. As soon as potent compounds are avail-
able, even trying to reposition the drug would be applicable. Similarly, basic in
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silico validation of targets is possible. For validating a target, the respective protein
would be selected as seed node based on which a module is subsequently extracted.
This module then can be a starting point for further analyses to conﬁrm the indi-
cation area or to check for potential side eﬀects or drawbacks of the target under
consideration.

Chapter 6
Conclusion & Future Work
In this work, I ﬁrst proposed a way to select the best suited normalization procedure
for the underlying expression data. Thereby, downstream analyses are founded on a
sound basis. The proposed statistical measures can easily be used for other expres-
sion experiments to guide the selection of an appropriate normalization procedure.
To analyze compounds' MoA, I introduced a method that weights interactions
between pairs of proteins based on diﬀerent kinds of evidence. As underlying net-
works, iRefIndex [96] and STRING [55] were exemplarily used. In general, other
types of networks could be used as additional sources for protein interaction. I did
not make use of protein interactions provided by CORUM [205], DIP [206], and
HPRD [102] since these were not freely available. In principle these data could be
easily added.
The relevance of proteins is based on the biological relatedness to other possi-
bly non-deregulated protein-coding genes. Thereby, I expand the analysis beyond
transcriptional deregulation. To elucidate the biological relatedness, information
on molecular function, biological processes and cellular compartment, information
on transcription factor binding sites and literature-based conﬁdence scores are in-
tegrated for weighting the edges between pairs of proteins. Integration of pheno-
typic information as, for example, taken from the mammalian phenotype ontol-
ogy [207,208], human phenotype ontology [209] or disease ontology [210212] could
be beneﬁcial. Thereby, it could be possible to further improve my method and
make it even more valuable for biological analysis. As the proposed information is
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represented as ontologies, it would be possible to apply the methods used in the
present work to integrate GO. Other information that could be integrated are, e. g.
information on miRNA targets [213] or information on phosphorylation sites [214].
To transfer the network into the biological context of interest, expression experi-
ments are used as anchoring points for the analyses. For all the methods proposed,
instead of using correlation/covariance of gene expression over time to calculate
scoreexp (Equations 3.27 - 3.29) it is also possible to use correlation/covariance of
diﬀerent dosages or over diﬀerent treatments or combinations of both. What is used
depends on the biological question.
Further, I introduced modEx, a method to extract small modules out of a weighted
protein interaction network. These modules hint at the MoA of the compounds used
in our expression experiment. In my analyses, ten networks were extracted based
on the strongest deregulated genes. This is a very pragmatic approach. A more
comprehensive analysis would determine the number of networks to extract based
on the actual data. One possibility could be to extract networks until all genes that
are deregulated based on a predeﬁned cutoﬀ (e.g. p-value < 0.01 and |log2 ratio|>1)
are contained in the extracted modules. Thereby, it would be more likely to explain
all eﬀects present in the experiment under investigation.
I show that for the expression data set used, the proposed edge scoring is supe-
rior to the STRING scoring. It would be worth investigating how the results are
changed if the native STRING score is used as further evidence in our edge score
(Equation 3.30). Finally, I could show that modEx extracts modules that better
represent the underlying mechanism than jActiveModule. In this work, modEx is
only compared to jActiveModule. It would be interesting to compare this method
to further available approaches like GXNA, ClustEx or Matisse. The disadvantage
of ClustEx is that is has very long run times and Matisse is only available for aca-
demically funded work.
One huge challenge that holds for all methods that return a subnetwork or a set
or list of genes is how to further analyze these genes. As long as the network or list is
small (<20 genes), one labor-intensive possibility is to manually go through the list
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and try to explain the biological process based on the individual genes in the list. I
proposed to use a very standardized method, gene set enrichment based on Fisher's
exact test. Drawback of gene set enrichment is that results are based on pre-deﬁned
gene sets which are very likely incomplete based on our current knowledge and de-
rived results are at most as good as the annotations. Further, it is not possible to
detect new relationships. To close this gap, further research is needed in this regard.
Scientists of diﬀerent disciplines are working together to continuously improve and
deepen our constantly increasing understanding of biology. By this means, results
derived by analyses as described in the present work are also permanently improving.
As more and more prior knowledge is available, developments in the direction of data
mining and data integration has to be done to ﬁnd optimal ways to make use of this
tremendous knowledge. Further, new or improved methods to extract the relevant
parts of information have to be developed. With the present work, I contributed
to the initial development of such methods. By further advancing research in these
directions, it will get more and more possible to elucidate diﬀerent kinds of biological
processes and to successively solve the secrets of life.

Appendix A
TGF-β Signaling
Figure A.1: Biological representation of the TGF-β signaling pathway. Dis-
played are the most important molecular events involved in TGF-β signaling via
SMAD proteins and via TRAF6, an exemplary SMAD independent way. Pathway
illustration was taken from Ingenuity Knowledge Base [144] library of canonical
signaling pathways.
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Appendix B
Comparison of Pre-Processing
Methods
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Figure B.1: Density plots of MSQwithin (blue) and MSQbetween (red).
MSQs were calculated based on the gene expression measured for the three sample
groups analyzed, namely untreated HaCaT cells after 2, 4, and 12 hours. The grey
dashed line indicates the expected value for theMSQbetween of 1.33 based on 6, 6, and
7 as measurements for the group means of four replicates for three time points. Three
examples of diﬀerent quality are shown.
Appendix C
Comparison Between STRINGorg,
STRINGmod, and iRefIndex
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Table C.3: Results of gene set enrichment by Fisher's exact test based on
KEGG. Fisher's exact test was conducted based on KEGG predeﬁned gene sets for
modules extracted by modEx based on STRINGorg, STRINGmod, and iRefIndex networks
(Table C.1). Displayed are p-values/ranks of KEGG TGF-β signaling gene set for p-
values < 1. Diﬀerent cutoﬀs were applied to the original STRING network, ﬁrst, to
approximate the size of iRefIndex, and, second, to exclude FP associations. The size of
iRefIndex is best approximated using 848 as cutoﬀ. As mentioned in Section 3.7, page 77,
data referring to this cutoﬀ was used in the main part of this thesis.
Conﬁdence score used as cutoﬀ for edges
STRINGorg STRINGmod iRefIndex
seed node ≥ 848 ≥ 900 ≥ 848 ≥ 900
VASN <0.0001/ 6 nnp 0.0002/ 2 nnp 0.0852/ 14
SERPINE1 - - - 0.0002/ 2 <0.0001/ 6
CTGF <0.0001/ 4 <0.0001/ 3 0.0002/ 2 <0.0001/ 2 0.0784/ 14
JUN <0.0001/ 5 <0.0001/ 5 0.0002/ 2 0.0002/ 2 -
TGM2 - - 0.0003/ 2 0.0003/ 2 0.112/ 16
KANK4 nnp nnp nnp nnp nnp
FOSB 0.1065/ 48 0.1194/ 48 0.0002/ 2 0.0001/ 2 -
BHLHE40 - - - 0.0251/ 8 <0.0001/ 2
CDKN2B 0.0063/ 16 0.008/ 16 0.036/ 16 0.0383/ 13 0.0715/ 11
SMAD7 <0.0001/ 1 <0.0001/ 1 0.0001/ 2 0.0002/ 2 <0.0001/ 1
SOX18 - nnp 0.039/ 15 nnp 0.0007/ 13
IER3 NA <0.0001/ 15 NA - NA
SKIL NA <0.0001/ 6 NA 0.0002/ 2 NA
union graph <0.0001/ 24 <0.0001/ 27 0.0003/ 8 <0.0001/ 4 <0.0001/ 2
conComp <0.0001/ 23 <0.0001/ 26 0.0005/ 2 0.0006/ 2 <0.0001/ 2
nnp: node not present; due to reduction of edges isolated nodes occur. These were removed
since it is useless to take them as seed nodes.
NA: nodes were not treated as seed nodes, since more signiﬁcant nodes are still present
(not nnp).
Union graph: Union graph refers to the network as obtained by the union of the ten individual
nets extracted.
conComp: Connected component containing most seed nodes.
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Table D.2: Results of gene set enrichment by Fisher's exact
test based on Reactome. P-values and ranks of Reactome TGF-β
signaling gene set based on Fisher's exact test conducted for modules
identiﬁed by jActiveModule in the iRefIndex network (Table D.1).
no-pval def-pval sub-net
greedyDef greedyDef greedyDef simAnnHub
Module1 4 · 10−4/94 7 · 10−4/128 −/−+ −/−+
Module2 4 · 10−4/81 0.2354/289 1 · 10−4/20 −/−+,#
Module3 3.6 · 10−3/139 −/−+ 0.0984/197 −/−+
Module4 4.3 · 10−3/168 −/−+ 0.0962/242 −/−+,#
Module5 2 · 10−4/95 −/−+ 0.0138/117 −/−+,∗
+ p-value>0.5, #subnet active at 2h, 4h, 12h, ∗active at 4h and 12h,
all others only active at 12h.
Table D.3: Results of gene set enrichment by Fisher's exact
test based on KEGG. P-values and ranks of KEGG's TGF-β sig-
naling gene set based on Fisher's exact test conducted for modules
identiﬁed by jActiveModule in the iRefIndex network (Table D.1).
no-pval def-pval sub-net
greedyDef greedyDef greedyDef simAnnHub
Module1 1.5 · 10− 6/14 7.3 · 10−3/45 0.24/57 0.23/36
Module2 2.0 · 10−4/28 0.16/55 5.5 · 10− 6/6 0.03/4
Module3 2.4 · 10−3/44 0.12/29 1.8 · 10−3/36 1/219
Module4 3.3 · 10−3/43 0.01/33 1.6 · 10−3/30 1/222
Module5 4.2 · 10− 7/9 1/248 3.4 · 10−4/18 0.02/6
all subnets are only active at 12h.
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Table D.4: Results of jActiveModule based on
STRING. Nodes of jActiveModule instances were weighted
according to the FDR-corrected p-values calculated for the
comparisons of TGF-β1-stimulated compared to unstimu-
lated cells at 2, 4, and 12 hours (see Section 3.3.1, page 55).
Displayed are the modules detected in the STRING network
(cutoﬀ of 848) using jActiveModule (nodes/edges/score).
Subsequently, the respective modules are used in gene
set enrichment analysis using Fisher's exact test (Ta-
bles D.5 and D.6).
no-pval def-pval sub-net
greedyDef greedyDef greedyDef
Module1 367/1882/19.0 998/5988/24.6 348/1628/19.1
Module2 387/2001/18.9 1009/7716/23.5 370/1844/18.8
Module3 361/1860/18.9 909/6734/23.4 373/1788/18.7
Module4 363/1825/18.8 938/6953/23.3 357/1618/18.5
Module5 395/2225/18.8 1012/7358/23.3 379/1874/18.4
all subnets are only active at 12h.
Table D.5: Results of gene set enrichment by Fisher's
exact test based on Reactome. P-values and ranks of
Reactome TGF-β signaling gene set based on Fisher's exact
test conducted for modules identiﬁed by jActiveModule in the
STRING network (Table D.4).
no-pval def-pval sub-net
greedyDef greedyDef greedyDef
Module1 1.38 · 10−6/113 3.83 · 10−4/102 3.20 · 10−4/137
Module2 1.57 · 10−6/126 1.12 · 10−6/68 8.93 · 10−7/67
Module3 3.54 · 10−8/98 2.00 · 10−5/75 2.14 · 10−5/77
Module4 1.62 · 10−3/243 2.05 · 10−5/77 3.42 · 10−4/103
Module5 3.43 · 10−9/96 6.28 · 10−3/202 4.31 · 10−4/122
all subnets are only active at 12h.
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Table D.6: Results of gene set enrichment by Fisher's
exact test based on KEGG. P-values and ranks of
KEGG's TGF-β signaling gene set based on Fisher's exact
test conducted for modules identiﬁed by jActiveModule in the
STRING network (Table D.4).
no-pval def-pval sub-net
greedyDef greedyDef greedyDef
Module1 2.08 · 10−10/22 8.52 · 10−8/37 7.60 · 10−8/17
Module2 4.28 · 10−11/15 2.07 · 10−11/38 2.23 · 10−9/27
Module3 1.76 · 10−9/19 4.81 · 10−21/8 2.21 · 10−11/16
Module4 1.93 · 10−11/20 1.12 · 10−9/34 1.16 · 10−8/22
Module5 4.09 · 10−9/22 1.04 · 10−16/18 1.95 · 10−7/30
all subnets are only active at 12h.
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Appendix E
Oﬀ-Target Analysis
E.1 Gene Sets Enriched for Union Graphs
Figure E.1: Gene sets enriched for proteins contained in the union graph of
BI1. Oﬀ-target analysis of BI1 was conducted as described in Section 4.3.3, pages 117 ﬀ..
Gene sets like MAPK and ErbB signaling can be directly linked to oﬀ-targets conﬁrmed in
wet-lab experiments (Appendix Table F). Though TGF-βR1 is the intended primary target
of BI1, only indirect hints like Focal adhesion or Cell junctions hint at TGF-β signaling.
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Figure E.2: Gene sets enriched for proteins contained in the union graph of
BI4. Oﬀ-target analysis of BI4 was conducted as described in Section 4.3.3, pages 117 ﬀ..
Only genes which do not exhibit an inverse change compared to TGF-β1 stimulation, the
desired eﬀect of the compound, were selected as seed nodes. Still, the connection of the
selected nodes to TGF-β related genes seems to be strong such that TGF-β signaling is
one of the most signiﬁcant gene sets (p-value < 4 · 10−10). As for BI1, additional gene
set hinting at conﬁrmed oﬀ-target eﬀects are present. Examples are MAPK singaling and
VEGF singaling (compare Appendix Table F).
Appendix F
Compounds' Wet-Lab Target
Validation
F.1 Kinase Screen BI1
Results of kinase screen for BI1 are summarized in Tables F.1 to F.3
F.2 Kinase Screen BI4
Results of kinase screen for BI4 are summarized in Tables F.4 to F.6
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